20. Literaturverzeichnis – Nierenzellkarzinom
1. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften - Ständige Kommission, Leitlinien, AWMF-Regelwerk "Leitlinien", 2. Auflage 2020. 12.12.2021:, http://www.awmf.org/leitlinien/awmf-regelwerk/awmf-regelwerk.html
2. Adams, K. F., Leitzmann, M. F., Albanes, D., Kipnis, V., Moore, S. C., Schatzkin, A., et.al. Body size and renal cell cancer incidence in a large US cohort study, Am J Epidemiol, 2008. 168(3): p. 268-77., http://www.ncbi.nlm.nih.gov/pubmed/18544571
3. Kreiger, N., Marrett, L. D., Dodds, L., Hilditch, S., Darlington, G. A., Risk factors for renal cell carcinoma: results of a population-based case-control study, Cancer Causes Control, 1993. 4(2): p. 101-10., http://www.ncbi.nlm.nih.gov/pubmed/8481488
4. Luo, J., Margolis, K. L., Adami, H. O., Lopez, A. M., Lessin, L., Ye, W., et.al. Body size, weight cycling, and risk of renal cell carcinoma among postmenopausal women: the Women's Health Initiative (United States), Am J Epidemiol, 2007. 166(7): p. 752-9., http://www.ncbi.nlm.nih.gov/pubmed/17615089
5. Nicodemus, K. K., Sweeney, C., Folsom, A. R., Evaluation of dietary, medical and lifestyle risk factors for incident kidney cancer in postmenopausal women, Int J Cancer, 2004. 108(1): p. 115-21., http://www.ncbi.nlm.nih.gov/pubmed/14618625
6. Parker, A. S., Cerhan, J. R., Janney, C. A., Lynch, C. F., Cantor, K. P., Smoking cessation and renal cell carcinoma, Ann Epidemiol, 2003. 13(4): p. 245-51., http://www.ncbi.nlm.nih.gov/pubmed/12684190
7. Pischon, T., Lahmann, P. H., Boeing, H., Tjonneland, A., Halkjaer, J., Overvad, K., et.al. Body size and risk of renal cell carcinoma in the European Prospective Investigation into Cancer and Nutrition (EPIC), Int J Cancer, 2006. 118(3): p. 728-38., http://www.ncbi.nlm.nih.gov/pubmed/16094628
8. Renehan, A. G., Tyson, M., Egger, M., Heller, R. F., Zwahlen, M., Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies, Lancet, 2008. 371(9612): p. 569-78., http://www.ncbi.nlm.nih.gov/pubmed/18280327
9. Theis, R. P., Dolwick Grieb, S. M., Burr, D., Siddiqui, T., Asal, N. R., Smoking, environmental tobacco smoke, and risk of renal cell cancer: a population-based case-control study, BMC Cancer, 2008. 8: p. 387., http://www.ncbi.nlm.nih.gov/pubmed/19108730
10. Hu, J., Ugnat, A. M., Canadian Cancer Registries Epidemiology Research, Group, Active and passive smoking and risk of renal cell carcinoma in Canada, Eur J Cancer, 2005. 41(5): p. 770-8., http://www.ncbi.nlm.nih.gov/pubmed/15763654
11. Hunt, J. D., van der Hel, O. L., McMillan, G. P., Boffetta, P., Brennan, P., Renal cell carcinoma in relation to cigarette smoking: meta-analysis of 24 studies, Int J Cancer, 2005. 114(1): p. 101-8., http://www.ncbi.nlm.nih.gov/pubmed/15523697
12. Choi, M. Y., Jee, S. H., Sull, J. W., Nam, C. M., The effect of hypertension on the risk for kidney cancer in Korean men, Kidney Int, 2005. 67(2): p. 647-52., http://www.ncbi.nlm.nih.gov/pubmed/15673312
13. Chow, W. H., Gridley, G., Fraumeni, J. F., Jr., Jarvholm, B., Obesity, hypertension, and the risk of kidney cancer in men, N Engl J Med, 2000. 343(18): p. 1305-11., http://www.ncbi.nlm.nih.gov/pubmed/11058675
14. Coughlin, S. S., Neaton, J. D., Randall, B., Sengupta, A., Predictors of mortality from kidney cancer in 332,547 men screened for the Multiple Risk Factor Intervention Trial, Cancer, 1997. 79(11): p. 2171-7., http://www.ncbi.nlm.nih.gov/pubmed/9179064
15. Shapiro, J. A., Williams, M. A., Weiss, N. S., Stergachis, A., LaCroix, A. Z., Barlow, W. E., Hypertension, antihypertensive medication use, and risk of renal cell carcinoma, Am J Epidemiol, 1999. 149(6): p. 521-30., http://www.ncbi.nlm.nih.gov/pubmed/10084241
16. Vatten, L. J., Trichopoulos, D., Holmen, J., Nilsen, T. I., Blood pressure and renal cancer risk: the HUNT Study in Norway, Br J Cancer, 2007. 97(1): p. 112-4., http://www.ncbi.nlm.nih.gov/pubmed/17519895
17. Weikert, S., Boeing, H., Pischon, T., Weikert, C., Olsen, A., Tjonneland, A., et.al. Blood pressure and risk of renal cell carcinoma in the European prospective investigation into cancer and nutrition, Am J Epidemiol, 2008. 167(4): p. 438-46., http://www.ncbi.nlm.nih.gov/pubmed/18048375
18. Flaherty, K. T., Fuchs, C. S., Colditz, G. A., Stampfer, M. J., Speizer, F. E., Willett, W. C., et.al. A prospective study of body mass index, hypertension, and smoking and the risk of renal cell carcinoma (United States), Cancer Causes Control, 2005. 16(9): p. 1099-106., http://www.ncbi.nlm.nih.gov/pubmed/16184476
19. Fryzek, J. P., Poulsen, A. H., Johnsen, S. P., McLaughlin, J. K., Sorensen, H. T., Friis, S., A cohort study of antihypertensive treatments and risk of renal cell cancer, Br J Cancer, 2005. 92(7): p. 1302-6., http://www.ncbi.nlm.nih.gov/pubmed/15812478
20. Cumberbatch, MG, Rota, M, Catto, JW, La Vecchia, C, The Role of Tobacco Smoke in Bladder and Kidney Carcinogenesis: A Comparison of Exposures and Meta-analysis of Incidence and Mortality Risks., Eur Urol, 2016. 70 (3)(3): p. 458-66., https://pubmed.ncbi.nlm.nih.gov/26149669/
21. Behrens, G, Leitzmann, MF, The association between physical activity and renal cancer: systematic review and meta-analysis., Br J Cancer, 2013. 108 (4)(4): p. 798-811., https://pubmed.ncbi.nlm.nih.gov/23412105/
22. Hidayat, K, Du, X, Zou, SY, Shi, BM, Blood pressure and kidney cancer risk: meta-analysis of prospective studies., J Hypertens, 2017. 35 (7)(7): p. 1333-1344., https://pubmed.ncbi.nlm.nih.gov/28157813/
23. Lee, J. E., Mannisto, S., Spiegelman, D., Hunter, D. J., Bernstein, L., van den Brandt, P. A., et.al. Intakes of fruit, vegetables, and carotenoids and renal cell cancer risk: a pooled analysis of 13 prospective studies, Cancer Epidemiol Biomarkers Prev, 2009. 18(6): p. 1730-9., http://www.ncbi.nlm.nih.gov/pubmed/19505906
24. Weikert, S., Boeing, H., Pischon, T., Olsen, A., Tjonneland, A., Overvad, K., et.al. Fruits and vegetables and renal cell carcinoma: findings from the European prospective investigation into cancer and nutrition (EPIC), Int J Cancer, 2006. 118(12): p. 3133-9., http://www.ncbi.nlm.nih.gov/pubmed/16425278
25. George, S. M., Park, Y., Leitzmann, M. F., Freedman, N. D., Dowling, E. C., Reedy, J., et.al. Fruit and vegetable intake and risk of cancer: a prospective cohort study, Am J Clin Nutr, 2009. 89(1): p. 347-53., http://www.ncbi.nlm.nih.gov/pubmed/19056579
26. BMAS, Wissenschaftliche Stellungnahme zur Berufskrankheit Nr. 1302 „Erkrankungen durch Halogenkohlenwasserstoffe“ – Nierenkrebs durch Trichlorethen. Bek. d. BMAS vom 1. Februar 2018a – IVa 4 -45222 – 1302; GMBl 12/13: 220-2, 2018., https://www.baua.de/DE/Angebote/Rechtstexte-und-Technische-Regeln/Berufskrankheiten/pdf/Stellungnahme-1302-1.pdf?__blob=publicationFile&v=2018
27. Jungmann, O. P., Schöps, W., Golka, K., Rohde, D., Beruflich bedingte urologische Tumoren, Zentralblatt für Arbeitsmedizin, Arbeitsschutz und Ergonomie, 2019. 5:, https://www.springermedizin.de/gesundheitsschaeden-und-berufskrankheiten/recht-fuer-aerzte/beruflich-bedingte-urologische-tumoren/17098732
28. Henschler, D, Vamvakas, S, Lammert, M, Dekant, W, Kraus, B, Thomas, B, et.al. Increased incidence of renal cell tumors in a cohort of cardboard workers exposed to trichloroethene., Arch Toxicol, 1995. 69 (5)(5): p. 291-9., https://pubmed.ncbi.nlm.nih.gov/7654132/
29. Bernauer, U, Birner, G, Dekant, W, Henschler, D, Biotransformation of trichloroethene: dose-dependent excretion of 2,2,2-trichloro-metabolites and mercapturic acids in rats and humans after inhalation., Arch Toxicol, 1996. 70 (6)(6): p. 338-46., https://pubmed.ncbi.nlm.nih.gov/8975632/
30. Brüning, T, Bolt, HM, Renal toxicity and carcinogenicity of trichloroethylene: key results, mechanisms, and controversies., Crit Rev Toxicol, 2000. 30 (3)(3): p. 253-85., https://pubmed.ncbi.nlm.nih.gov/10852497/
31. Trichlorethen [MAK Value Documentation in German language, 1996], The MAK‐Collection for Occupational Health and Safety, 2012. p. 1-43., https://doi.org/10.1002/3527600418.mb7901d0022
32. Brauch, H, Weirich, G, Hornauer, MA, Störkel, S, Wöhl, T, Brüning, T, Trichloroethylene exposure and specific somatic mutations in patients with renal cell carcinoma., J Natl Cancer Inst, 1999. 91 (10)(10): p. 854-61., https://pubmed.ncbi.nlm.nih.gov/10340905/
33. Hallscheidt, P., Schoenberg, S., Schenk, J. P., Zuna, I., Petirsch, O., Riedasch, G., [Multi-slice CT in the planning of nephron-sparing interventions for renal cell carcinoma: Prospective study correlated with histopathology], Röfo, 2002. 174(7): p. 898-903., http://www.ncbi.nlm.nih.gov/pubmed/12101482
34. Hallscheidt, Peter J, Bock, Michael, Riedasch, Gerd, Zuna, Ivan, Schoenberg, Stefan O, Autschbach, Frank, et.al. Diagnostic accuracy of staging renal cell carcinomas using multidetector-row computed tomography and magnetic resonance imaging: a prospective study with histopathologic correlation, Journal of computer assisted tomography, 2004. 28(3): p. 333-339., https://pubmed.ncbi.nlm.nih.gov/15100536/
35. Israel, G. M., Hecht, E., Bosniak, M. A., CT and MR imaging of complications of partial nephrectomy, Radiographics, 2006. 26(5): p. 1419-29., http://www.ncbi.nlm.nih.gov/pubmed/16973773
36. Prando, A., Prando, D., Prando, P., Renal cell carcinoma: unusual imaging manifestations, Radiographics, 2006. 26(1): p. 233-44., http://www.ncbi.nlm.nih.gov/pubmed/16418254
37. Guzzo, T. J., Pierorazio, P. M., Schaeffer, E. M., Fishman, E. K., Allaf, M. E., The accuracy of multidetector computerized tomography for evaluating tumor thrombus in patients with renal cell carcinoma, J Urol, 2009. 181(2): p. 486-90; discussion 491., http://www.ncbi.nlm.nih.gov/pubmed/19100567
38. Hallscheidt, Peter J, Fink, Christian, Haferkamp, Axel, Bock, Michael, Luburic, Ante, Zuna, Ivan, et.al. Preoperative staging of renal cell carcinoma with inferior vena cava thrombus using multidetector CT and MRI: prospective study with histopathological correlation, Journal of computer assisted tomography, 2005. 29(1): p. 64-68., https://insights.ovid.com/crossref?an=00004728-200501000-00012
39. Raman, Siva P, Johnson, Pamela T, Allaf, Mohamad E, Netto, George, Fishman, Elliot K, Chromophobe renal cell carcinoma: multiphase MDCT enhancement patterns and morphologic features, American Journal of Roentgenology, 2013. 201(6): p. 1268-1276., https://pubmed.ncbi.nlm.nih.gov/24261366/
40. Sheth, S., Scatarige, J. C., Horton, K. M., Corl, F. M., Fishman, E. K., Current concepts in the diagnosis and management of renal cell carcinoma: role of multidetector ct and three-dimensional CT, Radiographics, 2001. 21 Spec No: p. S237-54., http://www.ncbi.nlm.nih.gov/pubmed/11598260
41. Kim, Cherry, Choi, Hyuck Jae, Cho, Kyoung-Sik, Diagnostic value of multidetector computed tomography for renal sinus fat invasion in renal cell carcinoma patients, European journal of radiology, 2014. 83(6): p. 914-918., https://pubmed.ncbi.nlm.nih.gov/24713489/
42. Karlo, C. A., Donati, O. F., Marigliano, C., Tickoo, S. K., Hricak, H., Russo, P., et.al. Role of CT in the assessment of muscular venous branch invasion in patients with renal cell carcinoma, AJR Am J Roentgenol, 2013. 201(4): p. 847-52., http://www.ncbi.nlm.nih.gov/pubmed/24059374
43. Vargas, Hebert Alberto, Delaney, Holly G., Delappe, Eithne M., Wang, Ya, Zheng, Junting, Moskowitz, Chaya S., et.al. Multiphasic contrast-enhanced MRI: single-slice versus volumetric quantification of tumor enhancement for the assessment of renal clear-cell carcinoma fuhrman grade, Journal of magnetic resonance imaging : JMRI, 2013. 37(5): p. 1160-1167., http://www.ncbi.nlm.nih.gov/pubmed/23152173
44. Hallscheidt, P., Hansmann, J., Schenk, J. P., Radeleff, B. A., Kauffmann, G. W., Riedasch, G., [Organ-sparing surgery of renal cell carcinoma - operative technique and findings in radiological follow-up], Röfo, 2002. 174(4): p. 409-15., http://www.ncbi.nlm.nih.gov/pubmed/11960401
45. Engelmann, U., Schaub, T., Schweden, F., Jacobi, G. H., Thuroff, J. W., Digital subtraction angiography in staging renal cell carcinoma: comparison with computerized tomography and histopathology, J Urol, 1984. 132(6): p. 1093-6., http://www.ncbi.nlm.nih.gov/pubmed/6389902
46. Grups, J. W., Heller, V., Comparative value of ultrasonography, computerized tomography, angiography and excretory urography in the staging of renal cell carcinoma, J Urol, 1987. 138(3): p. 482-4., http://www.ncbi.nlm.nih.gov/pubmed/3305989
47. Tan, H. J., Jacobs, B. L., Hafez, K. S., Montgomery, J. S., Weizer, A. Z., Wood, D. P., Jr., et.al. Understanding the role of percutaneous biopsy in the management of patients with a small renal mass, Urology, 2012. 79(2): p. 372-7., https://pubmed.ncbi.nlm.nih.gov/22310755/
48. Kutikov, A., Uzzo, R. G., The R.E.N.A.L. nephrometry score: a comprehensive standardized system for quantitating renal tumor size, location and depth, J Urol, 2009. 182(3): p. 844-53., https://pubmed.ncbi.nlm.nih.gov/19616235/
49. Volpe, A., Finelli, A., Gill, I. S., Jewett, M. A., Martignoni, G., Polascik, T. J., et.al. Rationale for percutaneous biopsy and histologic characterisation of renal tumours, Eur Urol, 2012. 62(3): p. 491-504., http://www.ncbi.nlm.nih.gov/pubmed/22633318
50. Lane, B. R., Samplaski, M. K., Herts, B. R., Zhou, M., Novick, A. C., Campbell, S. C., Renal mass biopsy--a renaissance?, J Urol, 2008. 179(1): p. 20-7., http://www.ncbi.nlm.nih.gov/pubmed/17997455
51. Phé, V., Yates, D. R., Renard-Penna, R., Cussenot, O., Roupret, M., Is there a contemporary role for percutaneous needle biopsy in the era of small renal masses?, BJU Int, 2012. 109(6): p. 867-72., https://pubmed.ncbi.nlm.nih.gov/21895938/
52. Volpe, A., Kachura, J. R., Geddie, W. R., Evans, A. J., Gharajeh, A., Saravanan, A., et.al. Techniques, safety and accuracy of sampling of renal tumors by fine needle aspiration and core biopsy, J Urol, 2007. 178(2): p. 379-86., http://www.ncbi.nlm.nih.gov/pubmed/17561170
53. Barwari, K., Kummerlin, I. P., ten Kate, F. J., Algaba, F., Trias, I., Wijkstra, H., et.al. What is the added value of combined core biopsy and fine needle aspiration in the diagnostic process of renal tumours?, World J Urol, 2013. 31(4): p. 823-7., https://pubmed.ncbi.nlm.nih.gov/21626116/
54. Li, G., Cuilleron, M., Zhao, A., Obadia, F., Mouracade, P., Tostain, J., et.al. Combination of core biopsy and fine-needle aspiration increases diagnostic rate for small solid renal tumors, Anticancer Res, 2012. 32(8): p. 3463-6., http://www.ncbi.nlm.nih.gov/pubmed/22843931
55. Parks, G. E., Perkins, L. A., Zagoria, R. J., Garvin, A. J., Sirintrapun, S. J., Geisinger, K. R., Benefits of a combined approach to sampling of renal neoplasms as demonstrated in a series of 351 cases, Am J Surg Pathol, 2011. 35(6): p. 827-35., https://pubmed.ncbi.nlm.nih.gov/21552112/
56. Breda, A., Treat, E. G., Haft-Candell, L., Leppert, J. T., Harper, J. D., Said, J., et.al. Comparison of accuracy of 14-, 18- and 20-G needles in ex-vivo renal mass biopsy: a prospective, blinded study, BJU Int, 2010. 105(7): p. 940-5., https://pubmed.ncbi.nlm.nih.gov/19888984/
57. Hobbs, D. J., Zhou, M., Campbell, S. C., Aydin, H., Weight, C. J., Lane, B. R., The impact of location and number of cores on the diagnostic accuracy of renal mass biopsy: an ex vivo study, World J Urol, 2013. 31(5): p. 1159-64., http://www.ncbi.nlm.nih.gov/pubmed/22527673
58. Wunderlich, H., Hindermann, W., Al Mustafa, A. M., Reichelt, O., Junker, K., Schubert, J., The accuracy of 250 fine needle biopsies of renal tumors, J Urol, 2005. 174(1): p. 44-6., http://www.ncbi.nlm.nih.gov/pubmed/15947574
59. Menogue, S. R., O'Brien, B. A., Brown, A. L., Cohen, R. J., Percutaneous core biopsy of small renal mass lesions: a diagnostic tool to better stratify patients for surgical intervention, BJU Int, 2013. 111(4 Pt B): p. E146-51., http://www.ncbi.nlm.nih.gov/pubmed/22805186
60. Leveridge, M. J., Finelli, A., Kachura, J. R., Evans, A., Chung, H., Shiff, D. A., et.al. Outcomes of small renal mass needle core biopsy, nondiagnostic percutaneous biopsy, and the role of repeat biopsy, Eur Urol, 2011. 60(3): p. 578-84., http://www.ncbi.nlm.nih.gov/pubmed/21704449
61. Abel, E. J., Carrasco, A., Culp, S. H., Matin, S. F., Tamboli, P., Tannir, N. M., et.al. Limitations of preoperative biopsy in patients with metastatic renal cell carcinoma: comparison to surgical pathology in 405 cases, BJU Int, 2012. 110(11): p. 1742-6., http://www.ncbi.nlm.nih.gov/pubmed/22503066
62. Lang, E. K., Macchia, R. J., Gayle, B., Richter, F., Watson, R. A., Thomas, R., et.al. CT-guided biopsy of indeterminate renal cystic masses (Bosniak 3 and 2F): accuracy and impact on clinical management, Eur Radiol, 2002. 12(10): p. 2518-24., http://www.ncbi.nlm.nih.gov/pubmed/12271393
63. Harisinghani, M. G., Maher, M. M., Gervais, D. A., McGovern, F., Hahn, P., Jhaveri, K., et.al. Incidence of malignancy in complex cystic renal masses (Bosniak category III): should imaging-guided biopsy precede surgery?, AJR Am J Roentgenol, 2003. 180(3): p. 755-8., https://pubmed.ncbi.nlm.nih.gov/12591691/
64. Lechevallier, E., André, M., Barriol, D., Daniel, L., Eghazarian, C., De Fromont, M., et.al. Fine-needle percutaneous biopsy of renal masses with helical CT guidance, Radiology, 2000. 216(2): p. 506-10., https://pubmed.ncbi.nlm.nih.gov/10924578/
65. Tumoren, Landelijke Werkgroep Urologische, Renal cell carcinoma. Nation-wide guideline, Version: 2.0Integraal Kankercentrum Nederland (IKNL), 2010.
66. Srigley, J. R., Delahunt, B., Eble, J. N., Egevad, L., Epstein, J. I., Grignon, D., et.al. The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia, Am J Surg Pathol, 2013. 37(10): p. 1469-89., https://pubmed.ncbi.nlm.nih.gov/24025519/
67. Delahunt, B., Cheville, J. C., Martignoni, G., Humphrey, P. A., Magi-Galluzzi, C., McKenney, J., et.al. The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters, Am J Surg Pathol, 2013. 37(10): p. 1490-504., https://pubmed.ncbi.nlm.nih.gov/24025520/
68. Bechtold, R. E., Zagoria, R. J., Imaging approach to staging of renal cell carcinoma, Urol Clin North Am, 1997. 24(3): p. 507-22., http://www.ncbi.nlm.nih.gov/pubmed/9275976
69. Heidenreich, A., Ravery, V., European Society of Oncological, Urology, Preoperative imaging in renal cell cancer, World J Urol, 2004. 22(5): p. 307-15., http://www.ncbi.nlm.nih.gov/pubmed/15290202
70. Miles, K. A., London, N. J., Lavelle, J. M., Messios, N., Smart, J. G., CT staging of renal carcinoma: a prospective comparison of three dynamic computed tomography techniques, Eur J Radiol, 1991. 13(1): p. 37-42., http://www.ncbi.nlm.nih.gov/pubmed/1889427
71. Bamias, A., Tzannis, K., Beuselinck, B., Oudard, S., Escudier, B., Diosynopoulos, D., et.al. Development and validation of a prognostic model in patients with metastatic renal cell carcinoma treated with sunitinib: a European collaboration, Br J Cancer, 2013. 109(2): p. 332-41., http://www.ncbi.nlm.nih.gov/pubmed/23807171
72. Choueiri, T. K., Garcia, J. A., Elson, P., Khasawneh, M., Usman, S., Golshayan, A. R., et.al. Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy, Cancer, 2007. 110(3): p. 543-50., https://pubmed.ncbi.nlm.nih.gov/17577222/
73. Cindolo, L., Chiodini, P., Brookman-May, S., De Cobelli, O., May, M., Squillacciotti, S., et.al. Assessing the accuracy and generalizability of the preoperative and postoperative Karakiewicz nomograms for renal cell carcinoma: results from a multicentre European and US study, BJU Int, 2013. 112(5): p. 578-84., http://www.ncbi.nlm.nih.gov/pubmed/23470199
74. Cindolo, L., Chiodini, P., Gallo, C., Ficarra, V., Schips, L., Tostain, J., et.al. Validation by calibration of the UCLA integrated staging system prognostic model for nonmetastatic renal cell carcinoma after nephrectomy, Cancer, 2008. 113(1): p. 65-71., http://www.ncbi.nlm.nih.gov/pubmed/18473356
75. Cindolo, L., de la Taille, A., Messina, G., Romis, L., Abbou, C. C., Altieri, V., et.al. A preoperative clinical prognostic model for non-metastatic renal cell carcinoma, BJU Int, 2003. 92(9): p. 901-5., http://www.ncbi.nlm.nih.gov/pubmed/14632843
76. Cindolo, L., Patard, J. J., Chiodini, P., Schips, L., Ficarra, V., Tostain, J., et.al. Comparison of predictive accuracy of four prognostic models for nonmetastatic renal cell carcinoma after nephrectomy: a multicenter European study, Cancer, 2005. 104(7): p. 1362-71., http://www.ncbi.nlm.nih.gov/pubmed/16116599
77. Delahunt, B., Eble, J. N., Papillary renal cell carcinoma: a clinicopathologic and immunohistochemical study of 105 tumors, Mod Pathol, 1997. 10(6): p. 537-44., http://www.ncbi.nlm.nih.gov/pubmed/9195569
78. Karakiewicz, P. I., Briganti, A., Chun, F. K., Trinh, Q. D., Perrotte, P., Ficarra, V., et.al. Multi-institutional validation of a new renal cancer-specific survival nomogram, J Clin Oncol, 2007. 25(11): p. 1316-22., http://www.ncbi.nlm.nih.gov/pubmed/17416852
79. Karakiewicz, P. I., Suardi, N., Capitanio, U., Jeldres, C., Ficarra, V., Cindolo, L., et.al. A preoperative prognostic model for patients treated with nephrectomy for renal cell carcinoma, Eur Urol, 2009. 55(2): p. 287-95., http://www.ncbi.nlm.nih.gov/pubmed/18715700
80. Karakiewicz, P. I., Sun, M., Bellmunt, J., Sneller, V., Escudier, B., Prediction of progression-free survival rates after bevacizumab plus interferon versus interferon alone in patients with metastatic renal cell carcinoma: comparison of a nomogram to the Motzer criteria, Eur Urol, 2011. 60(1): p. 48-56., http://www.ncbi.nlm.nih.gov/pubmed/21190790
81. Kattan, M. W., Reuter, V., Motzer, R. J., Katz, J., Russo, P., A postoperative prognostic nomogram for renal cell carcinoma, J Urol, 2001. 166(1): p. 63-7., http://www.ncbi.nlm.nih.gov/pubmed/11435824
82. Klatte, T., Remzi, M., Zigeuner, R. E., Mannweiler, S., Said, J. W., Kabbinavar, F. F., et.al. Development and external validation of a nomogram predicting disease specific survival after nephrectomy for papillary renal cell carcinoma, J Urol, 2010. 184(1): p. 53-8., http://www.ncbi.nlm.nih.gov/pubmed/20478577
83. Lam, J. S., Shvarts, O., Leppert, J. T., Pantuck, A. J., Figlin, R. A., Belldegrun, A. S., Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system, J Urol, 2005. 174(2): p. 466-72; discussion 472; quiz 801., http://www.ncbi.nlm.nih.gov/pubmed/16006866
84. Leibovich, B. C., Blute, M. L., Cheville, J. C., Lohse, C. M., Frank, I., Kwon, E. D., et.al. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials, Cancer, 2003. 97(7): p. 1663-71., https://pubmed.ncbi.nlm.nih.gov/12655523/
85. Leibovich, B. C., Cheville, J. C., Lohse, C. M., Zincke, H., Frank, I., Kwon, E. D., et.al. A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials, J Urol, 2005. 174(5): p. 1759-63; discussion 1763., http://www.ncbi.nlm.nih.gov/pubmed/16217278
86. Leibovich, B. C., Han, K. R., Bui, M. H., Pantuck, A. J., Dorey, F. J., Figlin, R. A., et.al. Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials, Cancer, 2003. 98(12): p. 2566-75., http://www.ncbi.nlm.nih.gov/pubmed/14669275
87. Manola, J., Royston, P., Elson, P., McCormack, J. B., Mazumdar, M., Negrier, S., et.al. Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the international kidney cancer working group, Clin Cancer Res, 2011. 17(16): p. 5443-50., http://www.ncbi.nlm.nih.gov/pubmed/21828239
88. Mekhail, T. M., Abou-Jawde, R. M., Boumerhi, G., Malhi, S., Wood, L., Elson, P., et.al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma, J Clin Oncol, 2005. 23(4): p. 832-41., http://www.ncbi.nlm.nih.gov/pubmed/15681528
89. Motzer, R. J., Bacik, J., Murphy, B. A., Russo, P., Mazumdar, M., Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma, J Clin Oncol, 2002. 20(1): p. 289-96., https://pubmed.ncbi.nlm.nih.gov/11773181/
90. Motzer, R. J., Bacik, J., Schwartz, L. H., Reuter, V., Russo, P., Marion, S., et.al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma, J Clin Oncol, 2004. 22(3): p. 454-63., https://pubmed.ncbi.nlm.nih.gov/14752067/
91. Motzer, R. J., Mazumdar, M., Bacik, J., Berg, W., Amsterdam, A., Ferrara, J., Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma, J Clin Oncol, 1999. 17(8): p. 2530-40., http://www.ncbi.nlm.nih.gov/pubmed/10561319
92. Negrier, S., Escudier, B., Gomez, F., Douillard, J. Y., Ravaud, A., Chevreau, C., et.al. Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Francais d'Immunotherapie, Ann Oncol, 2002. 13(9): p. 1460-8., http://www.ncbi.nlm.nih.gov/pubmed/12196373
93. Patard, J. J., Kim, H. L., Lam, J. S., Dorey, F. J., Pantuck, A. J., Zisman, A., et.al. Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study, J Clin Oncol, 2004. 22(16): p. 3316-22., https://pubmed.ncbi.nlm.nih.gov/15310775/
94. Patil, S., Figlin, R. A., Hutson, T. E., Michaelson, M. D., Negrier, S., Kim, S. T., et.al. Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma, Ann Oncol, 2011. 22(2): p. 295-300., http://www.ncbi.nlm.nih.gov/pubmed/20657034
95. Pichler, M., Hutterer, G. C., Chromecki, T. F., Jesche, J., Kampel-Kettner, K., Rehak, P., et.al. External validation of the Leibovich prognosis score for nonmetastatic clear cell renal cell carcinoma at a single European center applying routine pathology, J Urol, 2011. 186(5): p. 1773-7., https://pubmed.ncbi.nlm.nih.gov/21944989/
96. Pichler, M., Hutterer, G. C., Stoeckigt, C., Chromecki, T. F., Stojakovic, T., Golbeck, S., et.al. Validation of the pre-treatment neutrophil-lymphocyte ratio as a prognostic factor in a large European cohort of renal cell carcinoma patients, Br J Cancer, 2013. 108(4): p. 901-7., https://pubmed.ncbi.nlm.nih.gov/23385728/
97. Tan, M. H., Li, H., Choong, C. V., Chia, K. S., Toh, C. K., Tang, T., et.al. The Karakiewicz nomogram is the most useful clinical predictor for survival outcomes in patients with localized renal cell carcinoma, Cancer, 2011. 117(23): p. 5314-24., https://pubmed.ncbi.nlm.nih.gov/21567386/
98. Veeratterapillay, R., Rakhra, S., El-Sherif, A., Johnson, M., Soomro, N., Heer, R., Can the Kattan nomogram still accurately predict prognosis in renal cell carcinoma using the revised 2010 tumor-nodes-metastasis reclassification?, Int J Urol, 2012. 19(8): p. 773-6., https://pubmed.ncbi.nlm.nih.gov/22487261/
99. Yaycioglu, O., Roberts, W. W., Chan, T., Epstein, J. I., Marshall, F. F., Kavoussi, L. R., Prognostic assessment of nonmetastatic renal cell carcinoma: a clinically based model, Urology, 2001. 58(2): p. 141-5., http://www.ncbi.nlm.nih.gov/pubmed/11489682
100. Zigeuner, R., Hutterer, G., Chromecki, T., Imamovic, A., Kampel-Kettner, K., Rehak, P., et.al. External validation of the Mayo Clinic stage, size, grade, and necrosis (SSIGN) score for clear-cell renal cell carcinoma in a single European centre applying routine pathology, Eur Urol, 2010. 57(1): p. 102-9., http://www.ncbi.nlm.nih.gov/pubmed/19062157
101. Zisman, A., Pantuck, A. J., Dorey, F., Said, J. W., Shvarts, O., Quintana, D., et.al. Improved prognostication of renal cell carcinoma using an integrated staging system, J Clin Oncol, 2001. 19(6): p. 1649-57., https://pubmed.ncbi.nlm.nih.gov/11250993/
102. Zisman, A., Pantuck, A. J., Figlin, R. A., Belldegrun, A. S., Validation of the ucla integrated staging system for patients with renal cell carcinoma, J Clin Oncol, 2001. 19(17): p. 3792-3., https://pubmed.ncbi.nlm.nih.gov/11533107/
103. Zisman, A., Pantuck, A. J., Wieder, J., Chao, D. H., Dorey, F., Said, J. W., et.al. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma, J Clin Oncol, 2002. 20(23): p. 4559-66., http://www.ncbi.nlm.nih.gov/pubmed/12454113
104. Han, K. R., Bleumer, I., Pantuck, A. J., Kim, H. L., Dorey, F. J., Janzen, N. K., et.al. Validation of an integrated staging system toward improved prognostication of patients with localized renal cell carcinoma in an international population, J Urol, 2003. 170(6 Pt 1): p. 2221-4., http://www.ncbi.nlm.nih.gov/pubmed/14634383
105. Heng, D. Y., Xie, W., Regan, M. M., Harshman, L. C., Bjarnason, G. A., Vaishampayan, U. N., et.al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study, Lancet Oncol, 2013. 14(2): p. 141-8., http://www.ncbi.nlm.nih.gov/pubmed/23312463
106. Heng, D. Y., Xie, W., Regan, M. M., Warren, M. A., Golshayan, A. R., Sahi, C., et.al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study, J Clin Oncol, 2009. 27(34): p. 5794-9., https://pubmed.ncbi.nlm.nih.gov/19826129/
107. Hupertan, V., Roupret, M., Poisson, J. F., Chretien, Y., Dufour, B., Thiounn, N., et.al. Low predictive accuracy of the Kattan postoperative nomogram for renal cell carcinoma recurrence in a population of French patients, Cancer, 2006. 107(11): p. 2604-8., http://www.ncbi.nlm.nih.gov/pubmed/17075871
108. Hutterer, G. C., Patard, J. J., Jeldres, C., Perrotte, P., de La Taille, A., Salomon, L., et.al. Patients with distant metastases from renal cell carcinoma can be accurately identified: external validation of a new nomogram, BJU Int, 2008. 101(1): p. 39-43., https://pubmed.ncbi.nlm.nih.gov/17908261/
109. Hutterer, G. C., Patard, J. J., Perrotte, P., Ionescu, C., de La Taille, A., Salomon, L., et.al. Patients with renal cell carcinoma nodal metastases can be accurately identified: external validation of a new nomogram, Int J Cancer, 2007. 121(11): p. 2556-61., https://pubmed.ncbi.nlm.nih.gov/17691107/
110. Ficarra, V., Novara, G., Galfano, A., Brunelli, M., Cavalleri, S., Martignoni, G., et.al. The 'Stage, Size, Grade and Necrosis' score is more accurate than the University of California Los Angeles Integrated Staging System for predicting cancer-specific survival in patients with clear cell renal cell carcinoma, BJU Int, 2009. 103(2): p. 165-70., https://pubmed.ncbi.nlm.nih.gov/18782313/
111. Frank, I., Blute, M. L., Cheville, J. C., Lohse, C. M., Weaver, A. L., Zincke, H., An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score, J Urol, 2002. 168(6): p. 2395-400., http://www.ncbi.nlm.nih.gov/pubmed/12441925
112. Escudier, BJ, Ravaud, A, Negrier, S, Szczylik, C, Bellmunt, J, Bracarda, S, Update on AVOREN trial in metastatic renal cell carcinoma (mRCC): efficacy and safety in subgroups of patients (pts) and pharmacokinetic (PK) analysis, J Clin Oncol, 2008. 26(Suppl): p. Abstr 5025., https://doi.org/10.1200/jco.2008.26.15_suppl.5025
113. Pichler, M., Hutterer, G. C., Chromecki, T. F., Jesche, J., Kampel-Kettner, K., Groselj-Strele, A., et.al. Predictive ability of the 2002 and 2010 versions of the Tumour-Node-Metastasis classification system regarding metastasis-free, cancer-specific and overall survival in a European renal cell carcinoma single-centre series, BJU Int, 2013. 111(4 Pt B): p. E191-5., http://www.ncbi.nlm.nih.gov/pubmed/23107473
114. Harrell, F. E., Jr., Califf, R. M., Pryor, D. B., Lee, K. L., Rosati, R. A., Evaluating the yield of medical tests, JAMA, 1982. 247(18): p. 2543-6., http://www.ncbi.nlm.nih.gov/pubmed/7069920
115. Hanley, J. A., McNeil, B. J., The meaning and use of the area under a receiver operating characteristic (ROC) curve, Radiology, 1982. 143(1): p. 29-36., https://pubmed.ncbi.nlm.nih.gov/7063747/
116. Sorbellini, M., Kattan, M. W., Snyder, M. E., Reuter, V., Motzer, R., Goetzl, M., et.al. A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma, J Urol, 2005. 173(1): p. 48-51., http://www.ncbi.nlm.nih.gov/pubmed/15592023
117. Diagnostic and prognostic molecular markers for renal cell carcinoma: a critical appraisal of the current state of research and clinical applicability, 2009.
118. Tan, P. H., Cheng, L., Rioux-Leclercq, N., Merino, M. J., Netto, G., Reuter, V. E., et.al. Renal tumors: diagnostic and prognostic biomarkers, Am J Surg Pathol, 2013. 37(10): p. 1518-31., http://www.ncbi.nlm.nih.gov/pubmed/24025522
119. Hu, Q., Gou, Y., Sun, C., Ding, W., Xu, K., Gu, B., et.al. The prognostic value of C-reactive protein in renal cell carcinoma: a systematic review and meta-analysis, Urol Oncol, 2014. 32(1): p. 50.e1-8., http://www.ncbi.nlm.nih.gov/pubmed/24239465
120. Junker, K., Ficarra, V., Kwon, E. D., Leibovich, B. C., Thompson, R. H., Oosterwijk, E., Potential role of genetic markers in the management of kidney cancer, Eur Urol, 2013. 63(2): p. 333-40., http://www.ncbi.nlm.nih.gov/pubmed/23040205
121. Finley, D. S., Pantuck, A. J., Belldegrun, A. S., Tumor biology and prognostic factors in renal cell carcinoma, Oncologist, 2011. 16 Suppl 2: p. 4-13., http://www.ncbi.nlm.nih.gov/pubmed/21346035
122. Klatte, T., Seligson, D. B., LaRochelle, J., Shuch, B., Said, J. W., Riggs, S. B., et.al. Molecular signatures of localized clear cell renal cell carcinoma to predict disease-free survival after nephrectomy, Cancer Epidemiol Biomarkers Prev, 2009. 18(3): p. 894-900., https://pubmed.ncbi.nlm.nih.gov/19240241/
123. Parker, A. S., Leibovich, B. C., Lohse, C. M., Sheinin, Y., Kuntz, S. M., Eckel-Passow, J. E., et.al. Development and evaluation of BioScore: a biomarker panel to enhance prognostic algorithms for clear cell renal cell carcinoma, Cancer, 2009. 115(10): p. 2092-103., https://pubmed.ncbi.nlm.nih.gov/19296514/
124. Sun, M., Shariat, S. F., Cheng, C., Ficarra, V., Murai, M., Oudard, S., et.al. Prognostic factors and predictive models in renal cell carcinoma: a contemporary review, Eur Urol, 2011. 60(4): p. 644-61., https://pubmed.ncbi.nlm.nih.gov/21741163/
125. Cancer Genome Atlas Research, Network, Comprehensive molecular characterization of clear cell renal cell carcinoma, Nature, 2013. 499(7456): p. 43-9., http://www.ncbi.nlm.nih.gov/pubmed/23792563
126. Sato, Y., Yoshizato, T., Shiraishi, Y., Maekawa, S., Okuno, Y., Kamura, T., et.al. Integrated molecular analysis of clear-cell renal cell carcinoma, Nat Genet, 2013. 45(8): p. 860-7., http://www.ncbi.nlm.nih.gov/pubmed/23797736
127. Brooks, S. A., Brannon, A. R., Parker, J. S., Fisher, J. C., Sen, O., Kattan, M. W., et.al. ClearCode34: A prognostic risk predictor for localized clear cell renal cell carcinoma, Eur Urol, 2014. 66(1): p. 77-84., http://www.ncbi.nlm.nih.gov/pubmed/24613583
128. Davis, C. F., Ricketts, C. J., Wang, M., Yang, L., Cherniack, A. D., Shen, H., et.al. The somatic genomic landscape of chromophobe renal cell carcinoma, Cancer Cell, 2014. 26(3): p. 319-30., http://www.ncbi.nlm.nih.gov/pubmed/25155756
129. Novick, AC, Campbell, SC, Belldegrun, A, Blute, ML, Chow, GK, Derweesh, IH, et.al. Guideline for management of the clinical stage 1 renal mass, 2009. p. 1-76., https://pubmed.ncbi.nlm.nih.gov/19683266/
130. Smaldone, M. C., Kutikov, A., Egleston, B. L., Canter, D. J., Viterbo, R., Chen, D. Y., et.al. Small renal masses progressing to metastases under active surveillance: a systematic review and pooled analysis, Cancer, 2012. 118(4): p. 997-1006., http://www.ncbi.nlm.nih.gov/pubmed/21766302
131. Chawla, S. N., Crispen, P. L., Hanlon, A. L., Greenberg, R. E., Chen, D. Y., Uzzo, R. G., The natural history of observed enhancing renal masses: meta-analysis and review of the world literature, J Urol, 2006. 175(2): p. 425-31., http://www.ncbi.nlm.nih.gov/pubmed/16406965
132. Kunkle, D. A., Egleston, B. L., Uzzo, R. G., Excise, ablate or observe: the small renal mass dilemma--a meta-analysis and review, J Urol, 2008. 179(4): p. 1227-33; discussion 1233-4., http://www.ncbi.nlm.nih.gov/pubmed/18280512
133. Lane, B. R., Abouassaly, R., Gao, T., Weight, C. J., Hernandez, A. V., Larson, B. T., et.al. Active treatment of localized renal tumors may not impact overall survival in patients aged 75 years or older, Cancer, 2010. 116(13): p. 3119-26., http://www.ncbi.nlm.nih.gov/pubmed/20564627
134. Jewett, M. A., Mattar, K., Basiuk, J., Morash, C. G., Pautler, S. E., Siemens, D. R., et.al. Active surveillance of small renal masses: progression patterns of early stage kidney cancer, Eur Urol, 2011. 60(1): p. 39-44., http://www.ncbi.nlm.nih.gov/pubmed/21477920
135. Lane, B. R., Tobert, C. M., Riedinger, C. B., Growth kinetics and active surveillance for small renal masses, Curr Opin Urol, 2012. 22(5): p. 353-9., http://www.ncbi.nlm.nih.gov/pubmed/22706068
136. Thompson, R. H., Hill, J. R., Babayev, Y., Cronin, A., Kaag, M., Kundu, S., et.al. Metastatic renal cell carcinoma risk according to tumor size, J Urol, 2009. 182(1): p. 41-5., http://www.ncbi.nlm.nih.gov/pubmed/19450840
137. Pierorazio, P. M., Hyams, E. S., Mullins, J. K., Allaf, M. E., Active surveillance for small renal masses, Rev Urol, 2012. 14(1-2): p. 13-9., http://www.ncbi.nlm.nih.gov/pubmed/23172995
138. MacLennan, S., Imamura, M., Lapitan, M. C., Omar, M. I., Lam, T. B., Hilvano-Cabungcal, A. M., et.al. Systematic review of oncological outcomes following surgical management of localised renal cancer, Eur Urol, 2012. 61(5): p. 972-93., https://pubmed.ncbi.nlm.nih.gov/22405593/
139. Siva, S., Pham, D., Gill, S., Corcoran, N. M., Foroudi, F., A systematic review of stereotactic radiotherapy ablation for primary renal cell carcinoma, BJU Int, 2012. 110(11 Pt B): p. E737-43., http://www.ncbi.nlm.nih.gov/pubmed/23107102
140. El Dib, R., Touma, N. J., Kapoor, A., Cryoablation vs radiofrequency ablation for the treatment of renal cell carcinoma: a meta-analysis of case series studies, BJU Int, 2012. 110(4): p. 510-6., https://pubmed.ncbi.nlm.nih.gov/22304329/
141. Van Poppel, H., Joniau, S., Is surveillance an option for the treatment of small renal masses?, Eur Urol, 2007. 52(5): p. 1323-30., https://pubmed.ncbi.nlm.nih.gov/17669584/
142. Desai, Mihir M., Aron, Monish, Gill, Inderbir S., Laparoscopic partial nephrectomy versus laparoscopic cryoablation for the small renal tumor, Urology, 2005. 66(5): p. 23-28., http://dx.doi.org/10.1016/j.urology.2005.06.114
143. Whitson, J. M., Harris, C. R., Meng, M. V., Population-based comparative effectiveness of nephron-sparing surgery vs ablation for small renal masses, BJU Int, 2012. 110(10): p. 1438-43; discussion 1443., https://pubmed.ncbi.nlm.nih.gov/22639860/
144. Ljungberg, B, Bensalah, K, Bex, A, Canfield, S, Dabestani, S, Hofmann, F, et.al. Guidelines on renal cell carcinoma.European Association of Urology (EAU), 2013.
145. MacLennan, S., Imamura, M., Lapitan, M. C., Omar, M. I., Lam, T. B., Hilvano-Cabungcal, A. M., et.al. Systematic review of perioperative and quality-of-life outcomes following surgical management of localised renal cancer, Eur Urol, 2012. 62(6): p. 1097-117., http://www.ncbi.nlm.nih.gov/pubmed/22841673
146. Xia, L, Wang, X, Xu, T, Guzzo, TJ, Systematic Review and Meta-Analysis of Comparative Studies Reporting Perioperative Outcomes of Robot-Assisted Partial Nephrectomy Versus Open Partial Nephrectomy., J Endourol, 2017. 31 (9)(9): p. 893-909., https://pubmed.ncbi.nlm.nih.gov/27305835/
147. Cacciamani, GE, Gill, T, Medina, L, Ashrafi, A, Winter, M, Sotelo, R, et.al. Impact of Host Factors on Robotic Partial Nephrectomy Outcomes: Comprehensive Systematic Review and Meta-Analysis., J Urol, 2018. 200 (4)(4): p. 716-730., https://pubmed.ncbi.nlm.nih.gov/29730203/
148. Grivas, N, Kalampokis, N, Larcher, A, Tyritzis, S, Rha, KH, Ficarra, V, et.al. Robot-assisted versus open partial nephrectomy: comparison of outcomes. A systematic review., Minerva Urol Nefrol, 2019. 71 (2)(2): p. 113-120., https://pubmed.ncbi.nlm.nih.gov/30895768/
149. Tsai, SH, Tseng, PT, Sherer, BA, Lai, YC, Lin, PY, Wu, CK, et.al. Open versus robotic partial nephrectomy: Systematic review and meta-analysis of contemporary studies., Int J Med Robot, 2019. 15 (1)(1): p. e1963., https://pubmed.ncbi.nlm.nih.gov/30265760/
150. Hemal, A. K., Kumar, A., Kumar, R., Wadhwa, P., Seth, A., Gupta, N. P., Laparoscopic versus open radical nephrectomy for large renal tumors: a long-term prospective comparison, J Urol, 2007. 177(3): p. 862-6., http://www.ncbi.nlm.nih.gov/pubmed/17296361
151. Tait, C., Tandon, S., Baker, L., Goodman, C., Townell, N., Nabi, G., Long-term oncologic outcomes of laparoscopic radical nephrectomy for kidney cancer resection: Dundee cohort and metaanalysis of observational studies, Surg Endosc, 2011. 25(10): p. 3154-61., http://www.ncbi.nlm.nih.gov/pubmed/21594741
152. Bragayrac, LA, Abbotoy, D, Attwood, K, Darwiche, F, Hoffmeyer, J, Kauffman, EC, et.al. Outcomes of Minimal Invasive vs Open Radical Nephrectomy for the Treatment of Locally Advanced Renal-Cell Carcinoma., J Endourol, 2016. 30 (8)(8): p. 871-6., https://pubmed.ncbi.nlm.nih.gov/27203682/
153. Golombos, DM, Chughtai, B, Trinh, QD, Mao, J, Te, A, O'Malley, P, et.al. Adoption of Technology and Its Impact on Nephrectomy Outcomes, a U.S. Population-Based Analysis (2008-2012)., J Endourol, 2017. 31 (1)(1): p. 91-99., https://pubmed.ncbi.nlm.nih.gov/27809567/
154. Golombos, DM, Chughtai, B, Trinh, QD, Thomas, D, Mao, J, Te, A, et.al. Minimally invasive vs open nephrectomy in the modern era: does approach matter?, World J Urol, 2017. 35 (10)(10): p. 1557-1568., https://pubmed.ncbi.nlm.nih.gov/28477204/
155. Khan, MMA, Patel, RA, Jain, N, Balakrishnan, A, Venkataraman, M, Prospective analysis of laparoscopic versus open radical nephrectomy for renal tumours more than 7 cm., J Minim Access Surg 15 (1)(1): p. 14-18., https://pubmed.ncbi.nlm.nih.gov/29582796/
156. Lee, H, Lee, CU, Yoo, JH, Sung, HH, Jeong, BC, Jeon, SS, et.al. Comparisons of oncological outcomes and perioperative complications between laparoscopic and open radical nephrectomies in patients with clinical T2 renal cell carcinoma (≥7cm)., PLoS One, 2018. 13 (1)(1): p. e0191786., https://pubmed.ncbi.nlm.nih.gov/29364958/
157. Jeong, IG, Khandwala, YS, Kim, JH, Han, DH, Li, S, Wang, Y, et.al. Association of Robotic-Assisted vs Laparoscopic Radical Nephrectomy With Perioperative Outcomes and Health Care Costs, 2003 to 2015., JAMA, 2017. 318 (16)(16): p. 1561-1568., https://pubmed.ncbi.nlm.nih.gov/29067427/
158. Anele, UA, Marchioni, M, Yang, B, Simone, G, Uzzo, RG, Lau, C, et.al. Robotic versus laparoscopic radical nephrectomy: a large multi-institutional analysis (ROSULA Collaborative Group)., World J Urol, 2019. 37 (11)(11): p. 2439-2450., https://pubmed.ncbi.nlm.nih.gov/30734072/
159. Robson, C. J., Churchill, B. M., Anderson, W., The results of radical nephrectomy for renal cell carcinoma, J Urol, 1969. 101(3): p. 297-301., http://www.ncbi.nlm.nih.gov/pubmed/5765875
160. MacLennan, S, Imamura, M, Lapitan, MC, Omar, MI, Lam, TB, Hilvano-Cabungcal, AM, et.al. Systematic review of perioperative and quality-of-life outcomes following surgical management of localised renal cancer., Eur Urol, 2012. 62 (6)(6): p. 1097-117., https://pubmed.ncbi.nlm.nih.gov/22841673/
161. Peng, B, Zheng, JH, Xu, DF, Ren, JZ, Retroperitoneal laparoscopic nephrectomy and open nephrectomy for radical treatment of renal cell carcinoma: A comparison of clinical outcomes., Academic Journal of Second Military Medical University, 2006. 27: p. 1167 - 1169.
162. Gratzke, C., Seitz, M., Bayrle, F., Schlenker, B., Bastian, P. J., Haseke, N., et.al. Quality of life and perioperative outcomes after retroperitoneoscopic radical nephrectomy (RN), open RN and nephron-sparing surgery in patients with renal cell carcinoma, BJU Int, 2009. 104(4): p. 470-5., http://www.ncbi.nlm.nih.gov/pubmed/19239445
163. Desai, M. M., Strzempkowski, B., Matin, S. F., Steinberg, A. P., Ng, C., Meraney, A. M., et.al. Prospective randomized comparison of transperitoneal versus retroperitoneal laparoscopic radical nephrectomy, J Urol, 2005. 173(1): p. 38-41., http://www.ncbi.nlm.nih.gov/pubmed/15592021
164. Nambirajan, T., Jeschke, S., Al-Zahrani, H., Vrabec, G., Leeb, K., Janetschek, G., Prospective, randomized controlled study: transperitoneal laparoscopic versus retroperitoneoscopic radical nephrectomy, Urology, 2004. 64(5): p. 919-24., http://www.ncbi.nlm.nih.gov/pubmed/15533478
165. Nadler, R. B., Loeb, S., Clemens, J. Q., Batler, R. A., Gonzalez, C. M., Vardi, I. Y., A prospective study of laparoscopic radical nephrectomy for T1 tumors--is transperitoneal, retroperitoneal or hand assisted the best approach?, J Urol, 2006. 175(4): p. 1230-3; discussion 1234., http://www.ncbi.nlm.nih.gov/pubmed/16515966
166. Fan, X., Xu, K., Lin, T., Liu, H., Yin, Z., Dong, W., et.al. Comparison of transperitoneal and retroperitoneal laparoscopic nephrectomy for renal cell carcinoma: a systematic review and meta-analysis, BJU Int, 2013. 111(4): p. 611-21., https://pubmed.ncbi.nlm.nih.gov/23106964/
167. Hemal, A. K., Kumar, A., A prospective comparison of laparoscopic and robotic radical nephrectomy for T1-2N0M0 renal cell carcinoma, World J Urol, 2009. 27(1): p. 89-94., http://www.ncbi.nlm.nih.gov/pubmed/18704439
168. Anele, U. A., Marchioni, M., Yang, B., Simone, G., Uzzo, R. G., Lau, C., et.al. Robotic versus laparoscopic radical nephrectomy: a large multi-institutional analysis (ROSULA Collaborative Group), World J Urol, 2019., https://pubmed.ncbi.nlm.nih.gov/30734072/
169. Grivas, N., Kalampokis, N., Larcher, A., Tyritzis, S., Rha, K. H., Ficarra, V., et.al. Robot-assisted versus open partial nephrectomy: comparison of outcomes. A systematic review, Minerva urologica e nefrologica = The Italian journal of urology and nephrology., 2019. 18:, ot-assisted, versus, open, partial, nephrectomy:, comparison, of, outcomes., A, systematic, review., Minerva, urologica, e, nefrologic
170. Shen, Z., Xie, L., Xie, W., Hu, H., Chen, T., Xing, C., et.al. The comparison of perioperative outcomes of robot-assisted and open partial nephrectomy: a systematic review and meta-analysis, World Journal of Surgical Oncology, 2016. 14(1): p. 220., https://pubmed.ncbi.nlm.nih.gov/27549155/
171. Vartolomei, M. D., Foerster, B., Kimura, S., Autorino, R., Shariat, S. F., Seitz, C., Oncologic outcomes after minimally invasive surgery for cT1 renal masses: a comprehensive review, Current Opinion in Urology, 2018. 28(2): p. 132-138., https://pubmed.ncbi.nlm.nih.gov/29278581/
172. Perez-Ardavin, J., Sanchez-Gonzalez, J. V., Martinez-Sarmiento, M., Monserrat-Monfort, J. J., Garcia-Olaverri, J., Boronat-Tormo, F., et.al. Surgical Treatment of Completely Endophytic Renal Tumor: a Systematic Review, Current Urology Reports, 2019. 20(1): p. 3., https://pubmed.ncbi.nlm.nih.gov/30649644/
173. Bhayani, S. B., Rha, K. H., Pinto, P. A., Ong, A. M., Allaf, M. E., Trock, B. J., et.al. Laparoscopic partial nephrectomy: effect of warm ischemia on serum creatinine, J Urol, 2004. 172(4 Pt 1): p. 1264-6., http://www.ncbi.nlm.nih.gov/pubmed/15371820
174. Khalifeh, A., Autorino, R., Hillyer, S. P., Laydner, H., Eyraud, R., Panumatrassamee, K., et.al. Comparative outcomes and assessment of trifecta in 500 robotic and laparoscopic partial nephrectomy cases: a single surgeon experience, J Urol, 2013. 189(4): p. 1236-42., https://pubmed.ncbi.nlm.nih.gov/23079376/
175. Kopp, R. P., Mehrazin, R., Palazzi, K., Bazzi, W. M., Patterson, A. L., Derweesh, I. H., Factors affecting renal function after open partial nephrectomy-a comparison of clampless and clamped warm ischemic technique, Urology, 2012. 80(4): p. 865-70., http://www.ncbi.nlm.nih.gov/pubmed/22951008
176. Krane, L. S., Mufarrij, P. W., Manny, T. B., Hemal, A. K., Comparison of clamping technique in robotic partial nephrectomy: does unclamped partial nephrectomy improve perioperative outcomes and renal function?, Can J Urol, 2013. 20(1): p. 6662-7., https://pubmed.ncbi.nlm.nih.gov/23433142/
177. Lane, B. R., Novick, A. C., Babineau, D., Fergany, A. F., Kaouk, J. H., Gill, I. S., Comparison of laparoscopic and open partial nephrectomy for tumor in a solitary kidney, J Urol, 2008. 179(3): p. 847-51; discussion 852., http://www.ncbi.nlm.nih.gov/pubmed/18221958
178. Lee, S., Oh, J., Hong, S. K., Lee, S. E., Byun, S. S., Open versus robot-assisted partial nephrectomy: effect on clinical outcome, J Endourol, 2011. 25(7): p. 1181-5., http://www.ncbi.nlm.nih.gov/pubmed/21657825
179. Novick, A. C., Renal hypothermia: in vivo and ex vivo, Urol Clin North Am, 1983. 10(4): p. 637-44., http://www.ncbi.nlm.nih.gov/pubmed/6356550
180. Raman, J. D., Raj, G. V., Lucas, S. M., Williams, S. K., Lauer, E. M., Ahrar, K., et.al. Renal functional outcomes for tumours in a solitary kidney managed by ablative or extirpative techniques, BJU Int, 2010. 105(4): p. 496-500., http://www.ncbi.nlm.nih.gov/pubmed/19681900
181. Shao, P., Qin, C., Yin, C., Meng, X., Ju, X., Li, J., et.al. Laparoscopic partial nephrectomy with segmental renal artery clamping: technique and clinical outcomes, Eur Urol, 2011. 59(5): p. 849-55., http://www.ncbi.nlm.nih.gov/pubmed/21146917
182. Wang, L., Li, M., Chen, W., Wu, Z., Cai, C., Xiang, C., et.al. Is diameter-axial-polar scoring predictive of renal functional damage in patients undergoing partial nephrectomy? An evaluation using technetium Tc 99m ((9)(9)Tcm) diethylene-triamine-penta-acetic acid (DTPA) glomerular filtration rate, BJU Int, 2013. 111(8): p. 1191-8., https://pubmed.ncbi.nlm.nih.gov/23651467/
183. Hillyer, S. P., Autorino, R., Laydner, H., Yang, B., Altunrende, F., White, M., et.al. Robotic versus laparoscopic partial nephrectomy for bilateral synchronous kidney tumors: single-institution comparative analysis, Urology, 2011. 78(4): p. 808-12., http://www.ncbi.nlm.nih.gov/pubmed/21855967
184. Hillyer, S. P., Bhayani, S. B., Allaf, M. E., Rogers, C. G., Stifelman, M. D., Tanagho, Y., et.al. Robotic partial nephrectomy for solitary kidney: a multi-institutional analysis, Urology, 2013. 81(1): p. 93-7., http://www.ncbi.nlm.nih.gov/pubmed/23153935
185. Kane, C. J., Mitchell, J. A., Meng, M. V., Anast, J., Carroll, P. R., Stoller, M. L., Laparoscopic partial nephrectomy with temporary arterial occlusion: description of technique and renal functional outcomes, Urology, 2004. 63(2): p. 241-6., http://www.ncbi.nlm.nih.gov/pubmed/14972462
186. Funahashi, Y., Hattori, R., Yamamoto, T., Sassa, N., Fujita, T., Gotoh, M., Effect of warm ischemia on renal function during partial nephrectomy: assessment with new 99mTc-mercaptoacetyltriglycine scintigraphy parameter, Urology, 2012. 79(1): p. 160-4., http://www.ncbi.nlm.nih.gov/pubmed/22070892
187. Thompson, R. H., Lane, B. R., Lohse, C. M., Leibovich, B. C., Fergany, A., Frank, I., et.al. Every minute counts when the renal hilum is clamped during partial nephrectomy, Eur Urol, 2010. 58(3): p. 340-5., https://pubmed.ncbi.nlm.nih.gov/20825756/
188. Campbell, S. C., A nonischemic approach to partial nephrectomy is optimal. No, J Urol, 2012. 187(2): p. 388-90., https://pubmed.ncbi.nlm.nih.gov/22338124/
189. Simmons, M. N., Lieser, G. C., Fergany, A. F., Kaouk, J., Campbell, S. C., Association between warm ischemia time and renal parenchymal atrophy after partial nephrectomy, J Urol, 2013. 189(5): p. 1638-42., https://pubmed.ncbi.nlm.nih.gov/23159462/
190. Kim, S. P., Thompson, R. H., Kidney function after partial nephrectomy: current thinking, Curr Opin Urol, 2013. 23(2): p. 105-11., http://www.ncbi.nlm.nih.gov/pubmed/23321635
191. Ward, J. P., Determination of the Optimum temperature for regional renal hypothermia during temporary renal ischaemia, Br J Urol, 1975. 47(1): p. 17-24., http://www.ncbi.nlm.nih.gov/pubmed/236801
192. Fandella, A., Pernetti, R., Marchiori, D., Bertaccini, A., The effects of renal ischemia on kidney function in renal cancer conservative surgery, Arch Ital Urol Androl, 2006. 78(3): p. 117-22., http://www.ncbi.nlm.nih.gov/pubmed/17137028
193. Steffens, J., Humke, U., Ziegler, M., Siemer, S., Partial nephrectomy with perfusion cooling for imperative indications: a 24-year experience, BJU Int, 2005. 96(4): p. 608-11., http://www.ncbi.nlm.nih.gov/pubmed/16104919
194. Gill, I. S., Eisenberg, M. S., Aron, M., Berger, A., Ukimura, O., Patil, M. B., et.al. "Zero ischemia" partial nephrectomy: novel laparoscopic and robotic technique, Eur Urol, 2011. 59(1): p. 128-34., https://pubmed.ncbi.nlm.nih.gov/20971550/
195. Wilson, D. H., Barton, B. B., Parry, W. L., Hinshaw, L. B., Effects of intermittent versus continuous renal arterial occlusion on hemodynamics and function of the kidney, Invest Urol, 1971. 8(5): p. 507-15., http://www.ncbi.nlm.nih.gov/pubmed/5556481
196. Borofsky, M. S., Gill, I. S., Hemal, A. K., Marien, T. P., Jayaratna, I., Krane, L. S., et.al. Near-infrared fluorescence imaging to facilitate super-selective arterial clamping during zero-ischaemia robotic partial nephrectomy, BJU Int, 2013. 111(4): p. 604-10., http://www.ncbi.nlm.nih.gov/pubmed/23253629
197. George, A. K., Herati, A. S., Srinivasan, A. K., Rais-Bahrami, S., Waingankar, N., Sadek, M. A., et.al. Perioperative outcomes of off-clamp vs complete hilar control laparoscopic partial nephrectomy, BJU Int, 2013. 111(4 Pt B): p. E235-41., http://www.ncbi.nlm.nih.gov/pubmed/23130741
198. Thompson, R. H., Lane, B. R., Lohse, C. M., Leibovich, B. C., Fergany, A., Frank, I., et.al. Comparison of warm ischemia versus no ischemia during partial nephrectomy on a solitary kidney, Eur Urol, 2010. 58(3): p. 331-6., http://www.ncbi.nlm.nih.gov/pubmed/20557996
199. Rais-Bahrami, S., George, A. K., Herati, A. S., Srinivasan, A. K., Richstone, L., Kavoussi, L. R., Off-clamp versus complete hilar control laparoscopic partial nephrectomy: comparison by clinical stage, BJU Int, 2012. 109(9): p. 1376-81., http://www.ncbi.nlm.nih.gov/pubmed/21992566
200. Vricella, G. J., Murray, S., Boncher, N. A., Madi, R., External validation of a model for tailoring the operative approach to minimally invasive partial nephrectomy, BJU Int, 2011. 107(11): p. 1806-10., http://www.ncbi.nlm.nih.gov/pubmed/21040363
201. O'Malley, R. L., Berger, A. D., Kanofsky, J. A., Phillips, C. K., Stifelman, M., Taneja, S. S., A matched-cohort comparison of laparoscopic cryoablation and laparoscopic partial nephrectomy for treating renal masses, BJU Int, 2007. 99(2): p. 395-8., http://www.ncbi.nlm.nih.gov/pubmed/17092288
202. Lane, B. R., Russo, P., Uzzo, R. G., Hernandez, A. V., Boorjian, S. A., Thompson, R. H., et.al. Comparison of cold and warm ischemia during partial nephrectomy in 660 solitary kidneys reveals predominant role of nonmodifiable factors in determining ultimate renal function, J Urol, 2011. 185(2): p. 421-7., http://www.ncbi.nlm.nih.gov/pubmed/21167524
203. Marszalek, M., Meixl, H., Polajnar, M., Rauchenwald, M., Jeschke, K., Madersbacher, S., Laparoscopic and open partial nephrectomy: a matched-pair comparison of 200 patients, Eur Urol, 2009. 55(5): p. 1171-8., http://www.ncbi.nlm.nih.gov/pubmed/19232819
204. Shikanov, S., Lifshitz, D., Chan, A. A., Okhunov, Z., Ordonez, M. A., Wheat, J. C., et.al. Impact of ischemia on renal function after laparoscopic partial nephrectomy: a multicenter study, J Urol, 2010. 183(5): p. 1714-8., http://www.ncbi.nlm.nih.gov/pubmed/20299052
205. Thompson, R. H., Frank, I., Lohse, C. M., Saad, I. R., Fergany, A., Zincke, H., et.al. The impact of ischemia time during open nephron sparing surgery on solitary kidneys: a multi-institutional study, J Urol, 2007. 177(2): p. 471-6., http://www.ncbi.nlm.nih.gov/pubmed/17222613
206. Shen, H. L., Chueh, S. C., Lai, M. K., Wu, C. H., Huang, C. C., Tsang, Y. M., et.al. Balloon occlusion and hypothermic perfusion of the renal artery in laparoscopic partial nephectomy, Int J Urol, 2008. 15(11): p. 967-70., http://www.ncbi.nlm.nih.gov/pubmed/18775030
207. Long, J. A., Yakoubi, R., Lee, B., Guillotreau, J., Autorino, R., Laydner, H., et.al. Robotic versus laparoscopic partial nephrectomy for complex tumors: comparison of perioperative outcomes, Eur Urol, 2012. 61(6): p. 1257-62., http://www.ncbi.nlm.nih.gov/pubmed/22464543
208. Lifshitz, D. A., Shikanov, S. A., Deklaj, T., Katz, M. H., Zorn, K. C., Eggener, S. E., et.al. Laparoscopic partial nephrectomy: a single-center evolving experience, Urology, 2010. 75(2): p. 282-7., http://www.ncbi.nlm.nih.gov/pubmed/19962732
209. Choi, J. D., Park, J. W., Lee, H. W., Lee, D. G., Jeong, B. C., Jeon, S. S., et.al. A comparison of surgical and functional outcomes of robot-assisted versus pure laparoscopic partial nephrectomy, JSLS, 2013. 17(2): p. 292-9., http://www.ncbi.nlm.nih.gov/pubmed/23925024
210. Berg, W. T., Rich, C. R., Badalato, G. M., Deibert, C. M., Wambi, C. O., Landman, J., et.al. The first assistant sparing technique robot-assisted partial nephrectomy decreases warm ischemia time while maintaining good perioperative outcomes, J Endourol, 2012. 26(11): p. 1448-53., https://pubmed.ncbi.nlm.nih.gov/22691152/
211. Ching, C. B., Li, J., Gill, I. S., Simmons, M. N., Functional and oncologic outcomes of bilateral open partial nephrectomy versus bilateral laparoscopic partial nephrectomy, J Endourol, 2011. 25(7): p. 1193-7., http://www.ncbi.nlm.nih.gov/pubmed/21671758
212. Blom, J. H., van Poppel, H., Marechal, J. M., Jacqmin, D., Schroder, F. H., de Prijck, L., et.al. Radical nephrectomy with and without lymph-node dissection: final results of European Organization for Research and Treatment of Cancer (EORTC) randomized phase 3 trial 30881, Eur Urol, 2009. 55(1): p. 28-34., https://pubmed.ncbi.nlm.nih.gov/18848382/
213. Bekema, H. J., MacLennan, S., Imamura, M., Lam, T. B., Stewart, F., Scott, N., et.al. Systematic review of adrenalectomy and lymph node dissection in locally advanced renal cell carcinoma, Eur Urol, 2013. 64(5): p. 799-810., http://www.ncbi.nlm.nih.gov/pubmed/23643550
214. Bensalah, K., Pantuck, A. J., Rioux-Leclercq, N., Thuret, R., Montorsi, F., Karakiewicz, P. I., et.al. Positive surgical margin appears to have negligible impact on survival of renal cell carcinomas treated by nephron-sparing surgery, Eur Urol, 2010. 57(3): p. 466-71., https://pubmed.ncbi.nlm.nih.gov/19359089/
215. Bernhard, J. C., Pantuck, A. J., Wallerand, H., Crepel, M., Ferriere, J. M., Bellec, L., et.al. Predictive factors for ipsilateral recurrence after nephron-sparing surgery in renal cell carcinoma, Eur Urol, 2010. 57(6): p. 1080-6., http://www.ncbi.nlm.nih.gov/pubmed/20188458
216. Kwon, E. O., Carver, B. S., Snyder, M. E., Russo, P., Impact of positive surgical margins in patients undergoing partial nephrectomy for renal cortical tumours, BJU Int, 2007. 99(2): p. 286-9., http://www.ncbi.nlm.nih.gov/pubmed/17155985
217. Marszalek, M., Carini, M., Chlosta, P., Jeschke, K., Kirkali, Z., Knuchel, R., et.al. Positive surgical margins after nephron-sparing surgery, Eur Urol, 2012. 61(4): p. 757-63., http://www.ncbi.nlm.nih.gov/pubmed/22136987
218. Peycelon, M., Hupertan, V., Comperat, E., Renard-Penna, R., Vaessen, C., Conort, P., et.al. Long-term outcomes after nephron sparing surgery for renal cell carcinoma larger than 4 cm, J Urol, 2009. 181(1): p. 35-41., https://pubmed.ncbi.nlm.nih.gov/19012929/
219. Permpongkosol, S., Colombo, J. R., Jr., Gill, I. S., Kavoussi, L. R., Positive surgical parenchymal margin after laparoscopic partial nephrectomy for renal cell carcinoma: oncological outcomes, J Urol, 2006. 176(6 Pt 1): p. 2401-4., http://www.ncbi.nlm.nih.gov/pubmed/17085113
220. Yossepowitch, O., Thompson, R. H., Leibovich, B. C., Eggener, S. E., Pettus, J. A., Kwon, E. D., et.al. Positive surgical margins at partial nephrectomy: predictors and oncological outcomes, J Urol, 2008. 179(6): p. 2158-63., https://pubmed.ncbi.nlm.nih.gov/18423758/
221. Khalifeh, A., Kaouk, J. H., Bhayani, S., Rogers, C., Stifelman, M., Tanagho, Y. S., et.al. Positive surgical margins in robot-assisted partial nephrectomy: a multi-institutional analysis of oncologic outcomes (leave no tumor behind), J Urol, 2013. 190(5): p. 1674-9., https://pubmed.ncbi.nlm.nih.gov/23764077/
222. Ray, E. R., Turney, B. W., Singh, R., Chandra, A., Cranston, D. W., O'Brien, T. S., Open partial nephrectomy: outcomes from two UK centres, BJU Int, 2006. 97(6): p. 1211-5., http://www.ncbi.nlm.nih.gov/pubmed/16686713
223. Raz, O., Mendlovic, S., Shilo, Y., Leibovici, D., Sandbank, J., Lindner, A., et.al. Positive surgical margins with renal cell carcinoma have a limited influence on long-term oncological outcomes of nephron sparing surgery, Urology, 2010. 75(2): p. 277-80., https://pubmed.ncbi.nlm.nih.gov/19896179/
224. Sundaram, V., Figenshau, R. S., Roytman, T. M., Kibel, A. S., Grubb, R. L., 3rd, Bullock, A., et.al. Positive margin during partial nephrectomy: does cancer remain in the renal remnant?, Urology, 2011. 77(6): p. 1400-3., https://pubmed.ncbi.nlm.nih.gov/21411126/
225. Palermo, S. M., Dechet, C., Trenti, E., Mian, C., Lodde, M., Comploj, E., et.al. Cytology as an alternative to frozen section at the time of nephron-sparing surgery to evaluate surgical margin status, Urology, 2013. 82(5): p. 1071-5., https://pubmed.ncbi.nlm.nih.gov/24044918/
226. Sterious, S. N., Simhan, J., Smaldone, M. C., Tsai, K. J., Canter, D., Wameedh, E., et.al. Is there a benefit to frozen section analysis at the time of partial nephrectomy?, Can J Urol, 2013. 20(3): p. 6778-84., https://pubmed.ncbi.nlm.nih.gov/23783047/
227. Timsit, M. O., Bazin, J. P., Thiounn, N., Fontaine, E., Chretien, Y., Dufour, B., et.al. Prospective study of safety margins in partial nephrectomy: intraoperative assessment and contribution of frozen section analysis, Urology, 2006. 67(5): p. 923-6., http://www.ncbi.nlm.nih.gov/pubmed/16635521
228. Venigalla, S., Wu, G., Miyamoto, H., The impact of frozen section analysis during partial nephrectomy on surgical margin status and tumor recurrence: a clinicopathologic study of 433 cases, Clin Genitourin Cancer, 2013. 11(4): p. 527-36., http://www.ncbi.nlm.nih.gov/pubmed/23871293
229. Hagemann, I. S., Lewis, J. S., Jr., A retrospective comparison of 2 methods of intraoperative margin evaluation during partial nephrectomy, J Urol, 2009. 181(2): p. 500-5., http://www.ncbi.nlm.nih.gov/pubmed/19084870
230. Hillyer, S. P., Yakoubi, R., Autorino, R., Isac, W., Miocinovic, R., Laydner, H., et.al. Utility of intraoperative frozen section during robot-assisted partial nephrectomy: a single institution experience, J Endourol, 2013. 27(3): p. 324-7., https://pubmed.ncbi.nlm.nih.gov/22963602/
231. Ljungberg, B., Cowan, N. C., Hanbury, D. C., Hora, M., Kuczyk, M. A., Merseburger, A. S., et.al. EAU guidelines on renal cell carcinoma: the 2010 update, Eur Urol, 2010. 58(3): p. 398-406., http://www.ncbi.nlm.nih.gov/pubmed/20633979
232. Campbell, S. C., Novick, A. C., Belldegrun, A., Blute, M. L., Chow, G. K., Derweesh, I. H., et.al. Guideline for management of the clinical T1 renal mass, J Urol, 2009. 182(4): p. 1271-9., https://pubmed.ncbi.nlm.nih.gov/19683266/
233. Minervini, A., Serni, S., Tuccio, A., Siena, G., Vittori, G., Masieri, L., et.al. Simple enucleation versus radical nephrectomy in the treatment of pT1a and pT1b renal cell carcinoma, Ann Surg Oncol, 2012. 19(2): p. 694-700., http://www.ncbi.nlm.nih.gov/pubmed/21861225
234. Coffin, G., Hupertan, V., Taksin, L., Vaessen, C., Chartier-Kastler, E., Bitker, M. O., et.al. Impact of elective versus imperative indications on oncologic outcomes after open nephron-sparing surgery for the treatment of sporadic renal cell carcinomas, Ann Surg Oncol, 2011. 18(4): p. 1151-7., http://www.ncbi.nlm.nih.gov/pubmed/21136181
235. Hansen, J., Sun, M., Bianchi, M., Rink, M., Tian, Z., Hanna, N., et.al. Assessment of cancer control outcomes in patients with high-risk renal cell carcinoma treated with partial nephrectomy, Urology, 2012. 80(2): p. 347-53., http://www.ncbi.nlm.nih.gov/pubmed/22698478
236. Becker, F., Roos, F. C., Janssen, M., Brenner, W., Hampel, C., Siemer, S., et.al. Short-term functional and oncologic outcomes of nephron-sparing surgery for renal tumours >/= 7 cm, Eur Urol, 2011. 59(6): p. 931-7., http://www.ncbi.nlm.nih.gov/pubmed/21371812
237. Huang, W. C., Levey, A. S., Serio, A. M., Snyder, M., Vickers, A. J., Raj, G. V., et.al. Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study, Lancet Oncol, 2006. 7(9): p. 735-40., http://www.ncbi.nlm.nih.gov/pubmed/16945768
238. Klarenbach, S., Moore, R. B., Chapman, D. W., Dong, J., Braam, B., Adverse renal outcomes in subjects undergoing nephrectomy for renal tumors: a population-based analysis, Eur Urol, 2011. 59(3): p. 333-9., http://www.ncbi.nlm.nih.gov/pubmed/21109345
239. Scosyrev, E., Messing, E. M., Sylvester, R., Campbell, S., Van Poppel, H., Renal function after nephron-sparing surgery versus radical nephrectomy: results from EORTC randomized trial 30904, Eur Urol, 2014. 65(2): p. 372-7., http://www.ncbi.nlm.nih.gov/pubmed/23850254
240. Huang, W. C., Elkin, E. B., Levey, A. S., Jang, T. L., Russo, P., Partial nephrectomy versus radical nephrectomy in patients with small renal tumors--is there a difference in mortality and cardiovascular outcomes?, J Urol, 2009. 181(1): p. 55-61; discussion 61-2., https://pubmed.ncbi.nlm.nih.gov/19012918/
241. Thompson, R. H., Boorjian, S. A., Lohse, C. M., Leibovich, B. C., Kwon, E. D., Cheville, J. C., et.al. Radical nephrectomy for pT1a renal masses may be associated with decreased overall survival compared with partial nephrectomy, J Urol, 2008. 179(2): p. 468-71; discussion 472-3., https://pubmed.ncbi.nlm.nih.gov/20825756/
242. Weight, C. J., Lieser, G., Larson, B. T., Gao, T., Lane, B. R., Campbell, S. C., et.al. Partial nephrectomy is associated with improved overall survival compared to radical nephrectomy in patients with unanticipated benign renal tumours, Eur Urol, 2010. 58(2): p. 293-8., https://pubmed.ncbi.nlm.nih.gov/20546991/
243. Van Poppel, H., Becker, F., Cadeddu, J. A., Gill, I. S., Janetschek, G., Jewett, M. A., et.al. Treatment of localised renal cell carcinoma, Eur Urol, 2011. 60(4): p. 662-72., https://pubmed.ncbi.nlm.nih.gov/21726933/
244. Van Poppel, H., Da Pozzo, L., Albrecht, W., Matveev, V., Bono, A., Borkowski, A., et.al. A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma, Eur Urol, 2011. 59(4): p. 543-52., http://www.ncbi.nlm.nih.gov/pubmed/21186077
245. Minervini, A., di Cristofano, C., Lapini, A., Marchi, M., Lanzi, F., Giubilei, G., et.al. Histopathologic analysis of peritumoral pseudocapsule and surgical margin status after tumor enucleation for renal cell carcinoma, Eur Urol, 2009. 55(6): p. 1410-8., http://www.ncbi.nlm.nih.gov/pubmed/18692300
246. Minervini, A., Serni, S., Tuccio, A., Raspollini, M. R., Di Cristofano, C., Siena, G., et.al. Local recurrence after tumour enucleation for renal cell carcinoma with no ablation of the tumour bed: results of a prospective single-centre study, BJU Int, 2011. 107(9): p. 1394-9., https://pubmed.ncbi.nlm.nih.gov/21166766/
247. Carini, M., Minervini, A., Lapini, A., Masieri, L., Serni, S., Simple enucleation for the treatment of renal cell carcinoma between 4 and 7 cm in greatest dimension: progression and long-term survival, J Urol, 2006. 175(6): p. 2022-6; discussion 2026., https://pubmed.ncbi.nlm.nih.gov/16697790/
248. Carini, M., Minervini, A., Masieri, L., Lapini, A., Serni, S., Simple enucleation for the treatment of PT1a renal cell carcinoma: our 20-year experience, Eur Urol, 2006. 50(6): p. 1263-8; discussion 1269-71., https://pubmed.ncbi.nlm.nih.gov/16787695/
249. Van Poppel, H., Da Pozzo, L., Albrecht, W., Matveev, V., Bono, A., Borkowski, A., et.al. A prospective randomized EORTC intergroup phase 3 study comparing the complications of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma, Eur Urol, 2007. 51(6): p. 1606-15., http://www.ncbi.nlm.nih.gov/pubmed/17140723
250. Schnoeller, T. J., de Petriconi, R., Hefty, R., Jentzmik, F., Waalkes, S., Zengerling, F., et.al. Partial nephrectomy using porcine small intestinal submucosa, World J Surg Oncol, 2011. 9: p. 126., https://pubmed.ncbi.nlm.nih.gov/21992771/
251. Sutherland, S. E., Resnick, M. I., Maclennan, G. T., Goldman, H. B., Does the size of the surgical margin in partial nephrectomy for renal cell cancer really matter?, J Urol, 2002. 167(1): p. 61-4., https://pubmed.ncbi.nlm.nih.gov/11743276/
252. Castilla, E. A., Liou, L. S., Abrahams, N. A., Fergany, A., Rybicki, L. A., Myles, J., et.al. Prognostic importance of resection margin width after nephron-sparing surgery for renal cell carcinoma, Urology, 2002. 60(6): p. 993-7., http://www.ncbi.nlm.nih.gov/pubmed/12475656
253. Gill, I. S., Kavoussi, L. R., Lane, B. R., Blute, M. L., Babineau, D., Colombo, J. R., Jr., et.al. Comparison of 1,800 laparoscopic and open partial nephrectomies for single renal tumors, J Urol, 2007. 178(1): p. 41-6., http://www.ncbi.nlm.nih.gov/pubmed/17574056
254. Gong, E. M., Orvieto, M. A., Zorn, K. C., Lucioni, A., Steinberg, G. D., Shalhav, A. L., Comparison of laparoscopic and open partial nephrectomy in clinical T1a renal tumors, J Endourol, 2008. 22(5): p. 953-7., http://www.ncbi.nlm.nih.gov/pubmed/18363510
255. Patard, J. J., Pantuck, A. J., Crepel, M., Lam, J. S., Bellec, L., Albouy, B., et.al. Morbidity and clinical outcome of nephron-sparing surgery in relation to tumour size and indication, Eur Urol, 2007. 52(1): p. 148-54., http://www.ncbi.nlm.nih.gov/pubmed/17240036
256. Zigeuner, R., Quehenberger, F., Pummer, K., Petritsch, P., Hubmer, G., Long-term results of nephron-sparing surgery for renal cell carcinoma in 114 patients: risk factors for progressive disease, BJU Int, 2003. 92(6): p. 567-71., http://www.ncbi.nlm.nih.gov/pubmed/14511035
257. Duvdevani, M., Renal artery occlusion during nephron-sparing surgery: retrospective review of 301 cases, 2006., http://www.ncbi.nlm.nih.gov/pubmed/17113887
258. Duvdevani, M., Is frozen section analysis in nephron sparing surgery necessary? A clinicopathological study of 301 cases, 2005., https://pubmed.ncbi.nlm.nih.gov/15643176/
259. Gill, I. S., Matin, S. F., Desai, M. M., Kaouk, J. H., Steinberg, A., Mascha, E., et.al. Comparative analysis of laparoscopic versus open partial nephrectomy for renal tumors in 200 patients, J Urol, 2003. 170(1): p. 64-8., http://www.ncbi.nlm.nih.gov/pubmed/12796646
260. Porpiglia, F., Fiori, C., Terrone, C., Bollito, E., Fontana, D., Scarpa, R. M., Assessment of surgical margins in renal cell carcinoma after nephron sparing: a comparative study: laparoscopy vs open surgery, J Urol, 2005. 173(4): p. 1098-101., http://www.ncbi.nlm.nih.gov/pubmed/15758709
261. Link, R. E., Bhayani, S. B., Allaf, M. E., Varkarakis, I., Inagaki, T., Rogers, C., et.al. Exploring the learning curve, pathological outcomes and perioperative morbidity of laparoscopic partial nephrectomy performed for renal mass, J Urol, 2005. 173(5): p. 1690-4., http://www.ncbi.nlm.nih.gov/pubmed/15821559
262. Porpiglia, F., Fiori, C., Bertolo, R., Scarpa, R. M., Does tumour size really affect the safety of laparoscopic partial nephrectomy?, BJU Int, 2011. 108(2): p. 268-73., https://pubmed.ncbi.nlm.nih.gov/21044241/
263. Breda, A., Stepanian, S. V., Liao, J., Lam, J. S., Guazzoni, G., Stifelman, M., et.al. Positive margins in laparoscopic partial nephrectomy in 855 cases: a multi-institutional survey from the United States and Europe, J Urol, 2007. 178(1): p. 47-50; discussion 50., http://www.ncbi.nlm.nih.gov/pubmed/17574057
264. Frank, I., Colombo, J. R., Jr., Rubinstein, M., Desai, M., Kaouk, J., Gill, I. S., Laparoscopic partial nephrectomy for centrally located renal tumors, J Urol, 2006. 175(3 Pt 1): p. 849-52., http://www.ncbi.nlm.nih.gov/pubmed/16469563
265. Venkatesh, R., Weld, K., Ames, C. D., Figenshau, S. R., Sundaram, C. P., Andriole, G. L., et.al. Laparoscopic partial nephrectomy for renal masses: effect of tumor location, Urology, 2006. 67(6): p. 1169-74; discussion 1174., http://www.ncbi.nlm.nih.gov/pubmed/16765174
266. Scoll, B. J., Uzzo, R. G., Chen, D. Y., Boorjian, S. A., Kutikov, A., Manley, B. J., et.al. Robot-assisted partial nephrectomy: a large single-institutional experience, Urology, 2010. 75(6): p. 1328-34., http://www.ncbi.nlm.nih.gov/pubmed/20080290
267. Benway, B. M., Bhayani, S. B., Rogers, C. G., Dulabon, L. M., Patel, M. N., Lipkin, M., et.al. Robot assisted partial nephrectomy versus laparoscopic partial nephrectomy for renal tumors: a multi-institutional analysis of perioperative outcomes, J Urol, 2009. 182(3): p. 866-72., http://www.ncbi.nlm.nih.gov/pubmed/19616229
268. Benway, B. M., Bhayani, S. B., Rogers, C. G., Porter, J. R., Buffi, N. M., Figenshau, R. S., et.al. Robot-assisted partial nephrectomy: an international experience, Eur Urol, 2010. 57(5): p. 815-20., http://www.ncbi.nlm.nih.gov/pubmed/20116163
269. Mellon, M. J., Lucas, S. M., Kum, J. B., Cheng, L., Sundaram, C., A comparison of pathologic outcomes of matched robotic and open partial nephrectomies, Int Urol Nephrol, 2013. 45(2): p. 381-5., http://www.ncbi.nlm.nih.gov/pubmed/23386247
270. Verze, P, Fusco, F, Minervini, A, Antonelli, A, Bianchi, G, Bocciardi, A, et.al. Simple enucleation versus standard partial nephrectomy for clinical T1 renal tumors: Intraoperative, early post-operative and pathological outcomes from a prospective multicenter comparative study (RECORd Project), European Urology Supplements, 2013. 12(1): p. e172.
271. Minervini, A., Ficarra, V., Rocco, F., Antonelli, A., Bertini, R., Carmignani, G., et.al. Simple enucleation is equivalent to traditional partial nephrectomy for renal cell carcinoma: results of a nonrandomized, retrospective, comparative study, J Urol, 2011. 185(5): p. 1604-10., https://pubmed.ncbi.nlm.nih.gov/21419454/
272. Saranchuk, J. W., Touijer, A. K., Hakimian, P., Snyder, M. E., Russo, P., Partial nephrectomy for patients with a solitary kidney: the Memorial Sloan-Kettering experience, BJU Int, 2004. 94(9): p. 1323-8., http://www.ncbi.nlm.nih.gov/pubmed/15610114
273. Lee, D. J., Hruby, G., Benson, M. C., McKiernan, J. M., Renal function and oncologic outcomes in nephron sparing surgery for renal masses in solitary kidneys, World J Urol, 2011. 29(3): p. 343-8., http://www.ncbi.nlm.nih.gov/pubmed/20623290
274. Wszolek, M. F., Kenney, P. A., Lee, Y., Libertino, J. A., Comparison of hilar clamping and non-hilar clamping partial nephrectomy for tumours involving a solitary kidney, BJU Int, 2011. 107(12): p. 1886-92., http://www.ncbi.nlm.nih.gov/pubmed/21070570
275. Ani, I., Finelli, A., Alibhai, S. M., Timilshina, N., Fleshner, N., Abouassaly, R., Prevalence and impact on survival of positive surgical margins in partial nephrectomy for renal cell carcinoma: a population-based study, BJU Int, 2013. 111(8): p. E300-5., http://www.ncbi.nlm.nih.gov/pubmed/23305148
276. Cheville, J. C., Lohse, C. M., Zincke, H., Weaver, A. L., Blute, M. L., Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma, Am J Surg Pathol, 2003. 27(5): p. 612-24., https://pubmed.ncbi.nlm.nih.gov/12717246/
277. Mancilla-Jimenez, R., Stanley, R. J., Blath, R. A., Papillary renal cell carcinoma: a clinical, radiologic, and pathologic study of 34 cases, Cancer, 1976. 38(6): p. 2469-80., http://www.ncbi.nlm.nih.gov/pubmed/1000477
278. Amin, M. B., Amin, M. B., Tamboli, P., Javidan, J., Stricker, H., de-Peralta Venturina, M., et.al. Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: an experience of 405 cases, Am J Surg Pathol, 2002. 26(3): p. 281-91., http://www.ncbi.nlm.nih.gov/pubmed/11859199
279. Patard, J. J., Leray, E., Rioux-Leclercq, N., Cindolo, L., Ficarra, V., Zisman, A., et.al. Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience, J Clin Oncol, 2005. 23(12): p. 2763-71., http://www.ncbi.nlm.nih.gov/pubmed/15837991
280. Gudbjartsson, T., Hardarson, S., Petursdottir, V., Thoroddsen, A., Magnusson, J., Einarsson, G. V., Histological subtyping and nuclear grading of renal cell carcinoma and their implications for survival: a retrospective nation-wide study of 629 patients, Eur Urol, 2005. 48(4): p. 593-600., https://pubmed.ncbi.nlm.nih.gov/15964127/
281. Margulis, V., Tamboli, P., Matin, S. F., Swanson, D. A., Wood, C. G., Analysis of clinicopathologic predictors of oncologic outcome provides insight into the natural history of surgically managed papillary renal cell carcinoma, Cancer, 2008. 112(7): p. 1480-8., http://www.ncbi.nlm.nih.gov/pubmed/18240184
282. Schrader, A. J., Rauer-Bruening, S., Olbert, P. J., Hegele, A., Rustemeier, J., Timmesfeld, N., et.al. Incidence and long-term prognosis of papillary renal cell carcinoma, J Cancer Res Clin Oncol, 2009. 135(6): p. 799-805., http://www.ncbi.nlm.nih.gov/pubmed/19023595
283. Steffens, S., Janssen, M., Roos, F. C., Becker, F., Schumacher, S., Seidel, C., et.al. Incidence and long-term prognosis of papillary compared to clear cell renal cell carcinoma--a multicentre study, Eur J Cancer, 2012. 48(15): p. 2347-52., http://www.ncbi.nlm.nih.gov/pubmed/22698386
284. Motzer, R. J., Bacik, J., Mariani, T., Russo, P., Mazumdar, M., Reuter, V., Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology, J Clin Oncol, 2002. 20(9): p. 2376-81., http://www.ncbi.nlm.nih.gov/pubmed/11981011
285. Herrmann, E., Brinkmann, O. A., Bode, M. E., Bierer, S., Kopke, T., Bogemann, M., et.al. Histologic subtype of metastatic renal cell carcinoma predicts response to combined immunochemotherapy with interleukin 2, interferon alpha and 5-fluorouracil, Eur Urol, 2007. 51(6): p. 1625-31; discussion 1631-2., http://www.ncbi.nlm.nih.gov/pubmed/17113215
286. Schrader, A. J., Olbert, P. J., Hegele, A., Varga, Z., Hofmann, R., Metastatic non-clear cell renal cell carcinoma: current therapeutic options, BJU Int, 2008. 101(11): p. 1343-5., http://www.ncbi.nlm.nih.gov/pubmed/18241246
287. Amato, R. J., Chemotherapy for renal cell carcinoma, Semin Oncol, 2000. 27(2): p. 177-86., http://www.ncbi.nlm.nih.gov/pubmed/10768596
288. Buti, S., Bersanelli, M., Sikokis, A., Maines, F., Facchinetti, F., Bria, E., et.al. Chemotherapy in metastatic renal cell carcinoma today? A systematic review, Anticancer Drugs, 2013. 24(6): p. 535-54., http://www.ncbi.nlm.nih.gov/pubmed/23552469
289. Motzer, R. J., Mazumdar, M., Bacik, J., Russo, P., Berg, W. J., Metz, E. M., Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma, J Clin Oncol, 2000. 18(9): p. 1928-35., http://www.ncbi.nlm.nih.gov/pubmed/10784634
290. Atzpodien, J., Buer, J., Sel, S., Janssen, J., Oevermann, K., [Chemoimmunotherapy in the systemic treatment of advanced renal carcinoma], Urologe A, 1999. 38(5): p. 474-8., http://www.ncbi.nlm.nih.gov/pubmed/10501706
291. Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Rixe, O., et.al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma, N Engl J Med, 2007. 356(2): p. 115-24., https://www.ncbi.nlm.nih.gov/pubmed/17215529
292. Rini, B. I., Halabi, S., Rosenberg, J. E., Stadler, W. M., Vaena, D. A., Ou, S. S., et.al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206, J Clin Oncol, 2008. 26(33): p. 5422-8., https://pubmed.ncbi.nlm.nih.gov/18936475/
293. Hudes, G., Carducci, M., Tomczak, P., Dutcher, J., Figlin, R., Kapoor, A., et.al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma, N Engl J Med, 2007. 356(22): p. 2271-81., https://pubmed.ncbi.nlm.nih.gov/17538086/
294. Escudier, B., Pluzanska, A., Koralewski, P., Ravaud, A., Bracarda, S., Szczylik, C., et.al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial, Lancet, 2007. 370(9605): p. 2103-11., http://www.ncbi.nlm.nih.gov/pubmed/18156031
295. Coppin, C., Porzsolt, F., Awa, A., Kumpf, J., Coldman, A., Wilt, T., Immunotherapy for advanced renal cell cancer, Cochrane Database Syst Rev, 2005. p. CD001425., http://www.ncbi.nlm.nih.gov/pubmed/15674877
296. Whelan, Peter, The medical treatment of metastatic renal cell cancer, EAU Update Series, 2003. 1(4): p. 237-246., http://dx.doi.org/10.1016/S1570-9124(03)00060-6
297. Yang, J. C., Sherry, R. M., Steinberg, S. M., Topalian, S. L., Schwartzentruber, D. J., Hwu, P., et.al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer, J Clin Oncol, 2003. 21(16): p. 3127-32., http://www.ncbi.nlm.nih.gov/pubmed/12915604
298. Minasian, L. M., Motzer, R. J., Gluck, L., Mazumdar, M., Vlamis, V., Krown, S. E., Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up, J Clin Oncol, 1993. 11(7): p. 1368-75., http://www.ncbi.nlm.nih.gov/pubmed/8315435
299. Law, T. M., Motzer, R. J., Mazumdar, M., Sell, K. W., Walther, P. J., O'Connell, M., et.al. Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma, Cancer, 1995. 76(5): p. 824-32., https://pubmed.ncbi.nlm.nih.gov/8625186/
300. Motzer, R. J., Russo, P., Systemic therapy for renal cell carcinoma, J Urol, 2000. 163(2): p. 408-17., http://www.ncbi.nlm.nih.gov/pubmed/10647643
301. Atzpodien, J., Kirchner, H., Jonas, U., Bergmann, L., Schott, H., Heynemann, H., et.al. Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN), J Clin Oncol, 2004. 22(7): p. 1188-94., http://www.ncbi.nlm.nih.gov/pubmed/14981107
302. Heidenreich, A., Schrader, A. J., Varga, Z., Basic science and research in renal cell carcinoma: from workbench to bedside, Curr Opin Urol, 2003. 13(6): p. 457-62., http://www.ncbi.nlm.nih.gov/pubmed/14560138
303. Huland, E., Heinzer, H., Jorres, R. A., Loppow, D., Huland, H., Therapeutic approaches in metastatic renal cell carcinoma: local immunotherapy, Urologe A, 2004. 43 Suppl 3: p. S140-4., http://www.ncbi.nlm.nih.gov/pubmed/15179553
304. Huland, E., Heinzer, H., Timm, S., Alamian, M., Huland, H., [Immunotherapy of metastatic renal cell carcinoma in Germany. An assessment of the current status], Urologe A, 2002. 41(3): p. 282-7., http://www.ncbi.nlm.nih.gov/pubmed/12132280
305. McDermott, D. F., Regan, M. M., Clark, J. I., Flaherty, L. E., Weiss, G. R., Logan, T. F., et.al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma, J Clin Oncol, 2005. 23(1): p. 133-41., http://www.ncbi.nlm.nih.gov/pubmed/15625368
306. Flanigan, R. C., Salmon, S. E., Blumenstein, B. A., Bearman, S. I., Roy, V., McGrath, P. C., et.al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer, N Engl J Med, 2001. 345(23): p. 1655-9., http://www.ncbi.nlm.nih.gov/pubmed/11759643
307. Mickisch, G. H., Garin, A., van Poppel, H., de Prijck, L., Sylvester, R., European Organisation for, Research, et.al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial, Lancet, 2001. 358(9286): p. 966-70., http://www.ncbi.nlm.nih.gov/pubmed/11583750
308. Gore, M. E., Griffin, C. L., Hancock, B., Patel, P. M., Pyle, L., Aitchison, M., et.al. Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial, Lancet, 2010. 375(9715): p. 641-8., http://www.ncbi.nlm.nih.gov/pubmed/20153039
309. Atzpodien, J., Kirchner, H., Duensing, S., Lopez Hanninen, E., Franzke, A., Buer, J., et.al. Biochemotherapy of advanced metastatic renal-cell carcinoma: results of the combination of interleukin-2, alpha-interferon, 5-fluorouracil, vinblastine, and 13-cis-retinoic acid, World J Urol, 1995. 13(3): p. 174-7., http://www.ncbi.nlm.nih.gov/pubmed/7550391
310. Lopez Hanninen, E., Kirchner, H., Atzpodien, J., Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients, J Urol, 1996. 155(1): p. 19-25., http://www.ncbi.nlm.nih.gov/pubmed/7490829
311. Hofmockel, G., Langer, W., Theiss, M., Gruss, A., Frohmuller, H. G., Immunochemotherapy for metastatic renal cell carcinoma using a regimen of interleukin-2, interferon-alpha and 5-fluorouracil, J Urol, 1996. 156(1): p. 18-21., https://pubmed.ncbi.nlm.nih.gov/8648791/
312. Joffe, J. K., Banks, R. E., Forbes, M. A., Hallam, S., Jenkins, A., Patel, P. M., et.al. A phase II study of interferon-alpha, interleukin-2 and 5-fluorouracil in advanced renal carcinoma: clinical data and laboratory evidence of protease activation, Br J Urol, 1996. 77(5): p. 638-49., http://www.ncbi.nlm.nih.gov/pubmed/8689103
313. Ellerhorst, J. A., Sella, A., Amato, R. J., Tu, S. M., Millikan, R. E., Finn, L. D., et.al. Phase II trial of 5-fluorouracil, interferon-alpha and continuous infusion interleukin-2 for patients with metastatic renal cell carcinoma, Cancer, 1997. 80(11): p. 2128-32., http://www.ncbi.nlm.nih.gov/pubmed/9392335
314. Tourani, J. M., Pfister, C., Berdah, J. F., Benhammouda, A., Salze, P., Monnier, A., et.al. Outpatient treatment with subcutaneous interleukin-2 and interferon alfa administration in combination with fluorouracil in patients with metastatic renal cell carcinoma: results of a sequential nonrandomized phase II study. Subcutaneous Administration Propeukin Program Cooperative Group, J Clin Oncol, 1998. 16(7): p. 2505-13., http://www.ncbi.nlm.nih.gov/pubmed/9667271
315. Ravaud, A., Audhuy, B., Gomez, F., Escudier, B., Lesimple, T., Chevreau, C., et.al. Subcutaneous interleukin-2, interferon alfa-2a, and continuous infusion of fluorouracil in metastatic renal cell carcinoma: a multicenter phase II trial. Groupe Francais d'Immunotherapie, J Clin Oncol, 1998. 16(8): p. 2728-32., http://www.ncbi.nlm.nih.gov/pubmed/9704724
316. Elias, L., Binder, M., Mangalik, A., Clark, D., Morrison, B., Altobelli, K. K., et.al. Pilot trial of infusional 5-fluorouracil, interleukin-2, and subcutaneous interferon-alpha for advanced renal cell carcinoma, Am J Clin Oncol, 1999. 22(2): p. 156-61., http://www.ncbi.nlm.nih.gov/pubmed/10199450
317. Samland, D., Steinbach, F., Reiher, F., Schmidt, U., Gruss, A., Allhoff, E. P., Results of immunochemotherapy with interleukin-2, interferon-alpha2 and 5-fluorouracil in the treatment of metastatic renal cell cancer, Eur Urol, 1999. 35(3): p. 204-9., http://www.ncbi.nlm.nih.gov/pubmed/10072621
318. Dutcher, J.P, Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study, 2000., http://www.ncbi.nlm.nih.gov/pubmed/10999727
319. van Herpen, C. M., Jansen, R. L., Kruit, W. H., Hoekman, K., Groenewegen, G., Osanto, S., et.al. Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Dutch Immunotherapy Working Party, Br J Cancer, 2000. 82(4): p. 772-6., http://www.ncbi.nlm.nih.gov/pubmed/10732744
320. Atzpodien, J., Kirchner, H., Illiger, H. J., Metzner, B., Ukena, D., Schott, H., et.al. IL-2 in combination with IFN- alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial, Br J Cancer, 2001. 85(8): p. 1130-6., http://www.ncbi.nlm.nih.gov/pubmed/11710825
321. Olencki, T., Peereboom, D., Wood, L., Budd, G. T., Novick, A., Finke, J., et.al. Phase I and II trials of subcutaneously administered rIL-2, interferon alfa-2a, and fluorouracil in patients with metastatic renal carcinoma, J Cancer Res Clin Oncol, 2001. 127(5): p. 319-24., http://www.ncbi.nlm.nih.gov/pubmed/11355147
322. Gez, E., Rubinov, R., Gaitini, D., Meretyk, S., Best, L. A., Native, O., et.al. Interleukin-2, interferon-alpha, 5-fluorouracil, and vinblastine in the treatment of metastatic renal cell carcinoma: a prospective phase II study: the experience of Rambam and Lin Medical Centers 1996-2000, Cancer, 2002. 95(8): p. 1644-9., http://www.ncbi.nlm.nih.gov/pubmed/12365011
323. Ryan, C. W., Vogelzang, N. J., Stadler, W. M., A phase II trial of intravenous gemcitabine and 5-fluorouracil with subcutaneous interleukin-2 and interferon-alpha in patients with metastatic renal cell carcinoma, Cancer, 2002. 94(10): p. 2602-9., http://www.ncbi.nlm.nih.gov/pubmed/12173327
324. Negrier, S., Perol, D., Ravaud, A., Chevreau, C., Bay, J. O., Delva, R., et.al. Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial, Cancer, 2007. 110(11): p. 2468-77., https://pubmed.ncbi.nlm.nih.gov/17932908/
325. Rini, B. I., Plimack, E. R., Stus, V., Gafanov, R., Hawkins, R., Nosov, D., et.al. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma, N Engl J Med, 2019. 380(12): p. 1116-1127., https://www.ncbi.nlm.nih.gov/pubmed/30779529
326. Choueiri, TK, Powles, T, Burotto, M, Escudier, B, Bourlon, MT, Zurawski, B, et.al. Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma., N Engl J Med, 2021. 384 (9)(9): p. 829-841., https://pubmed.ncbi.nlm.nih.gov/33657295/
327. Motzer, R, Alekseev, B, Rha, SY, Porta, C, Eto, M, Powles, T, et.al. Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma., N Engl J Med, 2021. 384 (14)(14): p. 1289-1300., https://pubmed.ncbi.nlm.nih.gov/33616314/
328. Motzer, R. J., Penkov, K., Haanen, J., Rini, B., Albiges, L., Campbell, M. T., et.al. Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma, N Engl J Med, 2019. 380(12): p. 1103-1115., http://www.ncbi.nlm.nih.gov/pubmed/30779531
329. Motzer, R. J., Tannir, N. M., McDermott, D. F., Aren Frontera, O., Melichar, B., Choueiri, T. K., et.al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma, N Engl J Med, 2018. 378(14): p. 1277-1290., https://www.ncbi.nlm.nih.gov/pubmed/29562145
330. Motzer, Robert J., Hutson, Thomas E., Cella, David, Reeves, James, Hawkins, Robert, Guo, Jun, et.al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma, The New England journal of medicine, 2013. 369(8): p. 722-731., http://www.ncbi.nlm.nih.gov/pubmed/23964934
331. Motzer, Robert J., Nosov, Dmitry, Eisen, Timothy, Bondarenko, Igor, Lesovoy, Vladimir, Lipatov, Oleg, et.al. Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013. 31(30): p. 3791-3799., http://www.ncbi.nlm.nih.gov/pubmed/24019545
332. Choueiri, T. K., Hessel, C., Halabi, S., Sanford, B., Michaelson, M. D., Hahn, O., et.al. Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update, Eur J Cancer, 2018. 94: p. 115-125., https://www.ncbi.nlm.nih.gov/pubmed/29550566
333. Choueiri, T. K., Escudier, B., Powles, T., Mainwaring, P. N., Rini, B. I., Donskov, F., et.al. Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma, N Engl J Med, 2015. 373(19): p. 1814-23., http://www.ncbi.nlm.nih.gov/pubmed/26406150
334. Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., et.al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma, N Engl J Med, 2015. 373(19): p. 1803-13., http://www.ncbi.nlm.nih.gov/pubmed/26406148
335. Choueiri, T. K., Escudier, B., Powles, T., Tannir, N. M., Mainwaring, P. N., Rini, B. I., et.al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial, Lancet Oncol, 2016. 17(7): p. 917-927., https://www.ncbi.nlm.nih.gov/pubmed/27279544
336. Motzer, R. J., Hutson, T. E., Ren, M., Dutcus, C., Larkin, J., Independent assessment of lenvatinib plus everolimus in patients with metastatic renal cell carcinoma, Lancet Oncol, 2016. 17(1): p. e4-5., https://www.ncbi.nlm.nih.gov/pubmed/26758760
337. Motzer, R. J., Escudier, B., Oudard, S., Hutson, T. E., Porta, C., Bracarda, S., et.al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial, Lancet, 2008. 372(9637): p. 449-56., http://www.ncbi.nlm.nih.gov/pubmed/18653228
338. Motzer, R. J., Escudier, B., Tomczak, P., Hutson, T. E., Michaelson, M. D., Negrier, S., et.al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial, Lancet Oncol, 2013. 14(6): p. 552-62., http://www.ncbi.nlm.nih.gov/pubmed/23598172
339. Eichelberg, C., Vervenne, W. L., De Santis, M., Fischer von Weikersthal, L., Goebell, P. J., Lerchenmuller, C., et.al. SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer, Eur Urol, 2015. 68(5): p. 837-47., http://www.ncbi.nlm.nih.gov/pubmed/25952317
340. Retz, M., Bedke, J., Bogemann, M., Grimm, M. O., Zimmermann, U., Muller, L., et.al. SWITCH II: Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33/11), Eur J Cancer, 2019. 107: p. 37-45., https://www.ncbi.nlm.nih.gov/pubmed/30529901
341. Motzer, R. J., Barrios, C. H., Kim, T. M., Falcon, S., Cosgriff, T., Harker, W. G., et.al. Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma, J Clin Oncol, 2014. 32(25): p. 2765-72., http://jco.ascopubs.org/content/32/25/2765.full.pdf
342. Sternberg, C. N., Davis, I. D., Mardiak, J., Szczylik, C., Lee, E., Wagstaff, J., et.al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial, J Clin Oncol, 2010. 28(6): p. 1061-8., https://pubmed.ncbi.nlm.nih.gov/20100962/
343. Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Oudard, S., et.al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma, J Clin Oncol, 2009. 27(22): p. 3584-90., http://www.ncbi.nlm.nih.gov/pubmed/19487381
344. Gore, M. E., Szczylik, C., Porta, C., Bracarda, S., Bjarnason, G. A., Oudard, S., et.al. Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma, Br J Cancer, 2015. 113(1): p. 12-9., https://www.ncbi.nlm.nih.gov/pubmed/26086878
345. Wagstaff, J., Jones, R., Hawkins, R., Porfiri, E., Pickering, L., Bahl, A., et.al. Treatment patterns and clinical outcomes in patients with renal cell carcinoma in the UK: insights from the RECCORD registry, Ann Oncol, 2016. 27(1): p. 159-65., https://www.ncbi.nlm.nih.gov/pubmed/26489444
346. Ruiz-Morales, J. M., Swierkowski, M., Wells, J. C., Fraccon, A. P., Pasini, F., Donskov, F., et.al. First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium, Eur J Cancer, 2016. 65: p. 102-8., https://www.ncbi.nlm.nih.gov/pubmed/27487293
347. Pal, S. K., Ghate, S. R., Li, N., Swallow, E., Peeples, M., Zichlin, M. L., et.al. Real-World Survival Outcomes and Prognostic Factors Among Patients Receiving First Targeted Therapy for Advanced Renal Cell Carcinoma: A SEER-Medicare Database Analysis, Clin Genitourin Cancer, 2017. 15(4): p. e573-e582., https://www.ncbi.nlm.nih.gov/pubmed/28139444
348. Motzer, RJ, Tannir, NM, McDermott, DF, Arén Frontera, O, Melichar, B, Choueiri, TK, et.al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma., N Engl J Med, 2018. 378 (14)(14): p. 1277-1290., https://pubmed.ncbi.nlm.nih.gov/29562145/
349. Motzer, RJ, Escudier, B, McDermott, DF, George, S, Hammers, HJ, Srinivas, S, et.al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma., N Engl J Med, 2015. 373 (19)(19): p. 1803-13., https://pubmed.ncbi.nlm.nih.gov/26406148/
350. Choueiri, T. K., Motzer, R. J., Rini, B. I., Haanen, J., Campbell, M. T., Venugopal, B., et.al. Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma, Ann Oncol, 2020. 31(8): p. 1030-1039., https://pubmed.ncbi.nlm.nih.gov/32339648/
351. Motzer, R. J., Rini, B. I., McDermott, D. F., Aren Frontera, O., Hammers, H. J., Carducci, M. A., et.al. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial, Lancet Oncol, 2019. 20(10): p. 1370-1385., https://www.ncbi.nlm.nih.gov/pubmed/31427204
352. Motzer, R. J., Hutson, T. E., Glen, H., Michaelson, M. D., Molina, A., Eisen, T., et.al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial, Lancet Oncol, 2015. 16(15): p. 1473-82., http://www.ncbi.nlm.nih.gov/pubmed/26482279
353. Nadal, R., Amin, A., Geynisman, D. M., Voss, M. H., Weinstock, M., Doyle, J., et.al. Safety and clinical activity of vascular endothelial growth factor receptor (VEGFR)-tyrosine kinase inhibitors after programmed cell death 1 inhibitor treatment in patients with metastatic clear cell renal cell carcinoma, Ann Oncol, 2016. 27(7): p. 1304-11., https://www.ncbi.nlm.nih.gov/pubmed/27059553
354. Albiges, L., Fay, A. P., Xie, W., Krajewski, K., McDermott, D. F., Heng, D. Y., et.al. Efficacy of targeted therapies after PD-1/PD-L1 blockade in metastatic renal cell carcinoma, Eur J Cancer, 2015. 51(17): p. 2580-6., https://www.ncbi.nlm.nih.gov/pubmed/26346135
355. Hutson, T. E., Lesovoy, V., Al-Shukri, S., Stus, V. P., Lipatov, O. N., Bair, A. H., et.al. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial, Lancet Oncol, 2013. 14(13): p. 1287-94., http://www.ncbi.nlm.nih.gov/pubmed/24206640
356. Hutson, T. E., Al-Shukri, S., Stus, V. P., Lipatov, O. N., Shparyk, Y., Bair, A. H., et.al. Axitinib Versus Sorafenib in First-Line Metastatic Renal Cell Carcinoma: Overall Survival From a Randomized Phase III Trial, Clin Genitourin Cancer, 2016., http://www.ncbi.nlm.nih.gov/pubmed/27498023
357. Escudier, B., Choueiri, T. K., Oudard, S., Szczylik, C., Negrier, S., Ravaud, A., et.al. Prognostic factors of metastatic renal cell carcinoma after failure of immunotherapy: new paradigm from a large phase III trial with shark cartilage extract AE 941, J Urol, 2007. 178(5): p. 1901-5., http://www.ncbi.nlm.nih.gov/pubmed/17868728
358. Melichar, B., Bracarda, S., Matveev, V., Alekseev, B., Ivanov, S., Zyryanov, A., et.al. A multinational phase II trial of bevacizumab with low-dose interferon-alpha2a as first-line treatment of metastatic renal cell carcinoma: BEVLiN, Ann Oncol, 2013. 24(9): p. 2396-402., https://pubmed.ncbi.nlm.nih.gov/23803225/
359. Choueiri, T. K., Escudier, B., Powles, T., Tannir, N. M., Mainwaring, P. N., Rini, B. I., et.al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial, Lancet Oncol, 2016. 17(7): p. 917-27., http://www.ncbi.nlm.nih.gov/pubmed/27279544
360. Choueiri, T. K., Hessel, C., Halabi, S., Sanford, B., Michaelson, M. D., Hahn, O., et.al. Corrigendum to 'Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update' [Eur J Cancer 94 (May 2018) 115-125], Eur J Cancer, 2018. 103: p. 287., https://www.ncbi.nlm.nih.gov/pubmed/30270112
361. Choueiri, T. K., Halabi, S., Sanford, B. L., Hahn, O., Michaelson, M. D., Walsh, M. K., et.al. Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial, J Clin Oncol, 2017. 35(6): p. 591-597., https://www.ncbi.nlm.nih.gov/pubmed/28199818
362. Motzer, R. J., Escudier, B., Oudard, S., Hutson, T. E., Porta, C., Bracarda, S., et.al. Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors, Cancer, 2010. 116(18): p. 4256-65., https://pubmed.ncbi.nlm.nih.gov/20549832/
363. Motzer, R. J., Rini, B. I., McDermott, D. F., Redman, B. G., Kuzel, T. M., Harrison, M. R., et.al. Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial, J Clin Oncol, 2015. 33(13): p. 1430-7., http://www.ncbi.nlm.nih.gov/pubmed/25452452
364. Sternberg, C. N., Hawkins, R. E., Wagstaff, J., Salman, P., Mardiak, J., Barrios, C. H., et.al. A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update, Eur J Cancer, 2013. 49(6): p. 1287-96., https://pubmed.ncbi.nlm.nih.gov/23321547/
365. Ratain, M. J., Eisen, T., Stadler, W. M., Flaherty, K. T., Kaye, S. B., Rosner, G. L., et.al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma, J Clin Oncol, 2006. 24(16): p. 2505-12., http://www.ncbi.nlm.nih.gov/pubmed/16636341
366. Escudier, B., Eisen, T., Stadler, W. M., Szczylik, C., Oudard, S., Staehler, M., et.al. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial, J Clin Oncol, 2009. 27(20): p. 3312-8., http://www.ncbi.nlm.nih.gov/pubmed/19451442
367. Escudier, B., Eisen, T., Stadler, W. M., Szczylik, C., Oudard, S., Siebels, M., et.al. Sorafenib in advanced clear-cell renal-cell carcinoma, N Engl J Med, 2007. 356(2): p. 125-34., http://www.ncbi.nlm.nih.gov/pubmed/17215530
368. Cella, D., Li, J. Z., Cappelleri, J. C., Bushmakin, A., Charbonneau, C., Kim, S. T., et.al. Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial, J Clin Oncol, 2008. 26(22): p. 3763-9., http://www.ncbi.nlm.nih.gov/pubmed/18669464
369. Masini, C., Sabbatini, R., Porta, C., Procopio, G., Di Lorenzo, G., Onofri, A., et.al. Use of tyrosine kinase inhibitors in patients with metastatic kidney cancer receiving haemodialysis: a retrospective Italian survey, BJU Int, 2012. 110(5): p. 692-8., https://pubmed.ncbi.nlm.nih.gov/22364110/
370. Park, S., Lee, J., Park, S. H., Park, J. O., Kang, W. K., Park, Y. S., et.al. Treatment of hemodialyzed patients with sunitinib in renal cell carcinoma, Chemotherapy, 2010. 56(6): p. 485-91., https://pubmed.ncbi.nlm.nih.gov/21099221/
371. Rey, P. M., Villavicencio, H., Sorafenib: tolerance in patients on chronic hemodialysis: a single-center experience, Oncology, 2008. 74(3-4): p. 245-6., https://pubmed.ncbi.nlm.nih.gov/18716419/
372. Shetty, A. V., Matrana, M. R., Atkinson, B. J., Flaherty, A. L., Jonasch, E., Tannir, N. M., Outcomes of patients with metastatic renal cell carcinoma and end-stage renal disease receiving dialysis and targeted therapies: a single institution experience, Clin Genitourin Cancer, 2014. 12(5): p. 348-53., https://pubmed.ncbi.nlm.nih.gov/24565697/
373. Bracarda, S., Sisani, M., Marrocolo, F., Hamzaj, A., del Buono, S., De Simone, V., GOAL: an inverse toxicity-related algorithm for daily clinical practice decision making in advanced kidney cancer, Crit Rev Oncol Hematol, 2014. 89(3): p. 386-93., https://www.ncbi.nlm.nih.gov/pubmed/24309065
374. Elhilali, M. M., Gleave, M., Fradet, Y., Davis, I., Venner, P., Saad, F., et.al. Placebo-associated remissions in a multicentre, randomized, double-blind trial of interferon ?-1b for the treatment of metastatic renal cell carcinoma, BJU International, 2000. 86(6): p. 613-618., http://dx.doi.org/10.1046/j.1464-410x.2000.00880.x
375. Janiszewska, A. D., Poletajew, S., Wasiutynski, A., Spontaneous regression of renal cell carcinoma, Contemp Oncol (Pozn), 2013. 17(2): p. 123-7., https://pubmed.ncbi.nlm.nih.gov/23788977/
376. Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., et.al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing, N Engl J Med, 2012. 366(10): p. 883-92., https://pubmed.ncbi.nlm.nih.gov/22397650/
377. Albiges, L., Oudard, S., Negrier, S., Caty, A., Gravis, G., Joly, F., et.al. Complete remission with tyrosine kinase inhibitors in renal cell carcinoma, J Clin Oncol, 2012. 30(5): p. 482-7., http://www.ncbi.nlm.nih.gov/pubmed/22231040
378. Nosov, D. A., Esteves, B., Lipatov, O. N., Lyulko, A. A., Anischenko, A. A., Chacko, R. T., et.al. Antitumor activity and safety of tivozanib (AV-951) in a phase II randomized discontinuation trial in patients with renal cell carcinoma, J Clin Oncol, 2012. 30(14): p. 1678-85., https://pubmed.ncbi.nlm.nih.gov/22493422/
379. Johannsen, M., Florcken, A., Bex, A., Roigas, J., Cosentino, M., Ficarra, V., et.al. Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis, Eur Urol, 2009. 55(6): p. 1430-8., https://www.ncbi.nlm.nih.gov/pubmed/18950936
380. Johannsen, M., Staehler, M., Ohlmann, C. H., Florcken, A., Schmittel, A., Otto, T., et.al. Outcome of treatment discontinuation in patients with metastatic renal cell carcinoma and no evidence of disease following targeted therapy with or without metastasectomy, Ann Oncol, 2011. 22(3): p. 657-63., http://www.ncbi.nlm.nih.gov/pubmed/20870911
381. Ornstein, M. C., Wood, L. S., Elson, P., Allman, K. D., Beach, J., Martin, A., et.al. A Phase II Study of Intermittent Sunitinib in Previously Untreated Patients With Metastatic Renal Cell Carcinoma, J Clin Oncol, 2017. 35(16): p. 1764-1769., https://www.ncbi.nlm.nih.gov/pubmed/28113029
382. Flanigan, R. C., Mickisch, G., Sylvester, R., Tangen, C., Van Poppel, H., Crawford, E. D., Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis, J Urol, 2004. 171(3): p. 1071-6., http://www.ncbi.nlm.nih.gov/pubmed/14767273
383. Kavoussi, L. R., Levine, S. R., Kadmon, D., Fair, W. R., Regression of metastatic renal cell carcinoma: a case report and literature review, J Urol, 1986. 135(5): p. 1005-7., http://www.ncbi.nlm.nih.gov/pubmed/3959224
384. Lokich, J., Spontaneous regression of metastatic renal cancer. Case report and literature review, Am J Clin Oncol, 1997. 20(4): p. 416-8., http://www.ncbi.nlm.nih.gov/pubmed/9256902
385. Spiess, P. E., Fishman, M. N., Cytoreductive nephrectomy vs medical therapy as initial treatment: a rational approach to the sequence question in metastatic renal cell carcinoma, Cancer Control, 2010. 17(4): p. 269-78., http://www.ncbi.nlm.nih.gov/pubmed/20861814
386. Gore, M. E., Szczylik, C., Porta, C., Bracarda, S., Bjarnason, G. A., Oudard, S., et.al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial, Lancet Oncol, 2009. 10(8): p. 757-63., http://www.ncbi.nlm.nih.gov/pubmed/19615940
387. Cost, N. G., Delacroix, S. E., Jr., Sleeper, J. P., Smith, P. J., Youssef, R. F., Chapin, B. F., et.al. The impact of targeted molecular therapies on the level of renal cell carcinoma vena caval tumor thrombus, Eur Urol, 2011. 59(6): p. 912-8., http://www.ncbi.nlm.nih.gov/pubmed/21367518
388. Cowey, C. L., Amin, C., Pruthi, R. S., Wallen, E. M., Nielsen, M. E., Grigson, G., et.al. Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma, J Clin Oncol, 2010. 28(9): p. 1502-7., http://www.ncbi.nlm.nih.gov/pubmed/20159822
389. Hellenthal, N. J., Underwood, W., Penetrante, R., Litwin, A., Zhang, S., Wilding, G. E., et.al. Prospective clinical trial of preoperative sunitinib in patients with renal cell carcinoma, J Urol, 2010. 184(3): p. 859-64., http://www.ncbi.nlm.nih.gov/pubmed/20643461
390. Jonasch, E., Wood, C. G., Matin, S. F., Tu, S. M., Pagliaro, L. C., Corn, P. G., et.al. Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma, J Clin Oncol, 2009. 27(25): p. 4076-81., http://www.ncbi.nlm.nih.gov/pubmed/19636008
391. De Meerleer, G., Khoo, V., Escudier, B., Joniau, S., Bossi, A., Ost, P., et.al. Radiotherapy for renal-cell carcinoma, Lancet Oncol, 2014. 15(4): p. e170-7., http://www.ncbi.nlm.nih.gov/pubmed/24694640
392. Kavolius, J. P., Mastorakos, D. P., Pavlovich, C., Russo, P., Burt, M. E., Brady, M. S., Resection of metastatic renal cell carcinoma, J Clin Oncol, 1998. 16(6): p. 2261-6., http://www.ncbi.nlm.nih.gov/pubmed/9626229
393. Kierney, P. C., van Heerden, J. A., Segura, J. W., Weaver, A. L., Surgeon's role in the management of solitary renal cell carcinoma metastases occurring subsequent to initial curative nephrectomy: an institutional review, Ann Surg Oncol, 1994. 1(4): p. 345-52., http://www.ncbi.nlm.nih.gov/pubmed/7850534
394. Ranck, M. C., Golden, D. W., Corbin, K. S., Hasselle, M. D., Liauw, S. L., Stadler, W. M., et.al. Stereotactic body radiotherapy for the treatment of oligometastatic renal cell carcinoma, Am J Clin Oncol, 2013. 36(6): p. 589-95., http://www.ncbi.nlm.nih.gov/pubmed/22868242
395. Stinauer, M. A., Kavanagh, B. D., Schefter, T. E., Gonzalez, R., Flaig, T., Lewis, K., et.al. Stereotactic body radiation therapy for melanoma and renal cell carcinoma: impact of single fraction equivalent dose on local control, Radiat Oncol, 2011. 6: p. 34., http://www.ncbi.nlm.nih.gov/pubmed/21477295
396. Svedman, C., Sandstrom, P., Pisa, P., Blomgren, H., Lax, I., Kalkner, K. M., et.al. A prospective Phase II trial of using extracranial stereotactic radiotherapy in primary and metastatic renal cell carcinoma, Acta Oncol, 2006. 45(7): p. 870-5., http://www.ncbi.nlm.nih.gov/pubmed/16982552
397. Teh, B., Bloch, C., Galli-Guevara, M., Doh, L., Richardson, S., Chiang, S., et.al. The treatment of primary and metastatic renal cell carcinoma (RCC) with image-guided stereotactic body radiation therapy (SBRT), Biomed Imaging Interv J, 2007. 3(1): p. e6., http://www.ncbi.nlm.nih.gov/pubmed/21614267
398. Tumoren, Landelijke Werkgroep Urologische, Renal cell carcinoma. Nation-wide guideline, Version: 2.0Integraal Kankercentrum Nederland (IKNL), 2010.
399. van der Poel, H. G., Roukema, J. A., Horenblas, S., van Geel, A. N., Debruyne, F. M., Metastasectomy in renal cell carcinoma: A multicenter retrospective analysis, Eur Urol, 1999. 35(3): p. 197-203., http://www.ncbi.nlm.nih.gov/pubmed/10072620
400. Wersaell, P. J., Blomgren, H., Lax, I., Kalkner, K. M., Linder, C., Lundell, G., et.al. Extracranial stereotactic radiotherapy for primary and metastatic renal cell carcinoma, Radiother Oncol, 2005. 77(1): p. 88-95., http://www.ncbi.nlm.nih.gov/pubmed/15972239
401. Zelefsky, M. J., Greco, C., Motzer, R., Magsanoc, J. M., Pei, X., Lovelock, M., et.al. Tumor control outcomes after hypofractionated and single-dose stereotactic image-guided intensity-modulated radiotherapy for extracranial metastases from renal cell carcinoma, Int J Radiat Oncol Biol Phys, 2012. 82(5): p. 1744-8., http://www.ncbi.nlm.nih.gov/pubmed/21596489
402. Alt, A. L., Boorjian, S. A., Lohse, C. M., Costello, B. A., Leibovich, B. C., Blute, M. L., Survival after complete surgical resection of multiple metastases from renal cell carcinoma, Cancer, 2011. 117(13): p. 2873-82., http://www.ncbi.nlm.nih.gov/pubmed/21692048
403. Kwak, C., Park, Y. H., Jeong, C. W., Lee, S. E., Ku, J. H., Metastasectomy without systemic therapy in metastatic renal cell carcinoma: comparison with conservative treatment, Urol Int, 2007. 79(2): p. 145-51., http://www.ncbi.nlm.nih.gov/pubmed/17851285
404. Renaud, S., Falcoz, P. E., Alifano, M., Olland, A., Magdeleinat, P., Pages, O., et.al. Systematic lymph node dissection in lung metastasectomy of renal cell carcinoma: an 18 years of experience, J Surg Oncol, 2014. 109(8): p. 823-9., http://www.ncbi.nlm.nih.gov/pubmed/24619772
405. Winter, H., Meimarakis, G., Angele, M. K., Hummel, M., Staehler, M., Hoffmann, R. T., et.al. Tumor infiltrated hilar and mediastinal lymph nodes are an independent prognostic factor for decreased survival after pulmonary metastasectomy in patients with renal cell carcinoma, J Urol, 2010. 184(5): p. 1888-94., http://www.ncbi.nlm.nih.gov/pubmed/20846691
406. Cerfolio, R. J., Bryant, A. S., McCarty, T. P., Minnich, D. J., A prospective study to determine the incidence of non-imaged malignant pulmonary nodules in patients who undergo metastasectomy by thoracotomy with lung palpation, Ann Thorac Surg, 2011. 91(6): p. 1696-700; discussion 1700-1., http://www.ncbi.nlm.nih.gov/pubmed/21619965
407. Parsons, Alden M, Detterbeck, Frank C, Parker, Leonard A, Accuracy of helical CT in the detection of pulmonary metastases: is intraoperative palpation still necessary?, The Annals of thoracic surgery, 2004. 78(6): p. 1910-1918., https://pubmed.ncbi.nlm.nih.gov/15561000/
408. Thoracoscopic or open surgery for pulmonary metastasectomy: an observer blinded study, 2014., http://www.ncbi.nlm.nih.gov/pubmed/24928676
409. Greenwood, Amy, West, Douglas, Is a thoracotomy rather than thoracoscopic resection associated with improved survival after pulmonary metastasectomy?, Interactive cardiovascular and thoracic surgery, 2013. 17(4): p. 720-4., https://pubmed.ncbi.nlm.nih.gov/23832919/
410. Oddsson, S.J., Synchronous pulmonary metastases from renal cell carcinoma--a whole nation study on prevalence and potential resectability, 2012., http://www.ncbi.nlm.nih.gov/pubmed/22968238
411. Piltz, S., Meimarakis, G., Wichmann, M. W., Hatz, R., Schildberg, F. W., Fuerst, H., Long-term results after pulmonary resection of renal cell carcinoma metastases, Ann Thorac Surg, 2002. 73(4): p. 1082-7., http://www.ncbi.nlm.nih.gov/pubmed/11996245
412. Pfannschmidt, J., Hoffmann, H., Muley, T., Krysa, S., Trainer, C., Dienemann, H., Prognostic factors for survival after pulmonary resection of metastatic renal cell carcinoma, Ann Thorac Surg, 2002. 74(5): p. 1653-7., http://www.ncbi.nlm.nih.gov/pubmed/12440625
413. Meimarakis, G., Angele, M., Staehler, M., Clevert, D. A., Crispin, A., Ruttinger, D., et.al. Evaluation of a new prognostic score (Munich score) to predict long-term survival after resection of pulmonary renal cell carcinoma metastases, Am J Surg, 2011. 202(2): p. 158-67., http://www.ncbi.nlm.nih.gov/pubmed/21810496
414. Kudelin, N., Boeluekbas, S., Eberlein, M., Schirren, J., Metastasectomy with standardized lymph node dissection for metastatic renal cell carcinoma: an 11-year single-center experience, Ann Thorac Surg, 2013. 96(1): p. 265-70: discussion 270-1., http://www.ncbi.nlm.nih.gov/pubmed/23731615
415. Boeluekbas, S., Kudelin, N., Eberlein, M., Fisseler-Eckhoff, A., Schirren, J., The influence of the primary tumor on the long-term results of pulmonary metastasectomy for metastatic renal cell carcinoma, Thorac Cardiovasc Surg, 2012. 60(6): p. 390-7., http://www.ncbi.nlm.nih.gov/pubmed/22207364
416. Kanzaki, R., Higashiyama, M., Fujiwara, A., Tokunaga, T., Maeda, J., Okami, J., et.al. Long-term results of surgical resection for pulmonary metastasis from renal cell carcinoma: a 25-year single-institution experience, Eur J Cardiothorac Surg, 2011. 39(2): p. 167-72., http://www.ncbi.nlm.nih.gov/pubmed/20591686
417. Rusch, V. W., Pulmonary metastasectomy. Current indications, Chest, 1995. 107(6 Suppl): p. 322S-331S., http://www.ncbi.nlm.nih.gov/pubmed/7781414
418. Murthy, S. C., Kim, K., Rice, T. W., Rajeswaran, J., Bukowski, R., DeCamp, M. M., et.al. Can we predict long-term survival after pulmonary metastasectomy for renal cell carcinoma?, Ann Thorac Surg, 2005. 79(3): p. 996-1003., http://www.ncbi.nlm.nih.gov/pubmed/15734422
419. Hofmann, H. S., Neef, H., Krohe, K., Andreev, P., Silber, R. E., Prognostic factors and survival after pulmonary resection of metastatic renal cell carcinoma, Eur Urol, 2005. 48(1): p. 77-81; discussion 81-2., http://www.ncbi.nlm.nih.gov/pubmed/15967255
420. Althausen, P., Althausen, A., Jennings, L. C., Mankin, H. J., Prognostic factors and surgical treatment of osseous metastases secondary to renal cell carcinoma, Cancer, 1997. 80(6): p. 1103-9., http://www.ncbi.nlm.nih.gov/pubmed/9305711
421. Kollender, Y., Bickels, J., Price, W. M., Kellar, K. L., Chen, J., Merimsky, O., et.al. Metastatic renal cell carcinoma of bone: indications and technique of surgical intervention, J Urol, 2000. 164(5): p. 1505-8., http://www.ncbi.nlm.nih.gov/pubmed/11025692
422. Lin, P. P., Mirza, A. N., Lewis, V. O., Cannon, C. P., Tu, S. M., Tannir, N. M., et.al. Patient survival after surgery for osseous metastases from renal cell carcinoma, J Bone Joint Surg Am, 2007. 89(8): p. 1794-801., http://www.ncbi.nlm.nih.gov/pubmed/17671020
423. Szendroi, A., Dinya, E., Kardos, M., Szasz, A. M., Nemeth, Z., Ats, K., et.al. Prognostic factors and survival of renal clear cell carcinoma patients with bone metastases, Pathol Oncol Res, 2010. 16(1): p. 29-38., http://www.ncbi.nlm.nih.gov/pubmed/19639393
424. Jung, S. T., Ghert, M. A., Harrelson, J. M., Scully, S. P., Treatment of osseous metastases in patients with renal cell carcinoma, Clin Orthop Relat Res, 2003. p. 223-31., http://www.ncbi.nlm.nih.gov/pubmed/12671506
425. Fottner, A., Szalantzy, M., Wirthmann, L., Stahler, M., Baur-Melnyk, A., Jansson, V., et.al. Bone metastases from renal cell carcinoma: patient survival after surgical treatment, BMC Musculoskelet Disord, 2010. 11: p. 145., http://www.ncbi.nlm.nih.gov/pubmed/20598157
426. Ulmar, B., Catalkaya, S., Naumann, U., Gerstner, S., Cakir, B., Schmidt, R., et.al. [Surgical treatment and evaluation of prognostic factors in spinal metastases of renal cell carcinoma], Z Orthop Ihre Grenzgeb, 2006. 144(1): p. 58-67., https://pubmed.ncbi.nlm.nih.gov/16498562/
427. Jackson, R. J., Loh, S. C., Gokaslan, Z. L., Metastatic renal cell carcinoma of the spine: surgical treatment and results, J Neurosurg, 2001. 94(1 Suppl): p. 18-24., http://www.ncbi.nlm.nih.gov/pubmed/11147860
428. Solitary spinal metastases. Is aggressive surgical management justified?, 2013.
429. Patchell, R. A., Tibbs, P. A., Regine, W. F., Payne, R., Saris, S., Kryscio, R. J., et.al. Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial, Lancet, 2005. 366(9486): p. 643-648., http://www.ncbi.nlm.nih.gov/pubmed/16112300
430. Gerszten, Peter C, Burton, Steven A, Ozhasoglu, Cihat, Vogel, William J, Welch, William C, Baar, Joseph, et.al. Stereotactic radiosurgery for spinal metastases from renal cell carcinoma, Journal of Neurosurgery: Spine, 2005. 3(4): p. 288-295., https://pubmed.ncbi.nlm.nih.gov/16266070/
431. Nguyen, Quynh-Nhu, Shiu, Almon S, Rhines, Laurence D, Wang, He, Allen, Pamela K, Wang, Xin Shelley, et.al. Management of spinal metastases from renal cell carcinoma using stereotactic body radiotherapy, International Journal of Radiation Oncology* Biology* Physics, 2010. 76(4): p. 1185-1192., https://pubmed.ncbi.nlm.nih.gov/19632064/
432. Balagamwala, E. H., Angelov, L., Koyfman, S. A., Suh, J. H., Reddy, C. A., Djemil, T., et.al. Single-fraction stereotactic body radiotherapy for spinal metastases from renal cell carcinoma, J Neurosurg Spine, 2012. 17(6): p. 556-64., http://www.ncbi.nlm.nih.gov/pubmed/23020208
433. Thibault, I., Al-Omair, A., Masucci, G. L., Masson-Cote, L., Lochray, F., Korol, R., et.al. Spine stereotactic body radiotherapy for renal cell cancer spinal metastases: analysis of outcomes and risk of vertebral compression fracture, J Neurosurg Spine, 2014. 21(5): p. 711-8., http://www.ncbi.nlm.nih.gov/pubmed/25170656
434. Sellin, J. N., Reichardt, W., Bishop, A. J., Suki, D., Rhines, L. D., Settle, S. H., et.al. Factors affecting survival in 37 consecutive patients undergoing de novo stereotactic radiosurgery for contiguous sites of vertebral body metastasis from renal cell carcinoma, J Neurosurg Spine, 2015. 22(1): p. 52-9., http://www.ncbi.nlm.nih.gov/pubmed/25360530
435. Hunter, G. K., Balagamwala, E. H., Koyfman, S. A., Bledsoe, T., Sheplan, L. J., Reddy, C. A., et.al. The efficacy of external beam radiotherapy and stereotactic body radiotherapy for painful spinal metastases from renal cell carcinoma, Pract Radiat Oncol, 2012. 2(4): p. e95-e100., http://www.ncbi.nlm.nih.gov/pubmed/24674192
436. Blanco, A. I., Teh, B. S., Amato, R. J., Role of radiation therapy in the management of renal cell cancer, Cancers (Basel), 2011. 3(4): p. 4010-23., http://www.ncbi.nlm.nih.gov/pubmed/24213122
437. Svedman, C., Karlsson, K., Rutkowska, E., Sandstrom, P., Blomgren, H., Lax, I., et.al. Stereotactic body radiotherapy of primary and metastatic renal lesions for patients with only one functioning kidney, Acta Oncol, 2008. 47(8): p. 1578-83., http://www.ncbi.nlm.nih.gov/pubmed/18607859
438. Scorsetti, M., Facoetti, A., Navarria, P., Bignardi, M., De Santis, M., Ninone, S. A., et.al. Hypofractionated stereotactic radiotherapy and radiosurgery for the treatment of patients with radioresistant brain metastases, Anticancer Res, 2009. 29(10): p. 4259-63., http://www.ncbi.nlm.nih.gov/pubmed/19846983
439. Kjaer, M., Frederiksen, P. L., Engelholm, S. A., Postoperative radiotherapy in stage II and III renal adenocarcinoma. A randomized trial by the Copenhagen Renal Cancer Study Group, Int J Radiat Oncol Biol Phys, 1987. 13(5): p. 665-72., http://www.ncbi.nlm.nih.gov/pubmed/3553111
440. Schouten, L. J., Rutten, J., Huveneers, H. A., Twijnstra, A., Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma, Cancer, 2002. 94(10): p. 2698-705., http://www.ncbi.nlm.nih.gov/pubmed/12173339
441. Kocher, M., Soffietti, R., Abacioglu, U., Villa, S., Fauchon, F., Baumert, B. G., et.al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study, J Clin Oncol, 2011. 29(2): p. 134-41., https://pubmed.ncbi.nlm.nih.gov/21041710/
442. Soffietti, R., Kocher, M., Abacioglu, U. M., Villa, S., Fauchon, F., Baumert, B. G., et.al. A European Organisation for Research and Treatment of Cancer phase III trial of adjuvant whole-brain radiotherapy versus observation in patients with one to three brain metastases from solid tumors after surgical resection or radiosurgery: quality-of-life results, J Clin Oncol, 2013. 31(1): p. 65-72., https://pubmed.ncbi.nlm.nih.gov/23213105/
443. Gaspar, L., Scott, C., Rotman, M., Asbell, S., Phillips, T., Wasserman, T., et.al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials, Int J Radiat Oncol Biol Phys, 1997. 37(4): p. 745-51., https://pubmed.ncbi.nlm.nih.gov/9128946/
444. Gaspar, L. E., Scott, C., Murray, K., Curran, W., Validation of the RTOG recursive partitioning analysis (RPA) classification for brain metastases, Int J Radiat Oncol Biol Phys, 2000. 47(4): p. 1001-6., https://pubmed.ncbi.nlm.nih.gov/10863071/
445. Nieder, C., Andratschke, N., Grosu, A. L., Molls, M., Recursive partitioning analysis (RPA) class does not predict survival in patients with four or more brain metastases, Strahlenther Onkol, 2003. 179(1): p. 16-20., https://pubmed.ncbi.nlm.nih.gov/12540980/
446. Sperduto, P. W., Berkey, B., Gaspar, L. E., Mehta, M., Curran, W., A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database, Int J Radiat Oncol Biol Phys, 2008. 70(2): p. 510-4., https://pubmed.ncbi.nlm.nih.gov/17931798/
447. Sperduto, P. W., Chao, S. T., Sneed, P. K., Luo, X., Suh, J., Roberge, D., et.al. Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients, Int J Radiat Oncol Biol Phys, 2010. 77(3): p. 655-61., https://pubmed.ncbi.nlm.nih.gov/19942357/
448. Cannady, S. B., Cavanaugh, K. A., Lee, S. Y., Bukowski, R. M., Olencki, T. E., Stevens, G. H., et.al. Results of whole brain radiotherapy and recursive partitioning analysis in patients with brain metastases from renal cell carcinoma: a retrospective study, Int J Radiat Oncol Biol Phys, 2004. 58(1): p. 253-8., https://pubmed.ncbi.nlm.nih.gov/14697446/
449. Muacevic, A., Kreth, F. W., Horstmann, G. A., Schmid-Elsaesser, R., Wowra, B., Steiger, H. J., et.al. Surgery and radiotherapy compared with gamma knife radiosurgery in the treatment of solitary cerebral metastases of small diameter, J Neurosurg, 1999. 91(1): p. 35-43., https://pubmed.ncbi.nlm.nih.gov/10389878/
450. Wronski, M., Maor, M. H., Davis, B. J., Sawaya, R., Levin, V. A., External radiation of brain metastases from renal carcinoma: a retrospective study of 119 patients from the M. D. Anderson Cancer Center, Int J Radiat Oncol Biol Phys, 1997. 37(4): p. 753-9., https://pubmed.ncbi.nlm.nih.gov/9128947/
451. Mintz, A. H., Kestle, J., Rathbone, M. P., Gaspar, L., Hugenholtz, H., Fisher, B., et.al. A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis, Cancer, 1996. 78(7): p. 1470-6., http://www.ncbi.nlm.nih.gov/pubmed/8839553
452. Noordijk, E. M., Vecht, C. J., Haaxma-Reiche, H., Padberg, G. W., Voormolen, J. H., Hoekstra, F. H., et.al. The choice of treatment of single brain metastasis should be based on extracranial tumor activity and age, Int J Radiat Oncol Biol Phys, 1994. 29(4): p. 711-7., http://www.ncbi.nlm.nih.gov/pubmed/8040016
453. Patchell, R. A., Tibbs, P. A., Walsh, J. W., Dempsey, R. J., Maruyama, Y., Kryscio, R. J., et.al. A randomized trial of surgery in the treatment of single metastases to the brain, N Engl J Med, 1990. 322(8): p. 494-500., https://www.ncbi.nlm.nih.gov/pubmed/2405271
454. Andrews, D. W., Scott, C. B., Sperduto, P. W., Flanders, A. E., Gaspar, L. E., Schell, M. C., et.al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial, Lancet, 2004. 363(9422): p. 1665-72., https://www.ncbi.nlm.nih.gov/pubmed/15158627
455. Sperduto, P. W., Shanley, R., Luo, X., Andrews, D., Werner-Wasik, M., Valicenti, R., et.al. Secondary analysis of RTOG 9508, a phase 3 randomized trial of whole-brain radiation therapy versus WBRT plus stereotactic radiosurgery in patients with 1-3 brain metastases; poststratified by the graded prognostic assessment (GPA), Int J Radiat Oncol Biol Phys, 2014. 90(3): p. 526-31., https://www.ncbi.nlm.nih.gov/pubmed/25304947
456. Muacevic, A., Wowra, B., Siefert, A., Tonn, J. C., Steiger, H. J., Kreth, F. W., Microsurgery plus whole brain irradiation versus Gamma Knife surgery alone for treatment of single metastases to the brain: a randomized controlled multicentre phase III trial, J Neurooncol, 2008. 87(3): p. 299-307., https://www.ncbi.nlm.nih.gov/pubmed/18157648
457. Elaimy, A. L., Mackay, A. R., Lamoreaux, W. T., Fairbanks, R. K., Demakas, J. J., Cooke, B. S., et.al. Multimodality treatment of brain metastases: an institutional survival analysis of 275 patients, World J Surg Oncol, 2011. 9: p. 69., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3148547/pdf/1477-7819-9-69.pdf
458. Aoyama, H., Shirato, H., Tago, M., Nakagawa, K., Toyoda, T., Hatano, K., et.al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial, JAMA, 2006. 295(21): p. 2483-91., https://pubmed.ncbi.nlm.nih.gov/16757720/
459. Aoyama, H., Tago, M., Kato, N., Toyoda, T., Kenjyo, M., Hirota, S., et.al. Neurocognitive function of patients with brain metastasis who received either whole brain radiotherapy plus stereotactic radiosurgery or radiosurgery alone, Int J Radiat Oncol Biol Phys, 2007. 68(5): p. 1388-95., https://www.ncbi.nlm.nih.gov/pubmed/17674975
460. Chang, E. L., Wefel, J. S., Hess, K. R., Allen, P. K., Lang, F. F., Kornguth, D. G., et.al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial, Lancet Oncol, 2009. 10(11): p. 1037-44., https://www.ncbi.nlm.nih.gov/pubmed/19801201
461. Sahgal, A., Aoyama, H., Kocher, M., Neupane, B., Collette, S., Tago, M., et.al. Phase 3 trials of stereotactic radiosurgery with or without whole-brain radiation therapy for 1 to 4 brain metastases: individual patient data meta-analysis, Int J Radiat Oncol Biol Phys, 2015. 91(4): p. 710-7., https://www.ncbi.nlm.nih.gov/pubmed/25752382
462. Kano, H., Iyer, A., Kondziolka, D., Niranjan, A., Flickinger, J. C., Lunsford, L. D., Outcome predictors of gamma knife radiosurgery for renal cell carcinoma metastases, Neurosurgery, 2011. 69(6): p. 1232-9., https://www.ncbi.nlm.nih.gov/pubmed/21716155
463. Yamamoto, M., Serizawa, T., Shuto, T., Akabane, A., Higuchi, Y., Kawagishi, J., et.al. Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study, Lancet Oncol, 2014., https://www.ncbi.nlm.nih.gov/pubmed/24621620
464. Brennan, C., Yang, T. J., Hilden, P., Zhang, Z., Chan, K., Yamada, Y., et.al. A phase 2 trial of stereotactic radiosurgery boost after surgical resection for brain metastases, Int J Radiat Oncol Biol Phys, 2014. 88(1): p. 130-6., https://www.ncbi.nlm.nih.gov/pubmed/24331659
465. Choi, C. Y., Chang, S. D., Gibbs, I. C., Adler, J. R., Harsh, G. R. th, Lieberson, R. E., et.al. Stereotactic radiosurgery of the postoperative resection cavity for brain metastases: prospective evaluation of target margin on tumor control, Int J Radiat Oncol Biol Phys, 2012. 84(2): p. 336-42., https://www.ncbi.nlm.nih.gov/pubmed/22652105
466. Iorio-Morin, C., Masson-Cote, L., Ezahr, Y., Blanchard, J., Ebacher, A., Mathieu, D., Early Gamma Knife stereotactic radiosurgery to the tumor bed of resected brain metastasis for improved local control, J Neurosurg, 2014. 121 Suppl: p. 69-74., https://www.ncbi.nlm.nih.gov/pubmed/25434939
467. Ling, D. C., Vargo, J. A., Wegner, R. E., Flickinger, J. C., Burton, S. A., Engh, J., et.al. Postoperative stereotactic radiosurgery to the resection cavity for large brain metastases: clinical outcomes, predictors of intracranial failure, and implications for optimal patient selection, Neurosurgery, 2015. 76(2): p. 150-6; discussion 156-7; quiz 157., https://www.ncbi.nlm.nih.gov/pubmed/25549189
468. Luther, N., Kondziolka, D., Kano, H., Mousavi, S. H., Engh, J. A., Niranjan, A., et.al. Predicting tumor control after resection bed radiosurgery of brain metastases, Neurosurgery, 2013. 73(6): p. 1001-6; discussion 1006., https://www.ncbi.nlm.nih.gov/pubmed/24264235
469. Ahmed, K. A., Freilich, J. M., Abuodeh, Y., Figura, N., Patel, N., Sarangkasiri, S., et.al. Fractionated stereotactic radiotherapy to the post-operative cavity for radioresistant and radiosensitive brain metastases, J Neurooncol, 2014. 118(1): p. 179-86., https://www.ncbi.nlm.nih.gov/pubmed/24604750
470. Hypofractionated radiosurgery has a better safety profile than single fraction radiosurgery for large resected brain metastases. J Neurooncol, 2015., https://www.ncbi.nlm.nih.gov/pubmed/25862006
471. Minniti, G., Esposito, V., Clarke, E., Scaringi, C., Lanzetta, G., Salvati, M., et.al. Multidose stereotactic radiosurgery (9 Gy x 3) of the postoperative resection cavity for treatment of large brain metastases, Int J Radiat Oncol Biol Phys, 2013. 86(4): p. 623-9., https://www.redjournal.org/article/S0360-3016(13)00361-1/abstract
472. Bates, J. E., Youn, P., Peterson, C. R., 3rd, Usuki, K. Y., Walter, K. A., Okunieff, P., et.al. Radiotherapy for Brain Metastases From Renal Cell Carcinoma in the Targeted Therapy Era: The University of Rochester Experience, Am J Clin Oncol, 2015., https://www.ncbi.nlm.nih.gov/pubmed/25730604
473. Staehler, M., Haseke, N., Nuhn, P., Tullmann, C., Karl, A., Siebels, M., et.al. Simultaneous anti-angiogenic therapy and single-fraction radiosurgery in clinically relevant metastases from renal cell carcinoma, BJU Int, 2011. 108(5): p. 673-8., https://www.ncbi.nlm.nih.gov/pubmed/21156017
474. Kalkanis, S. N., Kondziolka, D., Gaspar, L. E., Burri, S. H., Asher, A. L., Cobbs, C. S., et.al. The role of surgical resection in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline, J Neurooncol, 2010. 96(1): p. 33-43., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2808516/pdf/11060_2009_Article_61.pdf
475. Kocher, M., Wittig, A., Piroth, M. D., Treuer, H., Seegenschmiedt, H., Ruge, M., et.al. Stereotactic radiosurgery for treatment of brain metastases. A report of the DEGRO Working Group on Stereotactic Radiotherapy, Strahlenther Onkol, 2014. 190(6): p. 521-32., https://pubmed.ncbi.nlm.nih.gov/24715242/
476. Thelen, A., Jonas, S., Benckert, C., Lopez-Hanninen, E., Rudolph, B., Neumann, U., et.al. Liver resection for metastases from renal cell carcinoma, World J Surg, 2007. 31(4): p. 802-7., https://www.ncbi.nlm.nih.gov/pubmed/17354021
477. Ruys, A. T., Tanis, P. J., Iris, N. D., van Duijvendijk, P., Verhoef, C., Porte, R. J., et.al. Surgical treatment of renal cell cancer liver metastases: a population-based study, Ann Surg Oncol, 2011. 18(7): p. 1932-8., https://www.ncbi.nlm.nih.gov/pubmed/21347794
478. Staehler, M. D., Kruse, J., Haseke, N., Stadler, T., Roosen, A., Karl, A., et.al. Liver resection for metastatic disease prolongs survival in renal cell carcinoma: 12-year results from a retrospective comparative analysis, World J Urol, 2010. 28(4): p. 543-7., https://www.ncbi.nlm.nih.gov/pubmed/20440505
479. Sohn, T. A., Yeo, C. J., Cameron, J. L., Nakeeb, A., Lillemoe, K. D., Renal cell carcinoma metastatic to the pancreas: results of surgical management, J Gastrointest Surg, 2001. 5(4): p. 346-51., https://www.ncbi.nlm.nih.gov/pubmed/11985973
480. Ghavamian, R., Klein, K. A., Stephens, D. H., Welch, T. J., LeRoy, A. J., Richardson, R. L., et.al. Renal cell carcinoma metastatic to the pancreas: clinical and radiological features, Mayo Clin Proc, 2000. 75(6): p. 581-5., https://www.ncbi.nlm.nih.gov/pubmed/10852418
481. Zerbi, A., Ortolano, E., Balzano, G., Borri, A., Beneduce, A. A., Di Carlo, V., Pancreatic metastasis from renal cell carcinoma: which patients benefit from surgical resection?, Ann Surg Oncol, 2008. 15(4): p. 1161-8., https://pubmed.ncbi.nlm.nih.gov/18196343/
482. Reddy, S., Wolfgang, C. L., The role of surgery in the management of isolated metastases to the pancreas, Lancet Oncol, 2009. 10(3): p. 287-93., https://www.ncbi.nlm.nih.gov/pubmed/19261257
483. Bex, A., Horenblas, S., Meinhardt, W., Verra, N., de Gast, G. C., The role of initial immunotherapy as selection for nephrectomy in patients with metastatic renal cell carcinoma and the primary tumor in situ, Eur Urol, 2002. 42(6): p. 570-4; discussion 575-6., https://pubmed.ncbi.nlm.nih.gov/12477652/
484. Bex, A., van der Veldt, A. A., Blank, C., van den Eertwegh, A. J., Boven, E., Horenblas, S., et.al. Neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful resectability: initial experience with downsizing to reconsider cytoreductive surgery, World J Urol, 2009. 27(4): p. 533-9., https://pubmed.ncbi.nlm.nih.gov/19145434/
485. Krambeck, A. E., Leibovich, B. C., Lohse, C. M., Kwon, E. D., Zincke, H., Blute, M. L., The role of nephron sparing surgery for metastatic (pM1) renal cell carcinoma, J Urol, 2006. 176(5): p. 1990-5; discussion 1995., https://pubmed.ncbi.nlm.nih.gov/17070231/
486. Thomas, A. A., Rini, B. I., Lane, B. R., Garcia, J., Dreicer, R., Klein, E. A., et.al. Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma, J Urol, 2009. 181(2): p. 518-23; discussion 523., https://pubmed.ncbi.nlm.nih.gov/19100579/
487. Wagner, J. R., Walther, M. M., Linehan, W. M., White, D. E., Rosenberg, S. A., Yang, J. C., Interleukin-2 based immunotherapy for metastatic renal cell carcinoma with the kidney in place, J Urol, 1999. 162(1): p. 43-5., https://www.ncbi.nlm.nih.gov/pubmed/10379736
488. Klatte, T., Ittenson, A., Rohl, F. W., Ecke, M., Allhoff, E. P., Bohm, M., Perioperative immunomodulation with interleukin-2 in patients with renal cell carcinoma: results of a controlled phase II trial, Br J Cancer, 2006. 95(9): p. 1167-73., https://pubmed.ncbi.nlm.nih.gov/17031403/
489. Powles, T., Blank, C., Chowdhury, S., Horenblas, S., Peters, J., Shamash, J., et.al. The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer, Eur Urol, 2011. 60(3): p. 448-54., https://www.ncbi.nlm.nih.gov/pubmed/21612860
490. Powles, Thomas, Sarwar, Naveed, Stockdale, Andrew, Boleti, Ekaterini, Jones, Robert J, Protheroe, Andrew, et.al. Pazopanib prior to planned nephrectomy in metastatic clear cell renal cancer: a clinical and biomarker study, Journal of Clinical Oncology, 2013. 31(suppl; abstr 4508):, https://meetinglibrary.asco.org/record/85447/abstract
491. Rathmell, W. K., Pruthi, R., Wallen, E., Neoadjuvant treatment of renal cell carcinoma, Urol Oncol, 2010. 28(1): p. 69-73., https://www.ncbi.nlm.nih.gov/pubmed/20123351
492. Sciarra, A., Cattarino, S., Salciccia, S., Alfarone, A., Gentilucci, A., Parente, U., et.al. The emerging role of targeted therapy in renal cell carcinoma (RCC): is it time for a neoadjuvant or an adjuvant approach?, Crit Rev Oncol Hematol, 2012. 81(2): p. 151-62., https://pubmed.ncbi.nlm.nih.gov/21388825/
493. Smaldone, M. C., Fung, C., Uzzo, R. G., Haas, N. B., Adjuvant and neoadjuvant therapies in high-risk renal cell carcinoma, Hematol Oncol Clin North Am, 2011. 25(4): p. 765-91., https://www.ncbi.nlm.nih.gov/pubmed/21763967
494. Thillai, K., Allan, S., Powles, T., Rudman, S., Chowdhury, S., Neoadjuvant and adjuvant treatment of renal cell carcinoma, Expert Rev Anticancer Ther, 2012. 12(6): p. 765-76., https://www.ncbi.nlm.nih.gov/pubmed/22716493
495. Thomas, A. A., Rini, B. I., Stephenson, A. J., Garcia, J. A., Fergany, A., Krishnamurthi, V., et.al. Surgical resection of renal cell carcinoma after targeted therapy, J Urol, 2009. 182(3): p. 881-6., https://www.ncbi.nlm.nih.gov/pubmed/19616232
496. Kunkle, D. A., Haas, N. B., Uzzo, R. G., Adjuvant therapy for high-risk renal cell carcinoma patients, Curr Urol Rep, 2007. 8(1): p. 19-30., https://pubmed.ncbi.nlm.nih.gov/17239313/
497. Chapin, B. F., Delacroix, S. E., Jr., Culp, S. H., Nogueras Gonzalez, G. M., Tannir, N. M., Jonasch, E., et.al. Safety of presurgical targeted therapy in the setting of metastatic renal cell carcinoma, Eur Urol, 2011. 60(5): p. 964-71., https://www.ncbi.nlm.nih.gov/pubmed/21621907
498. Huguenin, P. U., Kieser, S., Glanzmann, C., Capaul, R., Lutolf, U. M., Radiotherapy for metastatic carcinomas of the kidney or melanomas: an analysis using palliative end points, Int J Radiat Oncol Biol Phys, 1998. 41(2): p. 401-5., https://pubmed.ncbi.nlm.nih.gov/9607358/
499. Powles, T, Sarwar, N, Stockdale, A, Sarker, SJ, Boleti, E, Protheroe, A, et.al. Safety and Efficacy of Pazopanib Therapy Prior to Planned Nephrectomy in Metastatic Clear Cell Renal Cancer., JAMA Oncol, 2016. 2 (10)(10): p. 1303-1309., https://pubmed.ncbi.nlm.nih.gov/27254750/
500. Tunio, M. A., Hashmi, A., Rafi, M., Need for a new trial to evaluate postoperative radiotherapy in renal cell carcinoma: a meta-analysis of randomized controlled trials, Ann Oncol, 2010. 21(9): p. 1839-45., https://pubmed.ncbi.nlm.nih.gov/20139152/
501. Rodríguez-Fernández, IA, Rodríguez-Romo, L, Hernandez-Barajas, D, Gonzalez-Conchas, GA, Verdines-Perez, A, Templeton, AJ, et.al. Adjuvant Radiation Therapy After Radical Nephrectomy in Patients with Localized Renal Cell Carcinoma: A Systematic Review and Meta-analysis., Eur Urol Oncol, 2019. 2 (4)(4): p. 448-455., https://pubmed.ncbi.nlm.nih.gov/31277782/
502. Bai, Y, Li, S, Jia, Z, Ding, Y, Gu, C, Yang, J, Adjuvant therapy for locally advanced renal cell carcinoma: A meta-analysis and systematic review., Urol Oncol, 2018. 36 (2)(2): p. 79.e1-79.e10., https://pubmed.ncbi.nlm.nih.gov/29110942/
503. Lenis, AT, Donin, NM, Johnson, DC, Faiena, I, Salmasi, A, Drakaki, A, et.al. Adjuvant Therapy for High Risk Localized Kidney Cancer: Emerging Evidence and Future Clinical Trials., J Urol, 2018. 199 (1)(1): p. 43-52., https://pubmed.ncbi.nlm.nih.gov/28479237/
504. Choueiri, TK, Tomczak, P, Park, SH, Venugopal, B, Ferguson, T, Chang, YH, et.al. Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma., N Engl J Med, 2021. 385 (8)(8): p. 683-694., https://pubmed.ncbi.nlm.nih.gov/34407342/
505. Rini, BI, Campbell, SC, Urinary Biomarkers for the Detection and Management of Localized Renal Cell Carcinoma., JAMA Oncol, 2015. 1 (2)(2): p. 212-3., https://pubmed.ncbi.nlm.nih.gov/26181026/
506. Haas, N. B., Manola, J., Uzzo, R. G., Flaherty, K. T., Wood, C. G., Kane, C., et.al. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial, Lancet, 2016. 387(10032): p. 2008-16., https://pubmed.ncbi.nlm.nih.gov/26969090/
507. Ravaud, A, Motzer, RJ, Pandha, HS, George, DJ, Pantuck, AJ, Patel, A, et.al. Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy., N Engl J Med, 2016. 375 (23)(23): p. 2246-2254., https://pubmed.ncbi.nlm.nih.gov/27718781/
508. Motzer, RJ, Ravaud, A, Patard, JJ, Pandha, HS, George, DJ, Patel, A, et.al. Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results., Eur Urol, 2018. 73 (1)(1): p. 62-68., https://pubmed.ncbi.nlm.nih.gov/28967554/
509. Synold, TW, Plets, M, Tangen, CM, Heath, EI, Palapattu, GS, Mack, PC, et.al. Everolimus Exposure as a Predictor of Toxicity in Renal Cell Cancer Patients in the Adjuvant Setting: Results of a Pharmacokinetic Analysis for SWOG S0931 (EVEREST), a Phase III Study (NCT01120249)., Kidney Cancer, 2019. 3 (2)(2): p. 111-118., https://pubmed.ncbi.nlm.nih.gov/31763512/
510. Motzer, RJ, Haas, NB, Donskov, F, Gross-Goupil, M, Varlamov, S, Kopyltsov, E, et.al. Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma., J Clin Oncol, 2017. 35 (35)(35): p. 3916-3923., https://pubmed.ncbi.nlm.nih.gov/28902533/
511. Gross-Goupil, M, Kwon, TG, Eto, M, Ye, D, Miyake, H, Seo, SI, et.al. Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial., Ann Oncol, 2018. 29 (12)(12): p. 2371-2378., https://pubmed.ncbi.nlm.nih.gov/30346481/
512. Riaz, IB, Faridi, W, Husnain, M, Malik, SU, Sipra, QUAR, Gondal, FR, et.al. Adjuvant Therapy in High-Risk Renal Cell Cancer: A Systematic Review and Meta-analysis., Mayo Clin Proc, 2019. 94 (8)(8): p. 1524-1534., https://pubmed.ncbi.nlm.nih.gov/31303430/
513. Mollica, V, Rizzo, A, Di Nunno, V, Santoni, M, Cheng, L, Lopez-Beltran, A, et.al. Adjuvant therapy in renal cell carcinoma: is it the right strategy to inhibit VEGF?, Transl Androl Urol, 2021. 10 (3)(3): p. 1581-1587., https://pubmed.ncbi.nlm.nih.gov/33850792/
514. Massari, F, Di Nunno, V, Mollica, V, Graham, J, Gatto, L, Heng, D, Adjuvant Tyrosine Kinase Inhibitors in Treatment of Renal Cell Carcinoma: A Meta-Analysis of Available Clinical Trials., Clin Genitourin Cancer, 2019. 17 (2)(2): p. e339-e344., https://pubmed.ncbi.nlm.nih.gov/30704796/
515. Chamie, K, Donin, NM, Klöpfer, P, Bevan, P, Fall, B, Wilhelm, O, et.al. Adjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell Carcinoma: The ARISER Randomized Clinical Trial., JAMA Oncol, 2017. 3 (7)(7): p. 913-920., https://pubmed.ncbi.nlm.nih.gov/27787547/
516. Wolff, I, May, M, Hoschke, B, Zigeuner, R, Cindolo, L, Hutterer, G, et.al. Do we need new high-risk criteria for surgically treated renal cancer patients to improve the outcome of future clinical trials in the adjuvant setting? Results of a comprehensive analysis based on the multicenter CORONA database., Eur J Surg Oncol, 2016. 42 (5)(5): p. 744-50., https://pubmed.ncbi.nlm.nih.gov/26899942/
517. Rini, BI, Campbell, SC, Escudier, B, Renal cell carcinoma., Lancet, 2009. 373 (9669)(9669): p. 1119-32., https://pubmed.ncbi.nlm.nih.gov/19269025/
518. Fuhrman, SA, Lasky, LC, Limas, C, Prognostic significance of morphologic parameters in renal cell carcinoma., Am J Surg Pathol, 1982. 6 (7)(7): p. 655-63., https://pubmed.ncbi.nlm.nih.gov/7180965/
519. Moch, H, Cubilla, AL, Humphrey, PA, Reuter, VE, Ulbright, TM, The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours., Eur Urol, 2016. 70 (1)(1): p. 93-105., https://pubmed.ncbi.nlm.nih.gov/26935559/
520. Dutcher, JP, de Souza, P, McDermott, D, Figlin, RA, Berkenblit, A, Thiele, A, et.al. Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies., Med Oncol, 2009. 26 (2)(2): p. 202-9., https://pubmed.ncbi.nlm.nih.gov/19229667/
521. Tannir, NM, Signoretti, S, Choueiri, TK, McDermott, DF, Motzer, RJ, Flaifel, A, et.al. Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma., Clin Cancer Res, 2021. 27 (1)(1): p. 78-86., https://pubmed.ncbi.nlm.nih.gov/32873572/
522. Ruiz-Bañobre, J, Anido, U, Abdulkader, I, Antúnez-López, J, López-López, R, García-González, J, Long-term Response to Nivolumab and Acute Renal Failure in a Patient with Metastatic Papillary Renal Cell Carcinoma and a PD-L1 Tumor Expression Increased with Sunitinib Therapy: A Case Report., Front Oncol, 2016. 6 (): p. 250., https://pubmed.ncbi.nlm.nih.gov/27921007/
523. Adrianzen Herrera, DA, Fleisig, SB, Gartrell, BA, Impressive and durable response to nivolumab in a patient with metastatic type 2 papillary renal cell carcinoma: On-label but without evidence., Invest New Drugs, 2017. 35 (5)(5): p. 665-668., https://pubmed.ncbi.nlm.nih.gov/28466375/
524. Koshkin, VS, Barata, PC, Zhang, T, George, DJ, Atkins, MB, Kelly, WJ, et.al. Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma., J Immunother Cancer, 2018. 6 (1)(1): p. 9., https://pubmed.ncbi.nlm.nih.gov/29378660/
525. Mizutani, K, Horie, K, Nagai, S, Tsuchiya, T, Saigo, C, Kobayashi, K, et.al. Response to nivolumab in metastatic collecting duct carcinoma expressing PD-L1: A case report., Mol Clin Oncol, 2017. 7 (6)(6): p. 988-990., https://pubmed.ncbi.nlm.nih.gov/29285361/
526. Chahoud, J, Msaouel, P, Campbell, MT, Bathala, T, Xiao, L, Gao, J, et.al. Nivolumab for the Treatment of Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma (nccRCC): A Single-Institutional Experience and Literature Meta-Analysis., Oncologist, 2020. 25 (3)(3): p. 252-258., https://pubmed.ncbi.nlm.nih.gov/32162795/
527. McDermott, DF, Lee, JL, Ziobro, M, Suarez, C, Langiewicz, P, Matveev, VB, et.al. Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma., J Clin Oncol, 2021. 39 (9)(9): p. 1029-1039., https://pubmed.ncbi.nlm.nih.gov/33529058/
528. Tannir, NM, Jonasch, E, Albiges, L, Altinmakas, E, Ng, CS, Matin, SF, et.al. Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial., Eur Urol, 2016. 69 (5)(5): p. 866-74., https://pubmed.ncbi.nlm.nih.gov/26626617/
529. Armstrong, AJ, Halabi, S, Eisen, T, Broderick, S, Stadler, WM, Jones, RJ, et.al. Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial., Lancet Oncol, 2016. 17 (3)(3): p. 378-388., https://pubmed.ncbi.nlm.nih.gov/26794930/
530. Bergmann, L, Grünwald, V, Maute, L, Grimm, MO, Weikert, S, Schleicher, J, et.al. A Randomized Phase IIa Trial with Temsirolimus versus Sunitinib in Advanced Non-Clear Cell Renal Cell Carcinoma: An Intergroup Study of the CESAR Central European Society for Anticancer Drug Research-EWIV and the Interdisciplinary Working Group on Renal Cell Cancer (IAGN) of the German Cancer Society., Oncol Res Treat, 2020. 43 (7-8)(7-8): p. 333-339., https://pubmed.ncbi.nlm.nih.gov/32541143/
531. Bersanelli, M, Brunelli, M, Gnetti, L, Maestroni, U, Buti, S, Pazopanib as a possible option for the treatment of metastatic non-clear cell renal carcinoma patients: a systematic review., Ther Adv Med Oncol, 2020. 12 (): p. 1758835920915303., https://pubmed.ncbi.nlm.nih.gov/32550862/
532. Choueiri, TK, Plantade, A, Elson, P, Negrier, S, Ravaud, A, Oudard, S, et.al. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma., J Clin Oncol, 2008. 26 (1)(1): p. 127-31., https://pubmed.ncbi.nlm.nih.gov/18165647/
533. Martínez Chanzá, N, Xie, W, Asim Bilen, M, Dzimitrowicz, H, Burkart, J, Geynisman, DM, et.al. Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study., Lancet Oncol, 2019. 20 (4)(4): p. 581-590., https://pubmed.ncbi.nlm.nih.gov/30827746/
534. Vera-Badillo, F. E., Templeton, A. J., Duran, I., Ocana, A., de Gouveia, P., Aneja, P., et.al. Systemic therapy for non-clear cell renal cell carcinomas: a systematic review and meta-analysis, Eur Urol, 2015. 67(4): p. 740-9., https://pubmed.ncbi.nlm.nih.gov/24882670/
535. Ciccarese, C., Iacovelli, R., Brunelli, M., Massari, F., Bimbatti, D., Fantinel, E., et.al. Addressing the best treatment for non-clear cell renal cell carcinoma: A meta-analysis of randomised clinical trials comparing VEGFR-TKis versus mTORi-targeted therapies, European Journal of Cancer, 2017. 83: p. 237-246., https://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med13&AN=28756136https://www.sciencedirect.com/science/article/abs/pii/S0959804917310961?via%3Dihub
536. Pal, SK, Tangen, C, Thompson, IM, Balzer-Haas, N, George, DJ, Heng, DYC, et.al. A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial., Lancet, 2021. 397 (10275)(10275): p. 695-703., https://pubmed.ncbi.nlm.nih.gov/33592176/
537. Trpkov, K, Hes, O, Williamson, SR, Adeniran, AJ, Agaimy, A, Alaghehbandan, R, et.al. New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasia., Mod Pathol, 2021. 34 (7)(7): p. 1392-1424., https://pubmed.ncbi.nlm.nih.gov/33664427/
538. Hutson, TE, Michaelson, MD, Kuzel, TM, Agarwal, N, Molina, AM, Hsieh, JJ, et.al. A Single-arm, Multicenter, Phase 2 Study of Lenvatinib Plus Everolimus in Patients with Advanced Non-Clear Cell Renal Cell Carcinoma., Eur Urol, 2021. 80 (2)(2): p. 162-170., https://pubmed.ncbi.nlm.nih.gov/33867192/
539. Motzer, RJ, Escudier, B, George, S, Hammers, HJ, Srinivas, S, Tykodi, SS, et.al. Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial., Cancer, 2020. 126 (18)(18): p. 4156-4167., https://pubmed.ncbi.nlm.nih.gov/32673417/
540. Motzer, RJ, Rini, BI, McDermott, DF, Arén Frontera, O, Hammers, HJ, Carducci, MA, et.al. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial., Lancet Oncol, 2019. 20 (10)(10): p. 1370-1385., https://pubmed.ncbi.nlm.nih.gov/31427204/
541. Rini, BI, Powles, T, Atkins, MB, Escudier, B, McDermott, DF, Suarez, C, et.al. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial., Lancet, 2019. 393 (10189)(10189): p. 2404-2415., https://pubmed.ncbi.nlm.nih.gov/31079938/
542. Penkov, S, Mitroulis, I, Hajishengallis, G, Chavakis, T, Immunometabolic Crosstalk: An Ancestral Principle of Trained Immunity?, Trends Immunol, 2019. 40 (1)(1): p. 1-11., https://pubmed.ncbi.nlm.nih.gov/30503793/
543. Choueiri, TK, Larkin, J, Pal, S, Motzer, RJ, Rini, BI, Venugopal, B, et.al. Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial., ESMO Open, 2021. 6 (3)(3): p. 100101., https://pubmed.ncbi.nlm.nih.gov/33901870/
544. Chahoud, J., Msaouel, P., Campbell, M. T., Bathala, T., Xiao, L., Gao, J., et.al. Nivolumab for the treatment of patients with metastatic non-clear cell renal cell carcinoma (nccRCC): a single-institutional experience and literature meta-analysis, Oncologist, 2019. Epub ahead of print:, http://ksrevidence.com/article/KSRA115453/
545. Kawakami, F, Sircar, K, Rodriguez-Canales, J, Fellman, BM, Urbauer, DL, Tamboli, P, et.al. Programmed cell death ligand 1 and tumor-infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation., Cancer, 2017. 123 (24)(24): p. 4823-4831., https://pubmed.ncbi.nlm.nih.gov/28832979/
546. Mouallem, NE, Smith, SC, Paul, AK, Sarcomatoid renal cell carcinoma: Biology and treatment advances., Urol Oncol, 2018. 36 (6)(6): p. 265-271., https://pubmed.ncbi.nlm.nih.gov/29306556/
547. Buonerba, C, Dolce, P, Iaccarino, S, Scafuri, L, Verde, A, Costabile, F, et.al. Outcomes Associated with First-Line anti-PD-1/ PD-L1 agents vs. Sunitinib in Patients with Sarcomatoid Renal Cell Carcinoma: A Systematic Review and Meta-Analysis., Cancers (Basel), 2020. 12 (2)(2):, https://pubmed.ncbi.nlm.nih.gov/32050629/
548. Raychaudhuri, R, Riese, MJ, Bylow, K, Burfeind, J, Mackinnon, AC, Tolat, PP, et.al. Immune Check Point Inhibition in Sarcomatoid Renal Cell Carcinoma: A New Treatment Paradigm., Clin Genitourin Cancer, 2017. 15 (5)(5): p. e897-e901., https://pubmed.ncbi.nlm.nih.gov/28645484/
549. Geynisman, DM, Anti-programmed Cell Death Protein 1 (PD-1) Antibody Nivolumab Leads to a Dramatic and Rapid Response in Papillary Renal Cell Carcinoma with Sarcomatoid and Rhabdoid Features., Eur Urol, 2015. 68 (5)(5): p. 912-4., https://pubmed.ncbi.nlm.nih.gov/26194044/
550. Lebacle, C, Pooli, A, Bessede, T, Irani, J, Pantuck, AJ, Drakaki, A, Epidemiology, biology and treatment of sarcomatoid RCC: current state of the art., World J Urol, 2019. 37 (1)(1): p. 115-123., https://pubmed.ncbi.nlm.nih.gov/29858701/
551. Maiti, A, Nemati-Shafaee, M, Msaouel, P, Pagliaro, LC, Jonasch, E, Tannir, NM, et.al. Phase 2 Trial of Capecitabine, Gemcitabine, and Bevacizumab in Sarcomatoid Renal-Cell Carcinoma., Clin Genitourin Cancer, 2017. ():, https://pubmed.ncbi.nlm.nih.gov/28870517/
552. Ahrens, M, Scheich, S, Hartmann, A, Bergmann, L, Non-Clear Cell Renal Cell Carcinoma - Pathology and Treatment Options., Oncol Res Treat, 2019. 42 (3)(3): p. 128-135., https://pubmed.ncbi.nlm.nih.gov/30799404/
553. Michaelson, MD, McKay, RR, Werner, L, Atkins, MB, Van Allen, EM, Olivier, KM, et.al. Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma., Cancer, 2015. 121 (19)(19): p. 3435-43., https://pubmed.ncbi.nlm.nih.gov/26058385/
554. Voss, MH, Bastos, DA, Karlo, CA, Ajeti, A, Hakimi, AA, Feldman, DR, et.al. Treatment outcome with mTOR inhibitors for metastatic renal cell carcinoma with nonclear and sarcomatoid histologies., Ann Oncol, 2014. 25 (3)(3): p. 663-668., https://pubmed.ncbi.nlm.nih.gov/24458473/
555. Park, I, Lee, HJ, Bae, WK, Yoon, S, Lee, JL, A multicenter, prospective phase II trial of gemcitabine plus axitinib in patients with renal cell carcinoma with a predominant sarcomatoid component., Invest New Drugs, 2019. 37 (6)(6): p. 1239-1246., https://pubmed.ncbi.nlm.nih.gov/31231787/
556. Shuch, B, Vourganti, S, Ricketts, CJ, Middleton, L, Peterson, J, Merino, MJ, et.al. Defining early-onset kidney cancer: implications for germline and somatic mutation testing and clinical management., J Clin Oncol, 2014. 32 (5)(5): p. 431-7., https://pubmed.ncbi.nlm.nih.gov/24378414/
557. Zhang, YD, Hurson, AN, Zhang, H, Choudhury, PP, Easton, DF, Milne, RL, et.al. Assessment of polygenic architecture and risk prediction based on common variants across fourteen cancers., Nat Commun, 2020. 11 (1)(1): p. 3353., https://pubmed.ncbi.nlm.nih.gov/32620889/
558. Schmidt, LS, Linehan, WM, Genetic predisposition to kidney cancer., Semin Oncol, 2016. 43 (5)(5): p. 566-574., https://pubmed.ncbi.nlm.nih.gov/27899189/
559. Yngvadottir, B, Andreou, A, Bassaganyas, L, Larionov, A, Cornish, AJ, Chubb, D, et.al. Frequency of pathogenic germline variants in cancer susceptibility genes in 1336 renal cell carcinoma cases., Hum Mol Genet, 2022. 31 (17)(17): p. 3001-3011., https://pubmed.ncbi.nlm.nih.gov/35441217/
560. Northrup, H, Aronow, ME, Bebin, EM, Bissler, J, Darling, TN, de Vries, PJ, et.al. Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations., Pediatr Neurol, 2021. 123 (): p. 50-66., https://pubmed.ncbi.nlm.nih.gov/34399110/
561. Carlo, MI, Hakimi, AA, Stewart, GD, Bratslavsky, G, Brugarolas, J, Chen, YB, et.al. Familial Kidney Cancer: Implications of New Syndromes and Molecular Insights., Eur Urol, 2019. 76 (6)(6): p. 754-764., https://pubmed.ncbi.nlm.nih.gov/31326218/
562. Guo, T, Shen, Q, Ouyang, R, Song, M, Zong, D, Shi, Z, et.al. The clinical characteristics of East Asian patients with Birt-Hogg-Dubé syndrome., Ann Transl Med, 2020. 8 (21)(21): p. 1436., https://pubmed.ncbi.nlm.nih.gov/33313181/
563. Linehan, WM, Srinivasan, R, Schmidt, LS, The genetic basis of kidney cancer: a metabolic disease., Nat Rev Urol, 2010. 7 (5)(5): p. 277-85., https://pubmed.ncbi.nlm.nih.gov/20448661/
564. Hendricks, LAJ, Hoogerbrugge, N, Schuurs-Hoeijmakers, JHM, Vos, JR, A review on age-related cancer risks in PTEN hamartoma tumor syndrome., Clin Genet, 2021. 99 (2)(2): p. 219-225., https://pubmed.ncbi.nlm.nih.gov/33140411/
565. Robert-Koch-Institut, Krebs in Deutschland, 2012., http://dx.doi.org/10.25646/3174
566. Singer, EA, Bratslavsky, G, Middelton, L, Srinivasan, R, Linehan, WM, Impact of genetics on the diagnosis and treatment of renal cancer., Curr Urol Rep, 2011. 12 (1)(1): p. 47-55., https://pubmed.ncbi.nlm.nih.gov/21128028/
567. Motzer, RJ, Jonasch, E, Agarwal, N, Alva, A, Baine, M, Beckermann, K, et.al. Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology., J Natl Compr Canc Netw, 2022. 20 (1)(1): p. 71-90., https://pubmed.ncbi.nlm.nih.gov/34991070/
568. Klingler, JH, Gläsker, S, Bausch, B, Urbach, H, Krauss, T, Jilg, CA, et.al. Hemangioblastoma and von Hippel-Lindau disease: genetic background, spectrum of disease, and neurosurgical treatment., Childs Nerv Syst, 2020. 36 (10)(10): p. 2537-2552., https://pubmed.ncbi.nlm.nih.gov/32507909/
569. Trpkov, K, Williamson, SR, Gill, AJ, Adeniran, AJ, Agaimy, A, Alaghehbandan, R, et.al. Novel, emerging and provisional renal entities: The Genitourinary Pathology Society (GUPS) update on renal neoplasia., Mod Pathol, 2021. 34 (6)(6): p. 1167-1184., https://pubmed.ncbi.nlm.nih.gov/33526874/
570. Yanus, GA, Kuligina, ES, Imyanitov, EN, Hereditary Renal Cancer Syndromes., Med Sci (Basel), 2024. 12 (1)(1):, https://pubmed.ncbi.nlm.nih.gov/38390862/
571. Mohanty, SK, Lobo, A, Cheng, L, The 2022 revision of the World Health Organization classification of tumors of the urinary system and male genital organs: advances and challenges., Hum Pathol, 2023. 136 (): p. 123-143., https://pubmed.ncbi.nlm.nih.gov/36084769/
572. Agaimy, A, Hartmann, A, Uncovering Hereditary Tumor Syndromes: Emerging Role of Surgical Pathology., Semin Diagn Pathol, 2018. 35 (3)(3): p. 154-160., https://pubmed.ncbi.nlm.nih.gov/29395463/
573. Rogala, J, Zhou, M, Hereditary succinate dehydrogenase-deficient renal cell carcinoma., Semin Diagn Pathol, 2024. 41 (1)(1): p. 32-41., https://pubmed.ncbi.nlm.nih.gov/37981479/
574. Trpkov, K, Hes, O, Agaimy, A, Bonert, M, Martinek, P, Magi-Galluzzi, C, et.al. Fumarate Hydratase-deficient Renal Cell Carcinoma Is Strongly Correlated With Fumarate Hydratase Mutation and Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome., Am J Surg Pathol, 2016. 40 (7)(7): p. 865-75., https://pubmed.ncbi.nlm.nih.gov/26900816/
575. Motzer, RJ, Jonasch, E, Boyle, S, Carlo, MI, Manley, B, Agarwal, N, et.al. NCCN Guidelines Insights: Kidney Cancer, Version 1.2021., J Natl Compr Canc Netw, 2020. 18 (9)(9): p. 1160-1170., https://pubmed.ncbi.nlm.nih.gov/32886895/
576. Louise M Binderup, M, Smerdel, M, Borgwadt, L, Beck Nielsen, SS, Madsen, MG, Møller, HU, et.al. von Hippel-Lindau disease: Updated guideline for diagnosis and surveillance., Eur J Med Genet, 2022. 65 (8)(8): p. 104538., https://pubmed.ncbi.nlm.nih.gov/35709961/
577. Lattouf, JB, Pautler, SE, Reaume, MN, Kim, RH, Care, M, Green, J, et.al. Structured assessment and followup for patients with hereditary kidney tumour syndromes., Can Urol Assoc J, 2016. 10 (7-8)(7-8): p. E214-E222., https://pubmed.ncbi.nlm.nih.gov/28255411/
578. Bissler, JJ, Kingswood, JC, Optimal treatment of tuberous sclerosis complex associated renal angiomyolipomata: a systematic review., Ther Adv Urol, 2016. 8 (4)(4): p. 279-290., https://pubmed.ncbi.nlm.nih.gov/27928430/
579. Gopie, JP, Vasen, HF, Tibben, A, Surveillance for hereditary cancer: does the benefit outweigh the psychological burden?--A systematic review., Crit Rev Oncol Hematol, 2012. 83 (3)(3): p. 329-40., https://pubmed.ncbi.nlm.nih.gov/22366115/
580. Signorelli, F, Piscopo, G, Giraud, S, Guerriero, S, Laborante, A, Latronico, ME, et.al. Von Hippel-Lindau disease: when neurosurgery meets nephrology, ophthalmology and genetics., J Neurosurg Sci, 2019. 63 (5)(5): p. 548-565., https://pubmed.ncbi.nlm.nih.gov/28748909/
581. Rouvière, O, Nivet, H, Grenier, N, Zini, L, Lechevallier, E, Kidney damage due to tuberous sclerosis complex: management recommendations., Diagn Interv Imaging, 2013. 94 (3)(3): p. 225-37., https://pubmed.ncbi.nlm.nih.gov/23415464/
582. Kim, JK, Park, SY, Shon, JH, Cho, KS, Angiomyolipoma with minimal fat: differentiation from renal cell carcinoma at biphasic helical CT., Radiology, 2004. 230 (3)(3): p. 677-84., https://pubmed.ncbi.nlm.nih.gov/14990834/
583. Dabbeche, C, Chaker, M, Chemali, R, Perot, V, El Hajj, L, Ferriere, JM, et.al. [Role of embolization in renal angiomyolipomas]., J Radiol, 2006. 87 (12 Pt 1)(12 Pt 1): p. 1859-67., https://pubmed.ncbi.nlm.nih.gov/17213770/
584. Hatano, T, Egawa, S, Renal angiomyolipoma with tuberous sclerosis complex: How it differs from sporadic angiomyolipoma in both management and care., Asian J Surg, 2020. 43 (10)(10): p. 967-972., https://pubmed.ncbi.nlm.nih.gov/31959574/
585. Bissler, JJ, Kingswood, JC, Radzikowska, E, Zonnenberg, BA, Frost, M, Belousova, E, et.al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial., Lancet, 2013. 381 (9869)(9869): p. 817-24., https://pubmed.ncbi.nlm.nih.gov/23312829/
586. Jonasch, E, Donskov, F, Iliopoulos, O, Rathmell, WK, Narayan, VK, Maughan, BL, et.al. Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease., N Engl J Med, 2021. 385 (22)(22): p. 2036-2046., https://pubmed.ncbi.nlm.nih.gov/34818478/
587. Jonasch, E, LITESPARK-004 (MK-6482-004) phase 2 study of belzutifan, an oral hypoxia-inducible factor 2α inhibitor (HIF-2α), for von Hippel-Lindau (VHL) disease: Update with more than two years of follow-up data., 2022., https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.4546
588. Choueiri, TK, Vaishampayan, U, Rosenberg, JE, Logan, TF, Harzstark, AL, Bukowski, RM, et.al. Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma., J Clin Oncol, 2013. 31 (2)(2): p. 181-6., https://pubmed.ncbi.nlm.nih.gov/23213094/
589. Deutsche Gesellschaft für Humangenetik e.V. (GfH) und Berufsverband Deutscher Humangenetiker e.V. (BVDH), S2k-Leitlinie: Humangenetische Diagnostik und Genetische Beratung, 2019.
590. Bennani, O., Derrey, S., Langlois, O., Castel, H., Laquerriere, A., Freger, P., et.al. Brain metastasis from renal cell carcinoma, Neurochirurgie, 2014. 60(1-2): p. 12-6., https://pubmed.ncbi.nlm.nih.gov/24636403/
591. Chow, E., Zeng, L., Salvo, N., Dennis, K., Tsao, M., Lutz, S., Update on the systematic review of palliative radiotherapy trials for bone metastases, Clin Oncol (R Coll Radiol), 2012. 24(2): p. 112-24., https://www.ncbi.nlm.nih.gov/pubmed/22130630
592. Lutz, S., The role of radiation therapy in controlling painful bone metastases, Curr Pain Headache Rep, 2012. 16(4): p. 300-6., https://www.ncbi.nlm.nih.gov/pubmed/22576786
593. Lutz, Stephen, Berk, Lawrence, Chang, Eric, Chow, Edward, Hahn, Carol, Hoskin, Peter, et.al. Palliative radiotherapy for bone metastases: an ASTRO evidence-based guideline, International Journal of Radiation Oncology* Biology* Physics, 2011. 79(4): p. 965-976., https://pubmed.ncbi.nlm.nih.gov/21277118/
594. Prewett, S., Venkitaraman, R., Metastatic spinal cord compression: review of the evidence for a radiotherapy dose fractionation schedule, Clin Oncol (R Coll Radiol), 2010. 22(3): p. 222-30., https://www.ncbi.nlm.nih.gov/pubmed/20138487
595. Rades, D., Weber, A., Bartscht, T., Bajrovic, A., Karstens, J. H., Schild, S. E., A new prognostic factor for the survival of patients with renal cell carcinoma developing metastatic spinal cord compression, Strahlenther Onkol, 2014. 190(7): p. 667-70., https://www.ncbi.nlm.nih.gov/pubmed/24535650
596. Fokas, Emmanouil, Henzel, Martin, Hamm, Klaus, Surber, Gunnar, Kleinert, Gabriele, Engenhart-Cabillic, Rita, Radiotherapy for Brain Metastases from Renal Cell Cancer: Should Whole-Brain Radiotherapy Be Added to Stereotactic Radiosurgery?, Strahlentherapie und Onkologie, 2010. 186(4): p. 210-217., https://pubmed.ncbi.nlm.nih.gov/20165820/
597. A survival score for patients with brain metastases from less radiosensitive tumors treated with whole-brain radiotherapy alone, 2014., https://www.ncbi.nlm.nih.gov/pubmed/23861153
598. Onufrey, V., Mohiuddin, M., Radiation therapy in the treatment of metastatic renal cell carcinoma, Int J Radiat Oncol Biol Phys, 1985. 11(11): p. 2007-9., https://www.ncbi.nlm.nih.gov/pubmed/2414257
599. Pongracz, N., Zimmerman, R., Kotz, R., Orthopaedic management of bony metastases of renal cancer, Semin Surg Oncol, 1988. 4(2): p. 139-42., https://pubmed.ncbi.nlm.nih.gov/3393777/
600. Wilson, D., Hiller, L., Gray, L., Grainger, M., Stirling, A., James, N., The effect of biological effective dose on time to symptom progression in metastatic renal cell carcinoma, Clin Oncol (R Coll Radiol), 2003. 15(7): p. 400-7., https://www.ncbi.nlm.nih.gov/pubmed/14570088
601. Halperin, E. C., Harisiadis, L., The role of radiation therapy in the management of metastatic renal cell carcinoma, Cancer, 1983. 51(4): p. 614-7., https://www.ncbi.nlm.nih.gov/pubmed/6185207
602. Fossa, S. D., Kjolseth, I., Lund, G., Radiotherapy of metastases from renal cancer, Eur Urol, 1982. 8(6): p. 340-2., https://pubmed.ncbi.nlm.nih.gov/6183119/
603. DiBiase, SJ, Valicenti, RK, Schultz, D, Xie, Y, Palliative irradiation for focally symptomatic metastatic renal cell carcinoma: support for dose escalation based on a biological model, J Urol, 1997. 158 (3 Pt 1): p. 746-9., https://pubmed.ncbi.nlm.nih.gov/9258072/
604. Kjaer, M., Engelholm, S. A., The clinical course and prognosis of patients with renal adenocarcinoma with solitary metastasis, Int J Radiat Oncol Biol Phys, 1982. 8(10): p. 1691-8., https://pubmed.ncbi.nlm.nih.gov/7153079/
605. Lee, J., Hodgson, D., Chow, E., Bezjak, A., Catton, P., Tsuji, D., et.al. A phase II trial of palliative radiotherapy for metastatic renal cell carcinoma, Cancer, 2005. 104(9): p. 1894-900., http://www.ncbi.nlm.nih.gov/pubmed/16177996
606. Reichel, L. M., Pohar, S., Heiner, J., Buzaianu, E. M., Damron, T. A., Radiotherapy to bone has utility in multifocal metastatic renal carcinoma, Clin Orthop Relat Res, 2007. 459: p. 133-8., https://pubmed.ncbi.nlm.nih.gov/17438472/
607. Townsend, P. W., Rosenthal, H. G., Smalley, S. R., Cozad, S. C., Hassanein, R. E., Impact of postoperative radiation therapy and other perioperative factors on outcome after orthopedic stabilization of impending or pathologic fractures due to metastatic disease, J Clin Oncol, 1994. 12(11): p. 2345-50., https://pubmed.ncbi.nlm.nih.gov/7669102/
608. Lagerwaard, F. J., Levendag, P. C., Nowak, P. J., Eijkenboom, W. M., Hanssens, P. E., Schmitz, P. I., Identification of prognostic factors in patients with brain metastases: a review of 1292 patients, Int J Radiat Oncol Biol Phys, 1999. 43(4): p. 795-803., https://www.ncbi.nlm.nih.gov/pubmed/10098435
609. Schellinger, P. D., Meinck, H. M., Thron, A., Diagnostic accuracy of MRI compared to CCT in patients with brain metastases, J Neurooncol, 1999. 44(3): p. 275-81., https://pubmed.ncbi.nlm.nih.gov/10720207/
610. Wronski, M., Maor, M. H., Davis, B. J., Sawaya, R., Levin, V. A., External radiation of brain metastases from renal carcinoma: a retrospective study of 119 patients from the M. D. Anderson Cancer Center, Int J Radiat Oncol Biol Phys, 1997. 37(4): p. 753-9., https://www.ncbi.nlm.nih.gov/pubmed/9128947
611. Samlowski, W. E., Majer, M., Boucher, K. M., Shrieve, A. F., Dechet, C., Jensen, R. L., et.al. Multidisciplinary treatment of brain metastases derived from clear cell renal cancer incorporating stereotactic radiosurgery, Cancer, 2008. 113(9): p. 2539-48., https://www.ncbi.nlm.nih.gov/pubmed/18780316
612. Gaspar, L. E., Mehta, M. P., Patchell, R. A., Burri, S. H., Robinson, P. D., Morris, R. E., et.al. The role of whole brain radiation therapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline, J Neurooncol, 2010. 96(1): p. 17-32., https://www.ncbi.nlm.nih.gov/pubmed/19960231
613. Hartenstein, R., Kleeberg, U. R., Schmerztherapie, in Kompendium Internistische Onkologie, Schmoll, Hans-JoachimHoeffken, Klaus and Possinger, Kurt, Editors. 2006, Springer: Berlin, Heidelberg. p. 2162-2179.
614. Hoeffler, D, Lasek, R, Berthold, HK, Empfehlungen zur Therapie von Tumorschmerzen, Arzneimittelkommission der deutschen Ärzteschaft (AkdÄ)(Hrsg.). Arzneiverordnung in der Praxis (AVP), 2007. 34:
615. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF), Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms, 2011.
616. V., Arbeitsgemeinschaft Gynaekologische Onkologie, Diagnostik und Therapie primaerer und metastasierter Mammakarzinome. Osteoonkologie und Knochengesundheit, Diagnostik und Therapie primaerer und metastasierter Mammakarzinome. Osteoonkologie und Knochengesundheit, 2013.
617. Tunn, U. W., Stenzl, A., Schultze-Seemann, W., Strauss, A., Kindler, M., Miller, K., et.al. Positive effects of zoledronate on skeletal-related events in patients with renal cell cancer and bone metastases, Can J Urol, 2012. 19(3): p. 6261-7., https://www.ncbi.nlm.nih.gov/pubmed/22704310
618. Yuen, K. K., Shelley, M., Sze, W. M., Wilt, T., Mason, M. D., Bisphosphonates for advanced prostate cancer, Cochrane Database Syst Rev, 2006. p. CD006250., https://www.ncbi.nlm.nih.gov/pubmed/17054286
619. Henry, D. H., Costa, L., Goldwasser, F., Hirsh, V., Hungria, V., Prausova, J., et.al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma, J Clin Oncol, 2011. 29(9): p. 1125-1132., https://pubmed.ncbi.nlm.nih.gov/21343556/
620. Groetz, KA, Piesold, JU, Al-Nawas, B, AWMF Leitlinie Bisphosphonat-assoziierte Kiefernekrose (BP-ONJ) und andere Medikamenten-assoziierte KiefernekrosenAWMF, 2012., https://www.bzaek.de/fileadmin/PDFs/za/007-091l_S3_Bisphosphonat-assoziierte_Kiefernekrose_2012-04.pdf
621. Fizazi, K., Carducci, M., Smith, M., Damiao, R., Brown, J., Karsh, L., et.al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study, Lancet, 2011. 377(9768): p. 813-822., https://pubmed.ncbi.nlm.nih.gov/21353695/
622. Schlimok, G, Wilhelm, M, Weissbach, L, Diagnostik von Knochenmetastasen urologischer Tumoren und deren Behandlung mit Bisphosphonaten, Onkologe, 2007. 13: p. 77-80., https://pubmed.ncbi.nlm.nih.gov/17091278/
623. Sutton, J. M., Evaluation of hematuria in adults, JAMA, 1990. 263(18): p. 2475-80., https://www.ncbi.nlm.nih.gov/pubmed/2184261
624. Davis, R., Jones, J. S., Barocas, D. A., Castle, E. P., Lang, E. K., Leveillee, R. J., et.al. Diagnosis, evaluation and follow-up of asymptomatic microhematuria (AMH) in adults: AUA guideline, J Urol, 2012. 188(6 Suppl): p. 2473-81., https://www.ncbi.nlm.nih.gov/pubmed/23098784
625. O'Grady, A. S., Morse, L. J., Lee, J. B., Parathyroid hormone-secreting renal carcinoma associated with hypercalcemia and metabolic alkalosis, Ann Intern Med, 1965. 63(5): p. 858-68., https://www.ncbi.nlm.nih.gov/pubmed/5848632
626. Lytton, B., Rosof, B., Evans, J. S., Parathyroid Hormone-Like Activity in a Renal Carcinoma Producing Hypercalcemia, J Urol, 1965. 93: p. 127-31., https://www.ncbi.nlm.nih.gov/pubmed/14260201
627. Goldberg, M. F., Tashjian, A. H., Jr., Order, S. E., Dammin, G. J., Renal Adenocarcinoma Containing a Parathyroid Hormone-Like Substance and Associated with Marked Hypercalcemia, Am J Med, 1964. 36: p. 805-14., https://www.ncbi.nlm.nih.gov/pubmed/14141455
628. Sandhu, DPS, Munson, KW, Harrop, JS, Hopton, MR, Ratcliffe, WA, Humoral hypercalcaemia in renal carcinoma due to parathyroid hormone related protein, British journal of urology, 1993. 72(6): p. 848-850., https://pubmed.ncbi.nlm.nih.gov/8306145/
629. de la Mata, J., Uy, H. L., Guise, T. A., Story, B., Boyce, B. F., Mundy, G. R., et.al. Interleukin-6 enhances hypercalcemia and bone resorption mediated by parathyroid hormone-related protein in vivo, J Clin Invest, 1995. 95(6): p. 2846-52., https://www.ncbi.nlm.nih.gov/pubmed/7769125
630. Weissglas, Max, Schamhart, Denis, Lowik, Clemens, Papapoulos, Socrates, Vos, Pieter, Kurth, Karl-Heinz, Investigative Urology: Hypercalcemia and Cosecretion of Interleukin-6 and Parathyroid Hormone Related Peptide by a Human Renal Cell Carcinoma Implanted Into Nude Mice, The Journal of urology, 1995. 153(3): p. 854-857., https://pubmed.ncbi.nlm.nih.gov/7861550/
631. Brereton, H. D., Halushka, P. V., Alexander, R. W., Mason, D. M., Keiser, H. R., DeVita, V. T., Jr., Indomethacin-responsive hypercalcemia in a patient with renal-cell adenocarcinoma, N Engl J Med, 1974. 291(2): p. 83-5., https://www.ncbi.nlm.nih.gov/pubmed/4835887
632. ROBERTSON, R PAUL, BAYLINK, DAVID J, MARINI, JOHN J, ADKISON, H WILLIAM, Elevated prostaglandins and suppressed parathyroid hormone associated with hypercalcemia and renal cell carcinoma, The Journal of Clinical Endocrinology & Metabolism, 1975. 41(1): p. 164-167., https://pubmed.ncbi.nlm.nih.gov/1150858/
633. Gold, P. J., Fefer, A., Thompson, J. A., Paraneoplastic manifestations of renal cell carcinoma, Semin Urol Oncol, 1996. 14(4): p. 216-22., https://www.ncbi.nlm.nih.gov/pubmed/8946620
634. McMullin, M. F., The classification and diagnosis of erythrocytosis, Int J Lab Hematol, 2008. 30(6): p. 447-59., https://www.ncbi.nlm.nih.gov/pubmed/18823397
635. Baumann, F. T., Zopf, E. M., Bloch, W., Clinical exercise interventions in prostate cancer patients--a systematic review of randomized controlled trials, Support Care Cancer, 2012. 20(2): p. 221-33., https://www.ncbi.nlm.nih.gov/pubmed/21989678
636. Bourke, L., Thompson, G., Gibson, D. J., Daley, A., Crank, H., Adam, I., et.al. Pragmatic lifestyle intervention in patients recovering from colon cancer: a randomized controlled pilot study, Arch Phys Med Rehabil, 2011. 92(5): p. 749-55., https://www.ncbi.nlm.nih.gov/pubmed/21530722
637. Brown, Justin C, Huedo-Medina, Tania B, Pescatello, Linda S, Pescatello, Shannon M, Ferrer, Rebecca A, Johnson, Blair T, Efficacy of exercise interventions in modulating cancer-related fatigue among adult cancer survivors: a meta-analysis, Cancer Epidemiology Biomarkers & Prevention, 2011. 20(1): p. 123-133., https://pubmed.ncbi.nlm.nih.gov/21051654/
638. Cantarero-Villanueva, I., Fernandez-Lao, C., Del Moral-Avila, R., Fernandez-de-Las-Penas, C., Feriche-Fernandez-Castanys, M. B., Arroyo-Morales, M., Effectiveness of core stability exercises and recovery myofascial release massage on fatigue in breast cancer survivors: a randomized controlled clinical trial, Evid Based Complement Alternat Med, 2012. 2012: p. 620619., https://www.ncbi.nlm.nih.gov/pubmed/21792370
639. Coleman, E. A., Goodwin, J. A., Kennedy, R., Coon, S. K., Richards, K., Enderlin, C., et.al. Effects of exercise on fatigue, sleep, and performance: a randomized trial, Oncol Nurs Forum, 2012. 39(5): p. 468-77., https://www.ncbi.nlm.nih.gov/pubmed/22940511
640. Cramp, F., Byron-Daniel, J., Exercise for the management of cancer-related fatigue in adults, Cochrane Database Syst Rev, 2012. 11: p. CD006145., https://www.ncbi.nlm.nih.gov/pubmed/23152233
641. Keogh, J. W., MacLeod, R. D., Body composition, physical fitness, functional performance, quality of life, and fatigue benefits of exercise for prostate cancer patients: a systematic review, J Pain Symptom Manage, 2012. 43(1): p. 96-110., https://www.ncbi.nlm.nih.gov/pubmed/21640547
642. Luctkar-Flude, M. F., Groll, D. L., Tranmer, J. E., Woodend, K., Fatigue and physical activity in older adults with cancer: a systematic review of the literature, Cancer Nurs, 2007. 30(5): p. E35-45., https://www.ncbi.nlm.nih.gov/pubmed/17876176
643. Markes, M., Brockow, T., Resch, K. L., Exercise for women receiving adjuvant therapy for breast cancer, Cochrane Database Syst Rev, 2006. p. CD005001., https://www.ncbi.nlm.nih.gov/pubmed/17054230
644. McMillan, Elliott M, Newhouse, Ian J, Exercise is an effective treatment modality for reducing cancer-related fatigue and improving physical capacity in cancer patients and survivors: a meta-analysis, Applied Physiology, Nutrition, and Metabolism, 2011. 36(6): p. 892-903., https://pubmed.ncbi.nlm.nih.gov/22067010/
645. Mishra, S. I., Scherer, R. W., Snyder, C., Geigle, P. M., Berlanstein, D. R., Topaloglu, O., Exercise interventions on health-related quality of life for people with cancer during active treatment, Cochrane Database Syst Rev, 2012. 8: p. Cd008465., https://pubmed.ncbi.nlm.nih.gov/22895974/
646. Puetz, T. W., Herring, M. P., Differential effects of exercise on cancer-related fatigue during and following treatment: a meta-analysis, Am J Prev Med, 2012. 43(2): p. e1-24., https://www.ncbi.nlm.nih.gov/pubmed/22813691
647. van Haren, I. E., Timmerman, H., Potting, C. M., Blijlevens, N. M., Staal, J. B., Nijhuis-van der Sanden, M. W., Physical exercise for patients undergoing hematopoietic stem cell transplantation: systematic review and meta-analyses of randomized controlled trials, Phys Ther, 2013. 93(4): p. 514-28., https://www.ncbi.nlm.nih.gov/pubmed/23224217
648. Velthuis, M. J., Agasi-Idenburg, S. C., Aufdemkampe, G., Wittink, H. M., The effect of physical exercise on cancer-related fatigue during cancer treatment: a meta-analysis of randomised controlled trials, Clin Oncol (R Coll Radiol), 2010. 22(3): p. 208-21., https://www.ncbi.nlm.nih.gov/pubmed/20110159
649. Vermaete, N., Wolter, P., Verhoef, G., Gosselink, R., Physical activity, physical fitness and the effect of exercise training interventions in lymphoma patients: a systematic review, Ann Hematol, 2013. 92(8): p. 1007-21., https://www.ncbi.nlm.nih.gov/pubmed/23408096
650. Jacobsen, P. B., Donovan, K. A., Vadaparampil, S. T., Small, B. J., Systematic review and meta-analysis of psychological and activity-based interventions for cancer-related fatigue, Health Psychol, 2007. 26(6): p. 660-7., https://www.ncbi.nlm.nih.gov/pubmed/18020836
651. Fong, D. Y., Ho, J. W., Hui, B. P., Lee, A. M., Macfarlane, D. J., Leung, S. S., et.al. Physical activity for cancer survivors: meta-analysis of randomised controlled trials, BMJ, 2012. 344: p. e70., https://www.ncbi.nlm.nih.gov/pubmed/22294757
652. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF), S3-Leitlinie Psychoonkologische Diagnostik, Beratung und Behandlung von erwachsenen Krebspatienten.DKG Eigenverlag, 2014.
653. Littman, A. J., Bertram, L. C., Ceballos, R., Ulrich, C. M., Ramaprasad, J., McGregor, B., et.al. Randomized controlled pilot trial of yoga in overweight and obese breast cancer survivors: effects on quality of life and anthropometric measures, Support Care Cancer, 2012. 20(2): p. 267-77., https://www.ncbi.nlm.nih.gov/pubmed/21207071
654. Wenzel, J. A., Griffith, K. A., Shang, J., Thompson, C. B., Hedlin, H., Stewart, K. J., et.al. Impact of a home-based walking intervention on outcomes of sleep quality, emotional distress, and fatigue in patients undergoing treatment for solid tumors, Oncologist, 2013. 18(4): p. 476-84., https://www.ncbi.nlm.nih.gov/pubmed/23568000
655. Yeo, Theresa P, Burrell, Sherry A, Sauter, Patricia K, Kennedy, Eugene P, Lavu, Harish, Leiby, Benjamin E, et.al. A progressive postresection walking program significantly improves fatigue and health-related quality of life in pancreas and periampullary cancer patients, Journal of the American College of Surgeons, 2012. 214(4): p. 463-475., https://pubmed.ncbi.nlm.nih.gov/22321518/
656. Courneya, K. S., Segal, R. J., Reid, R. D., Jones, L. W., Malone, S. C., Venner, P. M., et.al. Three independent factors predicted adherence in a randomized controlled trial of resistance exercise training among prostate cancer survivors, J Clin Epidemiol, 2004. 57(6): p. 571-9., https://www.ncbi.nlm.nih.gov/pubmed/15246125
657. Hayama, Yuka, Inoue, Tomoko, The effects of deep breathing on ‘tension–anxiety’and fatigue in cancer patients undergoing adjuvant chemotherapy, Complementary therapies in clinical practice, 2012. 18(2): p. 94-98., https://pubmed.ncbi.nlm.nih.gov/22500846/
658. Andersen, C., Rorth, M., Ejlertsen, B., Stage, M., Moller, T., Midtgaard, J., et.al. The effects of a six-week supervised multimodal exercise intervention during chemotherapy on cancer-related fatigue, Eur J Oncol Nurs, 2013. 17(3): p. 331-9., https://www.ncbi.nlm.nih.gov/pubmed/23084254
659. Cho, M. H., Dodd, M. J., Cooper, B. A., Miaskowski, C., Comparisons of exercise dose and symptom severity between exercisers and nonexercisers in women during and after cancer treatment, J Pain Symptom Manage, 2012. 43(5): p. 842-54., https://pubmed.ncbi.nlm.nih.gov/22436836/
660. Mock, V, Cameron, L, Tompkins, C, Every step counts: A walking exercise program for persons living with cancer, Baltimore: Johns Hopkins University, 1997.
661. Saarto, T., Penttinen, H. M., Sievanen, H., Kellokumpu-Lehtinen, P. L., Hakamies-Blomqvist, L., Nikander, R., et.al. Effectiveness of a 12-month exercise program on physical performance and quality of life of breast cancer survivors, Anticancer Res, 2012. 32(9): p. 3875-84., https://www.ncbi.nlm.nih.gov/pubmed/22993332
662. Kirchner, PD Dr H, Merseburger, AS, Nebenwirkungen von zielgerichteten Medikamenten bei der Behandlung des metastasierenden Nierenzellkarzinoms, Der Onkologe, 2011. 17(2): p. 155-162.
663. Schmidinger, M., Zielinski, C. C., Vogl, U. M., Bojic, A., Bojic, M., Schukro, C., et.al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma, J Clin Oncol, 2008. 26(32): p. 5204-12., https://www.ncbi.nlm.nih.gov/pubmed/18838713
664. Rini, B. I., Cohen, D. P., Lu, D. R., Chen, I., Hariharan, S., Gore, M. E., et.al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib, J Natl Cancer Inst, 2011. 103(9): p. 763-73., https://www.ncbi.nlm.nih.gov/pubmed/21527770
665. KG, GlaxoSmithKline GmbH & Co., Fachinformation Votrient/Pazopanib, 0000.
666. Hutson, T. E., Figlin, R. A., Kuhn, J. G., Motzer, R. J., Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies, Oncologist, 2008. 13(10): p. 1084-96., https://www.ncbi.nlm.nih.gov/pubmed/18838439
667. Bhojani, N., Jeldres, C., Patard, J. J., Perrotte, P., Suardi, N., Hutterer, G., et.al. Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma, Eur Urol, 2008. 53(5): p. 917-30., https://www.ncbi.nlm.nih.gov/pubmed/18054825
668. Wolter, P., Stefan, C., Decallonne, B., Dumez, H., Bex, M., Carmeliet, P., et.al. The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation, Br J Cancer, 2008. 99(3): p. 448-54., https://www.ncbi.nlm.nih.gov/pubmed/18665181
669. Senior, K., Fatigue with sunitinib-induced hypothyroidism, Lancet Oncol, 2007. 8(2): p. 101., https://www.ncbi.nlm.nih.gov/pubmed/17288042
670. Kollmannsberger, C., Bjarnason, G., Burnett, P., Creel, P., Davis, M., Dawson, N., et.al. Sunitinib in metastatic renal cell carcinoma: recommendations for management of noncardiovascular toxicities, Oncologist, 2011. 16(5): p. 543-53., https://www.ncbi.nlm.nih.gov/pubmed/21490127
671. Wood, Laura S, Managing the side effects of sorafenib and sunitinib, Community Oncology, 2006. 3(9): p. 558-562., http://dx.doi.org/10.1016%2FS1548-5315(11)70751-3
672. Udina, M., Castellvi, P., Moreno-Espana, J., Navines, R., Valdes, M., Forns, X., et.al. Interferon-induced depression in chronic hepatitis C: a systematic review and meta-analysis, J Clin Psychiatry, 2012. 73(8): p. 1128-38., https://www.ncbi.nlm.nih.gov/pubmed/22967776
673. Kraus, M. R., Schafer, A., Schottker, K., Keicher, C., Weissbrich, B., Hofbauer, I., et.al. Therapy of interferon-induced depression in chronic hepatitis C with citalopram: a randomised, double-blind, placebo-controlled study, Gut, 2008. 57(4): p. 531-6., https://www.ncbi.nlm.nih.gov/pubmed/18079286
674. Postow, MA, Hellmann, MD, Adverse Events Associated with Immune Checkpoint Blockade., N Engl J Med, 2018. 378 (12)(12): p. 1165., https://pubmed.ncbi.nlm.nih.gov/29562154/
675. Stelmachowska-Banaś, M, Czajka-Oraniec, I, Management of endocrine immune-related adverse events of immune checkpoint inhibitors: an updated review., Endocr Connect, 2020. 9 (10)(10): p. R207-R228., https://pubmed.ncbi.nlm.nih.gov/33064663/
676. Sznol, M, Postow, MA, Davies, MJ, Pavlick, AC, Plimack, ER, Shaheen, M, et.al. Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management., Cancer Treat Rev, 2017. 58 (): p. 70-76., https://pubmed.ncbi.nlm.nih.gov/28689073/
677. Grünwald, V, Voss, MH, Rini, BI, Powles, T, Albiges, L, Giles, RH, et.al. Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events., Br J Cancer, 2020. 123 (6)(6): p. 898-904., https://pubmed.ncbi.nlm.nih.gov/32587360/
678. Brahmer, JR, Lacchetti, C, Schneider, BJ, Atkins, MB, Brassil, KJ, Caterino, JM, et.al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline., J Clin Oncol, 2018. 36 (17)(17): p. 1714-1768., https://pubmed.ncbi.nlm.nih.gov/29442540/
679. Gupta, S, Cortazar, FB, Riella, LV, Leaf, DE, Immune Checkpoint Inhibitor Nephrotoxicity: Update 2020., Kidney360, 2020. 1 (2)(2): p. 130-140., https://pubmed.ncbi.nlm.nih.gov/35372904/
680. Manohar, S, Kompotiatis, P, Thongprayoon, C, Cheungpasitporn, W, Herrmann, J, Herrmann, SM, Programmed cell death protein 1 inhibitor treatment is associated with acute kidney injury and hypocalcemia: meta-analysis., Nephrol Dial Transplant, 2019. 34 (1)(1): p. 108-117., https://pubmed.ncbi.nlm.nih.gov/29762725/
681. Cortazar, FB, Marrone, KA, Troxell, ML, Ralto, KM, Hoenig, MP, Brahmer, JR, et.al. Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors., Kidney Int, 2016. 90 (3)(3): p. 638-47., https://pubmed.ncbi.nlm.nih.gov/27282937/
682. Anker, Stefan D., Hannemann, Lena, Benesova, K., Eckert, Christoph, Jordan, Karin, Müller-Tidow, Carsten, et.al. Renale Toxizitäten von Checkpoint-Inhibitoren bei onkologischen Therapien, Der Nephrologe, 2019. 15: p. 20-29.
683. Abou Alaiwi, S, Xie, W, Nassar, AH, Dudani, S, Martini, D, Bakouny, Z, et.al. Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma., J Immunother Cancer, 2020. 8 (1)(1):, https://pubmed.ncbi.nlm.nih.gov/32066646/
684. Simonaggio, A, Michot, JM, Voisin, AL, Le Pavec, J, Collins, M, Lallart, A, et.al. Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer., JAMA Oncol, 2019. 5 (9)(9): p. 1310-1317., https://pubmed.ncbi.nlm.nih.gov/31169866/
685. Grimm, MO, Bex, A, De Santis, M, Ljungberg, B, Catto, JWF, Rouprêt, M, et.al. Safe Use of Immune Checkpoint Inhibitors in the Multidisciplinary Management of Urological Cancer: The European Association of Urology Position in 2019., Eur Urol, 2019. 76 (3)(3): p. 368-380., https://pubmed.ncbi.nlm.nih.gov/31235192/
686. Grimm, MO, Oppel-Heuchel, H, Foller, S, [Treatment with PD-1/PD-L1 and CTLA-4 immune checkpoint inhibitors : Immune-mediated side effects]., Urologe A, 2018. 57 (5)(5): p. 543-551., https://pubmed.ncbi.nlm.nih.gov/29663063/
687. Wang, DY, Okoye, GD, Neilan, TG, Johnson, DB, Moslehi, JJ, Cardiovascular Toxicities Associated with Cancer Immunotherapies., Curr Cardiol Rep, 2017. 19 (3)(3): p. 21., https://pubmed.ncbi.nlm.nih.gov/28220466/
688. Organization, World Health, National cancer control programmes: policies and managerial guidelines, 2002., https://apps.who.int/iris/bitstream/handle/10665/42494/9241545577.pdf;jsessionid=BF33B06602DE8D6543B872A5BA9B9754?sequence=1
689. Temel, J. S., Greer, J. A., Muzikansky, A., Gallagher, E. R., Admane, S., Jackson, V. A., et.al. Early palliative care for patients with metastatic non-small-cell lung cancer, N Engl J Med, 2010. 363(8): p. 733-42., https://www.ncbi.nlm.nih.gov/pubmed/20818875
690. El-Jawahri, Areej, Greer, Joseph A, Temel, Jennifer S, Does palliative care improve outcomes for patients with incurable illness? A review of the evidence, The journal of supportive oncology, 2011. 9(3): p. 87-94., https://pubmed.ncbi.nlm.nih.gov/21702398/
691. Smith, T. J., Temin, S., Alesi, E. R., Abernethy, A. P., Balboni, T. A., Basch, E. M., et.al. American Society of Clinical Oncology provisional clinical opinion: the integration of palliative care into standard oncology care, J Clin Oncol, 2012. 30(8): p. 880-7., https://www.ncbi.nlm.nih.gov/pubmed/22312101
692. Ferris, F. D., Bruera, E., Cherny, N., Cummings, C., Currow, D., Dudgeon, D., et.al. Palliative cancer care a decade later: accomplishments, the need, next steps -- from the American Society of Clinical Oncology, J Clin Oncol, 2009. 27(18): p. 3052-8., https://www.ncbi.nlm.nih.gov/pubmed/19451437
693. Lordick, F, Oorschot B van (2012) Palliativmedizin in der Onkologie, Ziele der Arbeitsgemeinschaft Palliativmedizin der Deutschen Krebsgesellschaft, Forum, 0000. 27: p. 367-371.
694. Lindena, Gabriele, Woskanjan, Susanne, HOPE 2012CLARA Klinische Forschung Clinical Analysis, Research and Application. HOPE Hospiz- und Palliativmedizin Erfassung, ein gemeinsames Projekt der Deutschen Gesellschaft für Palliativmedizin, der Deutschen Krebsgesellschaft, des Deutschen Hospiz- und Palliativ-Verbandes., 2012.
695. Stephens, R. J., Hopwood, P., Girling, D. J., Machin, D., Randomized trials with quality of life endpoints: are doctors' ratings of patients' physical symptoms interchangeable with patients' self-ratings?, Qual Life Res, 1997. 6(3): p. 225-36., https://www.ncbi.nlm.nih.gov/pubmed/9226980
696. Morita, T., Fujimoto, K., Namba, M., Sasaki, N., Ito, T., Yamada, C., et.al. Palliative care needs of cancer outpatients receiving chemotherapy: an audit of a clinical screening project, Support Care Cancer, 2008. 16(1): p. 101-7., https://www.ncbi.nlm.nih.gov/pubmed/17611783
697. Tishelman, Carol, Loevgren, Malin, Broberger, Eva, Hamberg, Katarina, Sprangers, Mirjam AG, Are the most distressing concerns of patients with inoperable lung cancer adequately assessed? A mixed-methods analysis, Journal of Clinical Oncology, 2010. 28(11): p. 1942-1949., https://pubmed.ncbi.nlm.nih.gov/20212257/
698. Pearce, M. J., Coan, A. D., Herndon, J. E., 2nd, Koenig, H. G., Abernethy, A. P., Unmet spiritual care needs impact emotional and spiritual well-being in advanced cancer patients, Support Care Cancer, 2012. 20(10): p. 2269-76., https://www.ncbi.nlm.nih.gov/pubmed/22124529
699. Reilly, C. M., Bruner, D. W., Mitchell, S. A., Minasian, L. M., Basch, E., Dueck, A. C., et.al. A literature synthesis of symptom prevalence and severity in persons receiving active cancer treatment, Support Care Cancer, 2013. 21(6): p. 1525-50., https://www.ncbi.nlm.nih.gov/pubmed/23314601
700. Bradley, N., Davis, L., Chow, E., Symptom distress in patients attending an outpatient palliative radiotherapy clinic, J Pain Symptom Manage, 2005. 30(2): p. 123-31., https://www.ncbi.nlm.nih.gov/pubmed/16125027
701. Zimmermann, C., Swami, N., Krzyzanowska, M., Hannon, B., Leighl, N., Oza, A., et.al. Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial, Lancet, 2014. 383(9930): p. 1721-30., https://www.ncbi.nlm.nih.gov/pubmed/24559581
702. Dudgeon, D., et al., Cancer Care Ontario's experience with implementation of routine physical and psychological symptom distress screening., 2012., https://www.ncbi.nlm.nih.gov/pubmed/21308858
703. Loscalzo, M., Clark, K. L., Holland, J., Successful strategies for implementing biopsychosocial screening, Psychooncology, 2011. 20(5): p. 455-62., https://www.ncbi.nlm.nih.gov/pubmed/21456059
704. Carlson, L. E., Waller, A., Groff, S. L., Zhong, L., Bultz, B. D., Online screening for distress, the 6th vital sign, in newly diagnosed oncology outpatients: randomised controlled trial of computerised vs personalised triage, Br J Cancer, 2012. 107(4): p. 617-25., https://www.ncbi.nlm.nih.gov/pubmed/22828610
705. Stiel, S., Matthes, M. E., Bertram, L., Ostgathe, C., Elsner, F., Radbruch, L., [Validation of the new version of the minimal documentation system (MIDOS) for patients in palliative care : the German version of the edmonton symptom assessment scale (ESAS)], Schmerz, 2010. 24(6): p. 596-604., https://www.ncbi.nlm.nih.gov/pubmed/20882300
706. Bruera, E., Yennurajalingam, S., Palliative care in advanced cancer patients: how and when?, Oncologist, 2012. 17(2): p. 267-73., https://www.ncbi.nlm.nih.gov/pubmed/22252934
707. Neuwoehner, K., Lindena, G., Team, Hospice, Palliative Care, Evaluation, Assessment of distress with physical and psychological symptoms of patients in german palliative care services, Onkologie, 2011. 34(3): p. 94-8., https://www.ncbi.nlm.nih.gov/pubmed/21358213
708. Ontario, Cancer Care, Symptom Assessment and Management Tools, 2013.
709. Saito, A. M., Landrum, M. B., Neville, B. A., Ayanian, J. Z., Earle, C. C., The effect on survival of continuing chemotherapy to near death, BMC Palliat Care, 2011. 10: p. 14., https://www.ncbi.nlm.nih.gov/pubmed/21936940
710. Mack, J. W., Cronin, A., Keating, N. L., Taback, N., Huskamp, H. A., Malin, J. L., et.al. Associations between end-of-life discussion characteristics and care received near death: a prospective cohort study, J Clin Oncol, 2012. 30(35): p. 4387-95., https://www.ncbi.nlm.nih.gov/pubmed/23150700
711. Saito, A. M., Landrum, M. B., Neville, B. A., Ayanian, J. Z., Weeks, J. C., Earle, C. C., Hospice care and survival among elderly patients with lung cancer, J Palliat Med, 2011. 14(8): p. 929-39., https://pubmed.ncbi.nlm.nih.gov/21767153/
712. Wright, A. A., Zhang, B., Keating, N. L., Weeks, J. C., Prigerson, H. G., Associations between palliative chemotherapy and adult cancer patients' end of life care and place of death: prospective cohort study, Bmj, 2014. 348: p. g1219., https://pubmed.ncbi.nlm.nih.gov/24594868/
713. Identifying potential indicators of the quality of end-of-life cancer care from administrative data, 2003., https://www.ncbi.nlm.nih.gov/pubmed/12637481
714. Campion, F. X., Larson, L. R., Kadlubek, P. J., Earle, C. C., Neuss, M. N., Advancing performance measurement in oncology: quality oncology practice initiative participation and quality outcomes, J Oncol Pract, 2011. 7(3 Suppl): p. 31s-5s., https://www.ncbi.nlm.nih.gov/pubmed/21886517
715. Grundsaetze der Bundesaerztekammer zur aerztlichen Sterbebegleitung., Deutsches Aerzteblatt, 2011. 108(7): p. A 346-348.
716. D.G.f.P.e. V., D.H.-u.P.e. V., and Bundesaerztekammer, Charta zur Betreuung schwerst kranker und sterbender Menschen in Deutschland, 2010.
717. von Wartburg, Lea, Nationale Strategie Palliative Care, 2012.
718. Moran, M. S., Ma, S., Jagsi, R., Yang, T. J., Higgins, S. A., Weidhaas, J. B., et.al. A prospective, multicenter study of complementary/alternative medicine (CAM) utilization during definitive radiation for breast cancer, Int J Radiat Oncol Biol Phys, 2013. 85(1): p. 40-6., https://www.ncbi.nlm.nih.gov/pubmed/22658441
719. Naing, A., Stephen, S. K., Frenkel, M., Chandhasin, C., Hong, D. S., Lei, X., et.al. Prevalence of complementary medicine use in a phase 1 clinical trials program: the MD Anderson Cancer Center Experience, Cancer, 2011. 117(22): p. 5142-50., https://pubmed.ncbi.nlm.nih.gov/21538342/
720. Horneber, M, Bueschel, G, Kaiser, G, Kappauf, H, Wilhelm, M, Gallmeier, WM, Unkonventionelle Verfahren, Der Onkologe, 2003. 9(12): p. 1335-1342.
721. Ezzo, J. M., Richardson, M. A., Vickers, A., Allen, C., Dibble, S. L., Issell, B. F., et.al. Acupuncture-point stimulation for chemotherapy-induced nausea or vomiting, Cochrane Database Syst Rev, 2006. p. CD002285., https://www.ncbi.nlm.nih.gov/pubmed/16625560
722. Filshie, J., Redman, D., Acupuncture and malignant pain problems, Eur J Surg Oncol, 1985. 11(4): p. 389-94., https://pubmed.ncbi.nlm.nih.gov/4065352/
723. Lamanque, P., Daneault, S., [Does meditation improve the quality of life for patients living with cancer?], Can Fam Physician, 2006. 52: p. 474-5., https://pubmed.ncbi.nlm.nih.gov/17327889/
724. Ott, M. J., Norris, R. L., Bauer-Wu, S. M., Mindfulness meditation for oncology patients: a discussion and critical review, Integr Cancer Ther, 2006. 5(2): p. 98-108., https://pubmed.ncbi.nlm.nih.gov/16685074/
725. Kassab, S., Cummings, M., Berkovitz, S., van Haselen, R., Fisher, P., Homeopathic medicines for adverse effects of cancer treatments, Cochrane Database Syst Rev, 2009. p. CD004845., https://www.ncbi.nlm.nih.gov/pubmed/19370613
726. Horneber, M. A., Bueschel, G., Huber, R., Linde, K., Rostock, M., Mistletoe therapy in oncology, Cochrane Database Syst Rev, 2008. p. CD003297., https://www.ncbi.nlm.nih.gov/pubmed/18425885
727. Kleeberg, U. R., Suciu, S., Brocker, E. B., Ruiter, D. J., Chartier, C., Lienard, D., et.al. Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis, Eur J Cancer, 2004. 40(3): p. 390-402., https://www.ncbi.nlm.nih.gov/pubmed/14746858
728. Hildebrandt, B., Wust, P., Ahlers, O., Dieing, A., Sreenivasa, G., Kerner, T., et.al. The cellular and molecular basis of hyperthermia, Crit Rev Oncol Hematol, 2002. 43(1): p. 33-56., https://www.ncbi.nlm.nih.gov/pubmed/12098606
729. Mathis, S, Johnasson, T, Hyperthermie. Decision Support Document 36 (2010); Ludwig Boltzmann Institut für Health Technology Assessment (LBI-HTA) ISSN-online: 1992–0496, 2012.
730. Sauer, R, Creeze, H, Hulshof, M, Issels, R, Ott, O, Concerning the final report “Hyperthermia: a systematic review” of the Ludwig Boltzmann Institute for Health technology Assessment, Vienna, March 2010, Strahlentherapie und Onkologie, 2012. 188(3): p. 209-215., https://pubmed.ncbi.nlm.nih.gov/22318331/
731. Soares, P. I., Ferreira, I. M., Igreja, R. A., Novo, C. M., Borges, J. P., Application of hyperthermia for cancer treatment: recent patents review, Recent Pat Anticancer Drug Discov, 2012. 7(1): p. 64-73., https://www.ncbi.nlm.nih.gov/pubmed/21854362
732. Huebner, J., Muenstedt, K., Muecke, R., Micke, O., Stoll, C., Kleeberg, U. R., et.al. Counseling cancer patients on complementary and alternative medicine. Background, theory, and implementation of nationwide counseling facilities, Strahlenther Onkol, 2013. 189(8): p. 613-7., https://www.ncbi.nlm.nih.gov/pubmed/23824107
733. Dennert, G, Wolf, G, Ressourcenorientierte Beratung von Patientinnen und Patienten zur Komplementäronkologie, Ärztliche Psychotherapie, 2012. 7(3): p. 175-180.
734. Mills, J. T., Burris, M. B., Warburton, D. J., Conaway, M. R., Schenkman, N. S., Krupski, T. L., Positioning injuries associated with robotic assisted urological surgery, J Urol, 2013. 190(2): p. 580-4., https://www.ncbi.nlm.nih.gov/pubmed/23466240
735. Gunnarsson, U., Johansson, M., Strigard, K., Assessment of abdominal muscle function using the Biodex System-4. Validity and reliability in healthy volunteers and patients with giant ventral hernia, Hernia, 2011. 15(4): p. 417-21., https://pubmed.ncbi.nlm.nih.gov/21380564/
736. Clay, L., Gunnarsson, U., Franklin, K. A., Strigard, K., Effect of an elastic girdle on lung function, intra-abdominal pressure, and pain after midline laparotomy: a randomized controlled trial, Int J Colorectal Dis, 2014. 29(6): p. 715-21., https://www.ncbi.nlm.nih.gov/pubmed/24468797
737. Schover, L. R., Sexuality and fertility in urologic cancer patients, Cancer, 1987. 60(3 Suppl): p. 553-8., https://www.ncbi.nlm.nih.gov/pubmed/3036334
738. Zermann D-H, Vahlensieck, W, Rehabilitation, in Die Urologie, Michel, M.S., , Editor. im Druck, Springer: Berlin, Heidelberg. 2:
739. Steindorf, K, Schmidt, M, Ulrich, C, Welche Effekte hat körperliche Bewegung auf das Krebsrisiko und auf den Krankheitsverlauf nach einer Krebsdiagnose?, Bundesgesundheitsblatt-Gesundheitsforschung-Gesundheitsschutz, 2012. 55(1): p. 10-16., https://pubmed.ncbi.nlm.nih.gov/22286245/
740. Vahlensieck W, Ide W, Rehabilitation, Physiotherapie, Balneotherapie und physikalische Therapie, in Die urologische Praxis, Finke, Frank , Editor. 2007, Uni-Med: Bremen. p. 218-223.
741. Zermann, D-H, Beinert, T, Dauelsberg, T, Hoffmann, W, Rehabilitation funktioneller Probleme nach Therapie onkologischer Erkrankungen im Abdomial-und Beckenbereich, Der Onkologe, 2011. 17(10): p. 923-932., https://doi.org/10.1007/s00761-011-2112-y
742. Wang, W. M., Xu, Y., Yang, X. R., Wang, Y. H., Sun, H. X., Fan, J., Prognostic role of diabetes mellitus in hepatocellular carcinoma patients after curative treatments: a meta-analysis, Hepatobiliary Pancreat Dis Int, 2011. 10(4): p. 346-55., https://www.ncbi.nlm.nih.gov/pubmed/21813381?dopt=Citation
743. Yau, T., Chan, P., Epstein, R., Poon, R. T., Management of advanced hepatocellular carcinoma in the era of targeted therapy, Liver Int, 2009. 29(1): p. 10-7., https://www.ncbi.nlm.nih.gov/pubmed/19120940?dopt=Citation
744. Wang, Y. B., Chen, M. H., Yan, K., Yang, W., Dai, Y., Yin, S. S., Quality of life after radiofrequency ablation combined with transcatheter arterial chemoembolization for hepatocellular carcinoma: comparison with transcatheter arterial chemoembolization alone, Qual Life Res, 2007. 16(3): p. 389-97., https://www.ncbi.nlm.nih.gov/pubmed/17111232?dopt=Citation
745. Vahlensieck, PD Dr W, Gaeck, M, Gleissner, J, Liedke, S, Otto, U, Sauerwein, D, et.al. Struktur-und Prozessqualität der stationären urologischen Rehabilitation, Der Urologe, Ausgabe A, 2005. 44(1): p. 51-56.
746. Berger, J., Fardoun, T., Brassart, E., Capon, G., Bigot, P., Bernhard, J. C., et.al. Detailed analysis of morbidity following nephrectomy for renal cell carcinoma in octogenarians, J Urol, 2012. 188(3): p. 736-40., https://www.ncbi.nlm.nih.gov/pubmed/22818133
747. Zermann D-H, Stark I, Wolf I, Indikation und Effizienz psychoonkologischer Interventionen in der fachspezifischen urologischen Anschlussrehabilitation (AHB). 64. Kongress der Deutschen Gesellschaft für Urologie e.V., Leipzig, 2012., https://deutsche-akademie.info/resources/DGU+2012+Leipzig+Psychoonkologie.pdf
748. Schwarz, R, Psychosoziale Onkologie: Position, Prinzipien und Perspektiven.Deutsche Krebsgesellschaft, Forum, 2000. 15: p. 22-24.
749. Weis, J, Leitlinien und Qualitätssicherung in der Psychoonkologie., in Diagnostik und Behandlungsziele in der Psychoonkologie. Bericht der dapo-Jahrestagung 2004., Schumacher, Andrea , Editor. 2005, Pabst: Lengerich. p. 84-92., http://dx.doi.org/10.1016/B978-3-437-31602-9.00033-4
750. Cella, D, Quality of life., in Psycho-Oncology, JC, Holland , Editor. 1998, Oxford University Press: Oxford. p. 1135-1146.
751. Faller, H., Schuler, M., Richard, M., Heckl, U., Weis, J., Kuffner, R., Effects of psycho-oncologic interventions on emotional distress and quality of life in adult patients with cancer: systematic review and meta-analysis, J Clin Oncol, 2013. 31(6): p. 782-93., https://www.ncbi.nlm.nih.gov/pubmed/23319686
752. Koch U, Weis J, Krankheitsbewältigung bei Krebs und Möglichkeiten der Unterstützung : der Förderschwerpunkt "Rehabilitation von KrebskrankenSchattauer, 1998.
753. Mehnert, A, Lehmann, C, Koch, U, Prävalenz und Diagnostik psychischer Störungen in der Onkologie, Der Onkologe, 2006. 12(1): p. 18-26., http://dx.doi.org/10.1007/s00761-005-0994-2
754. Mehnert, Anja, Psychoonkologische Mitbetreuung und Nachsorge–Identifikation, Unterstützungsangebote und Umgang mit den Krankheitsfolgen, Der Klinikarzt, 2014. 43(07/08): p. 364-367., http://dx.doi.org/10.1055/s-0034-1393689
755. Zettl, S, Psychoonkologische Betreuung von Patienten mit Prostatakarzinom: Was kann der Urologe leisten, J Urol Urogyn, 2003. 10: p. 12-5.
756. Herschbach, Peter, Das „Zufriedenheitsparadox” in der Lebensqualitätsforschung, PPmP-Psychotherapie· Psychosomatik· Medizinische Psychologie, 2002. 52(03/04): p. 141-150., http://dx.doi.org/10.1055/s-2002-24953
757. Parker, P. A., Swartz, R., Fellman, B., Urbauer, D., Li, Y., Pisters, L. L., et.al. Comprehensive assessment of quality of life and psychosocial adjustment in patients with renal tumors undergoing open, laparoscopic and nephron sparing surgery, J Urol, 2012. 187(3): p. 822-6., https://www.ncbi.nlm.nih.gov/pubmed/22245327
758. Colleoni, M., Mandala, M., Peruzzotti, G., Robertson, C., Bredart, A., Goldhirsch, A., Depression and degree of acceptance of adjuvant cytotoxic drugs, Lancet, 2000. 356(9238): p. 1326-1327., https://www.ncbi.nlm.nih.gov/pubmed/11073026
759. Herschbach, Peter, Heussner, P, Sellschopp, A, Psycho-Onkologie: Perspektiven heutePabst, 2006.
760. Zettl, S., Hartlapp, J., Sexualstoerungen durch Krankheit und Therapie. Ein Kompendium fuer die aerztliche PraxisSpringer, 1997.
761. Novara, G., Secco, S., Botteri, M., De Marco, V., Artibani, W., Ficarra, V., Factors predicting health-related quality of life recovery in patients undergoing surgical treatment for renal tumors: prospective evaluation using the RAND SF-36 Health Survey, Eur Urol, 2010. 57(1): p. 112-20., https://www.ncbi.nlm.nih.gov/pubmed/19406562
762. Cohen, L., Cole, S. W., Sood, A. K., Prinsloo, S., Kirschbaum, C., Arevalo, J. M., et.al. Depressive symptoms and cortisol rhythmicity predict survival in patients with renal cell carcinoma: role of inflammatory signaling, PLoS One, 2012. 7(8): p. e42324., https://pubmed.ncbi.nlm.nih.gov/22870317/
763. Hoffmann, H, Urologische Malignome, in Rehabilitation und Teilhabe - Wegweiser für Aerzte und andere Fachkraefte der Rehabilitation, Rehabilitation, Bundesarbeitsgemeinschaft fuer , Editor. 2005, Deutscher Aerzte-Verlag: Koeln.
764. Deutsche Rentenversicherung Bund, Projektgruppe Sozialmedizinisches Glossar, Sozialmedizinisches GlossarDeutsche Rentenversicherung Bund, Geschaeftsbereich Sozialmedizin und Rehabilitationswissenschaften, 2007.
765. Vahlensieck, W., Sawal, O., Hoffmann, H., Urologische Erkrankungen, in Sozialmedizinische Begutachtung für die gesetzliche Rentenversicherung, Rentenversicherungstraeger, Verband Deutscher , Editor. 2011, Springer: Berlin, Heidelberg. p. 411-429.
766. Harrison-Paul, Jane, Drummond, Avril ER, A randomised controlled trial of occupational therapy in oncology: Challenges in conducting a pilot study, The British Journal of Occupational Therapy, 2006. 69(3): p. 130-133., https://doi.org/10.1177/030802260606900306
767. Hegel, M. T., Lyons, K. D., Hull, J. G., Kaufman, P., Urquhart, L., Li, Z., et.al. Feasibility study of a randomized controlled trial of a telephone-delivered problem-solving-occupational therapy intervention to reduce participation restrictions in rural breast cancer survivors undergoing chemotherapy, Psychooncology, 2011. 20(10): p. 1092-101., https://pubmed.ncbi.nlm.nih.gov/20821373/
768. McClure, M. K., McClure, R. J., Day, R., Brufsky, A. M., Randomized controlled trial of the Breast Cancer Recovery Program for women with breast cancer-related lymphedema, Am J Occup Ther, 2010. 64(1): p. 59-72., https://www.ncbi.nlm.nih.gov/pubmed/20131565
769. Yuen, H. K., Mitcham, M., Morgan, L., Managing post-therapy fatigue for cancer survivors using energy conservation training, J Allied Health, 2006. 35(2): p. 121e-139e., https://pubmed.ncbi.nlm.nih.gov/19759966/
770. Zini, L., Perrotte, P., Capitanio, U., Jeldres, C., Shariat, S. F., Antebi, E., et.al. Radical versus partial nephrectomy: effect on overall and noncancer mortality, Cancer, 2009. 115(7): p. 1465-71., https://www.ncbi.nlm.nih.gov/pubmed/19195042
771. Jeldres, C., Patard, J. J., Capitanio, U., Perrotte, P., Suardi, N., Crepel, M., et.al. Partial versus radical nephrectomy in patients with adverse clinical or pathologic characteristics, Urology, 2009. 73(6): p. 1300-5., https://www.ncbi.nlm.nih.gov/pubmed/19376568
772. Sandhu, S. S., Symes, A., A'Hern, R., Sohaib, S. A., Eisen, T., Gore, M., et.al. Surgical excision of isolated renal-bed recurrence after radical nephrectomy for renal cell carcinoma, BJU Int, 2005. 95(4): p. 522-5., https://www.ncbi.nlm.nih.gov/pubmed/15705072
773. Patard, J. J., Shvarts, O., Lam, J. S., Pantuck, A. J., Kim, H. L., Ficarra, V., et.al. Safety and efficacy of partial nephrectomy for all T1 tumors based on an international multicenter experience, J Urol, 2004. 171(6 Pt 1): p. 2181-5, quiz 2435., https://pubmed.ncbi.nlm.nih.gov/15126781/
774. Breau, R. H., Blute, M. L., Surgery for renal cell carcinoma metastases, Curr Opin Urol, 2010. 20(5): p. 375-81., https://www.ncbi.nlm.nih.gov/pubmed/20592612
775. Tosco, L., Van Poppel, H., Frea, B., Gregoraci, G., Joniau, S., Survival and impact of clinical prognostic factors in surgically treated metastatic renal cell carcinoma, Eur Urol, 2013. 63(4): p. 646-52., https://www.ncbi.nlm.nih.gov/pubmed/23041360
776. Skolarikos, A., Alivizatos, G., Laguna, P., de la Rosette, J., A review on follow-up strategies for renal cell carcinoma after nephrectomy, Eur Urol, 2007. 51(6): p. 1490-500; discussion 1501., https://www.ncbi.nlm.nih.gov/pubmed/17229521
777. Chin, A. I., Lam, J. S., Figlin, R. A., Belldegrun, A. S., Surveillance strategies for renal cell carcinoma patients following nephrectomy, Rev Urol, 2006. 8(1): p. 1-7., https://www.ncbi.nlm.nih.gov/pubmed/16985554
778. Weis, J., Schumacher, A., Blettner, G., Determann, M., Reinert, E., Rueffer, J. U., et.al. Psychoonkologie: Konzepte und Aufgaben einer jungen Fachdisziplin, Onkologe, 2007. 13(2): p. 185-194., http://134.95.56.236/ccmedimages/2007/67042.pdf
779. Sanson-Fisher, R., Girgis, A., Boyes, A., Bonevski, B., Burton, L., Cook, P., The unmet supportive care needs of patients with cancer. Supportive Care Review Group, Cancer, 2000. 88(1): p. 226-37., https://www.ncbi.nlm.nih.gov/pubmed/10618627
780. Kleeberg, U. R., Tews, J. T., Ruprecht, T., Hoing, M., Kuhlmann, A., Runge, C., Patient satisfaction and quality of life in cancer outpatients: results of the PASQOC study, Support Care Cancer, 2005. 13(5): p. 303-10., https://www.ncbi.nlm.nih.gov/pubmed/15729552
781. Ong, L. M., Visser, M. R., Lammes, F. B., de Haes, J. C., Doctor-patient communication and cancer patients' quality of life and satisfaction, Patient Educ Couns, 2000. 41(2): p. 145-56., https://www.ncbi.nlm.nih.gov/pubmed/12024540
782. Fallowfield, L., Jenkins, V., Communicating sad, bad, and difficult news in medicine, Lancet, 2004. 363(9405): p. 312-9., https://www.ncbi.nlm.nih.gov/pubmed/14751707
783. de Haes, H., Teunissen, S., Communication in palliative care: a review of recent literature, Curr Opin Oncol, 2005. 17(4): p. 345-50., https://www.ncbi.nlm.nih.gov/pubmed/15933465
784. Fukui, S., Ogawa, K., Ohtsuka, M., Fukui, N., A randomized study assessing the efficacy of communication skill training on patients' psychologic distress and coping: nurses' communication with patients just after being diagnosed with cancer, Cancer, 2008. 113(6): p. 1462-70., https://www.ncbi.nlm.nih.gov/pubmed/18661509
785. Keller, M, Barthel, Y, Patientenzentrierte Kommunikation in der Onkologie–Erfahrungen mit dem KoMPASS Training In: Weis J, Brähler E, Hrsg, Psychoonkologie in Forschung und Praxis. Stuttgart: Schattauer, 2012., https://www.imabe.org/fileadmin/imago_hominis/pdf/IH020_267-276.pdf
786. Baile, W. F., Aaron, J., Patient-physician communication in oncology: past, present, and future, Curr Opin Oncol, 2005. 17(4): p. 331-5., https://www.ncbi.nlm.nih.gov/pubmed/15933462
787. Massie, M. J., Prevalence of depression in patients with cancer, J Natl Cancer Inst Monogr, 2004. p. 57-71., https://www.ncbi.nlm.nih.gov/pubmed/15263042
788. Jefford, M., Tattersall, M. H., Informing and involving cancer patients in their own care, Lancet Oncol, 2002. 3(10): p. 629-37., https://www.ncbi.nlm.nih.gov/pubmed/12372725
789. Adler, Nancy E, Page, Ann EK, Cancer care for the whole patient: Meeting psychosocial health needsNational Academies Press, 2008., https://pubmed.ncbi.nlm.nih.gov/20669419/
790. Zabora, J., BrintzenhofeSzoc, K., Curbow, B., Hooker, C., Piantadosi, S., The prevalence of psychological distress by cancer site, Psychooncology, 2001. 10(1): p. 19-28., https://www.ncbi.nlm.nih.gov/pubmed/11180574
791. Sharpe, M., Strong, V., Allen, K., Rush, R., Postma, K., Tulloh, A., et.al. Major depression in outpatients attending a regional cancer centre: screening and unmet treatment needs, Br J Cancer, 2004. 90(2): p. 314-20., https://www.ncbi.nlm.nih.gov/pubmed/14735170
792. Keller, M., Sommerfeldt, S., Fischer, C., Knight, L., Riesbeck, M., Lowe, B., et.al. Recognition of distress and psychiatric morbidity in cancer patients: a multi-method approach, Ann Oncol, 2004. 15(8): p. 1243-9., https://www.ncbi.nlm.nih.gov/pubmed/15277265
793. Zwahlen, D., Hagenbuch, N., Carley, M. I., Recklitis, C. J., Buchi, S., Screening cancer patients' families with the distress thermometer (DT): a validation study, Psychooncology, 2008. 17(10): p. 959-66., https://www.ncbi.nlm.nih.gov/pubmed/18203146
794. Stark, D., Kiely, M., Smith, A., Velikova, G., House, A., Selby, P., Anxiety disorders in cancer patients: their nature, associations, and relation to quality of life, J Clin Oncol, 2002. 20(14): p. 3137-48., https://www.ncbi.nlm.nih.gov/pubmed/12118028
795. Miovic, M., Block, S., Psychiatric disorders in advanced cancer, Cancer, 2007. 110(8): p. 1665-76., https://www.ncbi.nlm.nih.gov/pubmed/17847017
796. Fallowfield, L., Ratcliffe, D., Jenkins, V., Saul, J., Psychiatric morbidity and its recognition by doctors in patients with cancer, Br J Cancer, 2001. 84(8): p. 1011-5., https://www.ncbi.nlm.nih.gov/pubmed/11308246
797. Sollner, W., DeVries, A., Steixner, E., Lukas, P., Sprinzl, G., Rumpold, G., et.al. How successful are oncologists in identifying patient distress, perceived social support, and need for psychosocial counselling?, Br J Cancer, 2001. 84(2): p. 179-85., https://www.ncbi.nlm.nih.gov/pubmed/11161373
798. Newell, S., Sanson-Fisher, R. W., Girgis, A., Bonaventura, A., How well do medical oncologists' perceptions reflect their patients' reported physical and psychosocial problems? Data from a survey of five oncologists, Cancer, 1998. 83(8): p. 1640-51., https://www.ncbi.nlm.nih.gov/pubmed/9781960
799. Herschbach P, Weis J, Screeningverfahren in der Psychoonkologie. Testinstrumente zur Identifikation betreuungsbedürftiger Krebspatienten. Eine Empfehlung der PSO für die psychoonkologische BehandlungspraxisDeutsche Krebsgesellschaft, 2010., https://www.wpo-ev.de/wp-content/uploads/2023/07/Screening_broschuere.pdf
800. Weis, J., Domann, U., [Interventions in the rehabilitation of breast cancer patients - a critical literature review of the state of the art], Rehabilitation (Stuttg), 2006. 45(3): p. 129-45., https://www.ncbi.nlm.nih.gov/pubmed/16755432
801. Holland, J. C., Bultz, B. D., (NCCN), National Comprehensive Cancer Network, The NCCN guideline for distress management: a case for making distress the sixth vital sign, J Natl Compr Canc Netw, 2007. 5(1): p. 3-7., https://www.ncbi.nlm.nih.gov/pubmed/17323529
802. Whooley, M. A., Avins, A. L., Miranda, J., Browner, W. S., Case-finding instruments for depression. Two questions are as good as many, J Gen Intern Med, 1997. 12(7): p. 439-45., https://www.ncbi.nlm.nih.gov/pubmed/9229283
803. Sommerfeldt, S., Ihrig, A., Brechtel, A., Keller, M., Psychoonkologisches Screening in der Routineversorgung, Psychosom Konsiliarpsychiatr, 2007. 1(4): p. 293-297., https://link.springer.com/article/10.1007%2Fs11800-007-0063-3
804. Northouse, L. L., Katapodi, M. C., Song, L., Zhang, L., Mood, D. W., Interventions with family caregivers of cancer patients: meta-analysis of randomized trials, CA Cancer J Clin, 2010. 60(5): p. 317-39., https://www.ncbi.nlm.nih.gov/pubmed/20709946
805. (AZQ), Aerztliches Zentrum fuer Qualitaet in der Medizin, E, Gramsch, JD, Hoppe, G, Jonitz, A, Koehler, al., Ollenschlaeger G et, Kompendium Q-M-A. Qualitätsmanagement in der ambulanten VersorgungDt. Ärzte-Verl., 2008.
806. (AZQ), Aerztliches Zentrum fuer Qualitaet in der Medizin, Manual Qualitätsindikatoren. Manual für Autoren., 2009. äzq Schriftenreihe: 36:, https://www.aezq.de/mdb/edocs/pdf/schriftenreihe/schriftenreihe36.pdf